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1 Summary 
Proposed investment 
Onchocerciasis (river blindness) is a parasitic disease transmitted by blackflies. Notable 
symptoms include severe itching, skin lesions, and vision impairment including blindness. 
The disease is endemic in parts of Africa, Latin America, and Yemen, and more than 99% of 
all cases are found in sub-Saharan Africa [1]. Onchocerciasis has affected the poorest 
population in remote rural areas in Africa, resulting in negative socioeconomic impacts on 
them. In Africa, morbidity caused by onchocerciasis was significantly reduced by the vector 
control activities of the Onchocerciasis Control Programme (OCP) in West Africa (1975–
2002) and by the community-directed treatment with ivermectin (CDTi) under the African 
Programme for Onchocerciasis Control (APOC) in sub-Saharan Africa and parts of West 
Africa (1995–present). Studies of foci in Mali, Senegal, and Uganda have proved that 
eliminating onchocerciasis through ivermectin administration is feasible for amenable 
epidemiological settings under effective treatments and surveillance [2,3]. The successful 
treatment programs and the proven feasibility of elimination have provided policymakers and 
donors of the rationale to pursue the elimination and subsequent eradication of onchocerciasis. 
The treatment goal for onchocerciasis has shifted from control to elimination as shown by the 
World Health Organization’s (WHO’s) roadmap for neglected tropical diseases (NTDs) and 
the London Declaration on NTDs in 2012 [4,5].  
The assessment of the potential impacts of onchocerciasis elimination strategies can provide 
valuable information to national and global policymakers and donors. This assessment should 
consider not only epidemiological evidence but also costs, benefits, and risks, given limited 
resources and competing health priorities. 
2 
 
Scenarios of onchocerciasis elimination and eradication 
We assessed the value of investing in onchocerciasis elimination by comparing potential 
elimination strategies with a control strategy representing a general practice conducted in 
Africa until recently. The alternative strategies were developed as the control, elimination, 
and eradication scenarios (Table 1), which describe all required activities leading to the goal if 
implemented effectively and sustained as long as required [6]. Each scenario consists of 
treatment strategies and surveillance strategies – epidemiological (to assess the infection level 
in humans) and/or entomological (to assess the infectivity in blackflies). The main differences 
of the elimination/eradication scenarios from the control scenario are that treatments are 
scaled up from meso-/hyper-endemic areas to hypo-endemic and operationally challenging 
areas and that surveillance is conducted on a regular basis and includes entomological 
surveillance in addition to epidemiological surveillance (Box 1).   
 
 
 
 
 
 
 
 
With the scale-up of treatments, population living in entire target areas in endemic African 
regions would increase from around 140 million in the control scenario to 170 million−180 
million in the elimination and eradication scenarios. Also, population living in operationally 
challenging areas – the Central African Republic, Democratic Republic of the Congo, and 
South Sudan due to political insecurity and Gabon due to co-endemicity with Loa loa– would 
Control scenario: to reduce disease prevalence to a locally acceptable level, all endemic African countries 
implement annual CDTi in hyper- and meso-endemic areas, and after at least 25-years of CDTi, conduct 
epidemiological surveillance to confirm that CDTi can be safely stopped  
Elimination scenario: to reduce the incidence of infection to zero in a defined area, all endemic African 
countries except those with epidemiological and political challenges implement annual or biannual CDTi, and 
conduct regular active epidemiological and entomological surveillance to evaluate epidemiological trends, to 
decide a proper time to stop CDTi, and to detect and respond to possible recrudescence. 
Eradication scenario: to reduce the incidence of infection to zero in Africa, which would lead to global 
eradication, all endemic African countries implement not only annual or biannual CDTi but also locally tailored 
treatment strategies to deliver sustainable treatments to areas with operational challenges, and implement regular 
active epidemiological and entomological surveillance to evaluate epidemiological trends, to decide a proper time 
to stop CDTi, and to detect and respond to possible recrudescence. 
Box1. Scenarios description 
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be 42 million (2014 population). The details on the scenarios and target populations are 
described in Kim et al. 2015 [6].  
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Table1. Proposed scenarios of control, elimination, and eradication of onchocerciasis 
 
Control Elimination Eradication 
Ultimate goal 
Reduce disease prevalence to a locally 
acceptable level 
Reduce the incidence of infection to 
zero in a defined geographical area 
Reduce the worldwide incidence of 
infection to zero 
Target areas  
Endemicity Hyper, meso Hyper, meso, hypo Hyper, meso, hypo 
Feasibility 
concerns for 
CDTi1 
Partially targeted Partially targeted Targeted2 
Activities at project level 
Phase 1. Intervention  
1. Community-directed treatment with ivermectin (CDTi) 
Frequency Once a year Once or twice3 a year 
Treatment 
coverage 
65%+ 65%+ 
Start year of 
new projects4 
2014–2015 2014–2015: hyper-/meso-endemic 2014–2015: hyper-/meso-endemic 
 2016–2017: hypo-endemic 
2016–2017: hypo-endemic, with no 
feasibility concerns for CDTi 
  
2020–2021: hypo-endemic, with 
feasibility concerns for CDTi 
Duration 
25 years; another 25 years in case of 
insufficient treatment coverage 
Until the probability of local elimination is ≥ 99%5 
2. Surveillance 
Type 
Epidemiological 1A) Epidemiological  
 1B) Epidemiological and entomological  
Frequency 
Last year of MDA (25th, 50th year) 1A) Every 4 years from 9th year of MDA 
 1B) Last one year 
Site 
10 villages 1A) 10 villages  
 1B) 20 villages (epidemiological surveys) and 4 catching sites (entomological) 
Phase 2. Confirmation of elimination  
Surveillance 
Type NA Epidemiological and entomological  
Frequency 
NA Epidemiological: last one year (3rd year) 
NA Entomological: last two years (2nd and 3rd year) 
Site NA 10 villages and 4 catching sites 
Phase 3. Post-elimination  
Surveillance 
Type NA Epidemiological and entomological 
Frequency 
NA Epidemiological: every 3 years 
NA Entomological: every 4 years 
Site NA 5 villages and 2 catching sites 
1 Political insecurity and co-endemicity with Loa loa. 
2 Hypo-endemic areas with feasibility concerns were included in the eradication scenario only. 
3 Twice a year in new projects in Ethiopia and Uganda where the respective ministries of health announced six-monthly CDTi in new projects 
to bring them in line with ongoing projects (The Carter Center (2013) Fighting Disease: Ethiopia - Eliminating River Blindness. 
http://www.cartercenter.org/countries/ethiopia-health-river-blindness.html Accessed on 20 April 2014; Uganda Ministry of Health (2010) 
Health Sector Strategic Plan III, 2010/11-2014/15. http://www.health.go.ug/docs/HSSP_III_2010.pdf Accessed on 25 January 2015) 
4 Predicted considering APOC’s strategic plan to focus on the onchocerciasis elimination for the next decade 2016–2025 and the current 
epidemiological and political situation 
5 A dynamical transmission model ONCHOSIM (Plaisier AP, van Oortmarssen GJ, Habbema JD, Remme J, Alley ES (1990) ONCHOSIM: a 
model and computer simulation program for the transmission and control of onchocerciasis. Comput Methods Programs Biomed 31: 43-56) 
was used. 
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Rationale for investment 
Treatment needs 
Ivermectin has been the main drug for preventing and treating early onchocercal symptoms. 
Merck has donated ivermectin since late 1980s [7]. The timeline when treatment is expected 
to be stopped was predicted for each endemic country using a dynamical transmission model 
(ONCHOSIM [8]) and incorporating the heterogeneity in the onchocerciasis type 
(savannah/forest), the pre-control endemicity, and the history of treatment coverage at project 
level, which were available from APOC database. The details on the timeline for the 
treatment phase are described in Kim et al. 2015 [6]. 
In the elimination scenario, all endemic countries except the four countries with feasibility 
concerns (the Central African Republic, the Democratic Republic of the Congo, Gabon and 
South Sudan) were expected to end the treatment phase and shift to the post-treatment 
surveillance phase by 2028, and those four countries with feasibility concerns were expected 
to continue CDTi beyond 2045 (Figure 1). In the eradication scenario, all endemic countries 
were expected to reach the end of the treatment phase and enter the post-treatment 
surveillance phase by 2040, assuming sufficient treatments would be delivered sustainably in 
the four countries with feasibility concerns. In the control scenario, most endemic countries 
except several West African countries were predicted to continue CDTi beyond 2045.  
The time horizon for our analysis was 2013 to 2045 based on the predicted timeline: the last 
project in the eradication scenario was expected to stop CDTi in 2040, and at least three years 
would be required to confirm local elimination. 
The ivermectin treatment needs were predicted based on the predicted timeline for the 
treatment phase, population in endemic areas (from APOC database) adjusted for population 
growth rates [9], the expected treatment coverage based on the history data (from APOC 
database), and the frequency of CDTi (bi-annual if officially announced by ministry of health, 
otherwise annual). 
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The cumulative number of required ivermectin treatments over 2013–2045 was estimated at 
1.5 billion (95% central range: 1.4bn–1.8bn) for the elimination scenario and 1.3 billion 
(1.2bn–1.5bn) for the eradication scenario. The control scenario would require 1.8–2.0 times 
higher number of ivermectin treatments, 2.6 billion (2.4bn–3.0bn) over the same period. 
Compared to the control scenario, the elimination and eradication scenarios would reduce the 
total number of required ivermectin treatments by 44% and 50%, respectively. As Figure 2 
shows, in the elimination and eradication scenarios, the ivermectin treatment needs would be 
concentrated in the first several years, as the ivermectin treatments are scaled up to remaining 
endemic areas uncovered by CDTi, mostly in hypo-endemic areas. In the long term, the 
ivermectin treatment needs in the elimination and eradication scenarios would be lower than 
those in the control scenario, as regular active surveillance would enable to decide a proper 
time to stop CDTi, leading to a shorter treatment phase as compared to the control scenario 
lacking such surveillance systems. The details on the ivermectin treatment needs are described 
in Kim et al. 2015 [6]. 
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Figure 1. Years when CDTi is expected to be stopped in endemic African regions 
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Figure 2. Cumulative number of ivermectin treatments and annual number of projects with ongoing CDTi in endemic African regions over 
2013–2045 
(PSA: Probabilistic Sensitivity Analysis) 
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Financial and economic costs 
We estimated financial costs to predict how much the governments of endemic countries and 
donors would have to pay for implementing the required interventions for control, elimination, 
and eradication, and economic costs to assess societal opportunity costs associated with 
donated ivermectin and community volunteers’ unpaid time. We used a micro-costing 
(bottom-up) approach to estimate the costs more precisely by incorporating the heterogeneity 
in the demographic, epidemiological, and political situation at project level. The main data 
sources were 2012 project budgets that cover 67 of 112 ongoing (as of November 2013) 
projects in sub-Saharan Africa, made available by APOC.  
The elimination and eradication scenarios would allow substantial cost-savings of US$1.6bn 
and $1.7bn, respectively, compared to the control scenario for the period 2013−2045. This is 
mainly because regular surveillance would lead to a shorter period of CDTi, and consequently 
to the savings of economic costs associated with donated ivermectin and community 
volunteers’ unpaid time. The savings would be realized despite that the elimination and 
eradication scenarios would require five times higher surveillance costs than the control 
scenario.  
The total financial and economic costs would be concentrated in the early stage during which 
treatments are scaled up to remaining endemic areas, and decrease as the treatment phase 
nears the end (Figure 3). In endemic African regions, total financial and economic costs over 
the period 2013−2045 would be $4.3 billion ($3.9bn−$5.0bn) for the control scenario, $2.9 
billion ($2.6bn−$3.4bn) for the elimination scenario, and $2.7 billion ($2.4bn−$3.2bn) for the 
eradication scenario. That is, switching from the control scenario to the elimination and 
eradication scenarios would lead to cost-savings of $1.5 billion ($1.0bn−$1.9bn) and $1.6 
billion ($1.2bn−$2.1bn), respectively.  
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Total financial costs over the period 2013−2045 would be $640 million ($572m−$711m) for 
the control scenario, $650 million ($574m−$751m) for the elimination scenario, and $649 
million ($566m−$745m) for the eradication scenario. The main difference between scenarios 
is the proportion of surveillance costs in total costs. Total surveillance costs over 2013–2045 
would increase from 7% ($47m) of total financial costs under the control scenario to 33% 
($215m) and 37% ($242m) under the elimination and eradication scenarios, respectively. 
Economic costs would be six times higher than financial costs under the control scenario and 
three times higher under the elimination and eradiation scenarios. Total economic costs over 
2013−2045 would be $3.7 billion ($3.3bn−$4.3bn) for the control scenario, $2.2 billion 
($2.0bn−$2.7bn) for the elimination scenario, and $2.1 billion ($1.8bn−$2.5bn) for the 
eradication scenario. That is, the total economic costs for the elimination and eradication 
scenarios are lower than those for the control scenario by $1.5 billion ($1.1bn−$1.9bn) and 
$1.6 billion ($1.2bn−$2.1bn), respectively. Donated ivermectin and community volunteers’ 
unpaid time would account for 75% and 25% of the total economic costs in all scenarios. 
11 
 
Figure 3. Annual and cumulative financial and economic costs in endemic African regions over 2013−2045 
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Assessment of health benefits 
To estimate the health benefits of onchocerciasis elimination, we estimated the number of 
cases for severe itching, low vision, and blindness, and disability-adjusted life years (DALYs) 
for the control, elimination, and eradication scenarios. We used ONCHOSIM to simulate the 
prevalence of severe itching, low vision, and blindness at project level. We ran the 
simulations by incorporating the onchocerciasis type (savanna or forest), the endemicity level 
(none, hypo, meso, hyper), and the history of treatment coverage, all of which were available 
from APOC databases. We defined the endemicity levels based on pre-control nodule 
prevalence for APOC countries, and for former OCP countries, based on pre-control 
microfilariae prevalence with reference to Kim et al. 2015 [6]. We used the average treatment 
coverage over 2010−2012 as an expected coverage for 2013−2045. If the average treatment 
coverage was below 65%, which is the required level for effective control [10], we used the 
highest treatment coverage achieved during 2010−2012. For potential new projects, we used 
the national average treatment coverage and, if there was no relevant data, we used the 
regional average (across available national averages in either APOC or former OCP regions). 
To estimate the number of prevalent cases of severe itching, low vision, and blindness, we 
multiplied the predicted prevalence of each symptom with population living in a project area. 
Population (2012) was available from APOC database for all projects, and we adjusted for 
population growth rates for the period 2013−2045 [9]. 
To estimate DALYs we estimated the years lost due to disability (YLD) by multiplying the 
number of prevalent cases with relevant disability weights, namely, 0.108 for severe itching, 
0.033 for low vision, and 0.195 for blindness [11]; and then the years of life lost (YLL) by 
assigning eight years of life-expectancy loss for each blindness incidence assuming that 
blindness causes premature death [12]. 
13 
 
Under the elimination and eradication scenarios, the prevalence of severe itching in endemic 
African regions would decrease from 30/1,000 to 2/1,000 and to less than 1/1,000, 
respectively over 2013−2045 (Figure 4). The number of patients with severe itching under the 
control scenario would be 231.3 million over 2013–2045. Switching to the elimination and 
eradication scenarios would lead to the reduction of the number of patients with severe itching 
by 34.2 million and 46.4 million (15% and 20%), respectively.  
The prevalence of low vision would decrease from 51/10,000 to 6/10,000 for the control 
scenario, to 4/10,000 for the elimination scenario, and to 3/10,000 for the eradication scenario 
(Figure 4). The number of patients with low vision under the control scenario would be 33.1 
million over 2013–2045. Switching to the elimination and eradication scenarios would lead to 
the reduction of the number of patients with low vision by 1.5 million and 1.8 million (4% 
and 5%).  
The prevalence of blindness would decrease from 17/10,000 to 2/10,000 for the control 
scenario, and to less than 1/10,000 for the elimination and eradication scenarios (Figure 4). 
The number of patients with blindness under the control scenario would be 11.3 million over 
2013–2045. Switching to the elimination and eradication scenarios would lead to the 
reduction of the number of patients with blindness by 670 thousand and 778 thousand (6% 
and 7%), respectively.  
The elimination and eradication scenarios would avert DALYs by 33%, 4.3 million 
(2.1m−5.5m), and by 43%, 5.6 million (2.7m−7.2m), respectively over 2013−2045, as 
compared to the control scenario (Figure 5). The additional benefits of the eradication 
scenario compared to the elimination scenario would be 1.3 million (0.6m−1.7m) of averted 
DALYs. 
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Figure 4.Prevalence of severe itching, low vision, and blindness in endemic African 
regions over 2013−2045 
 
 
Figure 5. DALYs averted in endemic AFrican regions over 2013−2045, baseline: control 
scenario 
 
(The ranges are from PSA.) 
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Assessment of the impacts on health systems 
Eliminating onchocerciasis may have important consequences on endemic African countries’ 
health systems that are generally weak and characterized by a shortage of health workforce, 
especially in remote and rural areas [13]. Although it is hard to quantify these impacts, we 
assessed the main implications on the health systems building blocks with a focus on the 
impact on health workforce. Due to the challenges posed by weak health systems, CDTi has 
been the primary approach for onchocerciasis interventions. In CDTi, community volunteers 
play a central operational role by deciding when and how to distribute drugs, administering 
drugs, managing adverse reactions, keeping records, and reporting to health workers [14]. 
Also community health workers are important, as they train community volunteers, and 
monitor and evaluate CDTi performance [15]. To examine the potential impacts of alternative 
treatment strategies on these health workforces, we estimated the number of required 
community volunteers and community health workers over 2013−2045 for each scenario. We 
multiplied the ratio of community volunteers, and community health workers, over population 
with population living in endemic areas, and adjusted for the predicted treatment timeline at 
project level. The ratios of community volunteers and of community health workers over 
population were available in 2012 budget documents for 67 ongoing projects in sub-Saharan 
Africa (as of November 2013). We assumed the ratios would be stable until the end of CDTi. 
For projects without relevant ratios, we used the national average ratio and, if there was no 
relevant data, we used the regional average. We used population from APOC database after 
adjusting for population growth rates over 2013−2045 [9]. The predicted treatment timeline at 
project level for each scenario was available in Kim et al. 2015 [6].  
The total number of required community volunteers for implementing CDTi in endemic 
African regions would be 23.9 million (18.6m−30.4m) over 2013−2045 for the control 
scenario, 12.3 million (10.1m−17.4m) for the elimination scenario, and 11.6 million 
(9.2m−17.4m) for the eradication scenario (Figure 6). Switching to the elimination and 
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eradication scenarios from the control scenario would lead to the reduction of required 
community volunteers by 45%, 10.7 million (5.9m−14.1m), and by 52%, 12.4 million 
(6.9m−15.7m). This suggests that volunteers willing to continue to volunteer and their well-
established networks would be able to contribute to other health care services such as primary 
health care services in remote rural areas lacking human resources. 
The total number of community health workers for implementing CDTi in endemic African 
regions would be 2.3 million (1.6m−3.2m) over 2013−2045 for the control scenario, 1.0 
million (0.8m−1.7m) for the elimination scenario, and 917 thousands (0.7m−1.6m) for the 
eradication scenario (Figure 6). Switching to the elimination and eradication scenarios from 
the control scenario would lead to the reduction of required health workers by 56%, 1.3 
million (0.5m−1.9m), and 60%, 1.4 million (0.6m−2.0m), respectively. 
Figure 6. Health workforce needs for CDTi in endemic African regions over 2013–2045: 
community volunteers and community health workers 
 
(The ranges are from PSA.) 
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Another relevant aspect that is rarely taken into account is the burden on health systems of 
patients’ visits to health facilities due to severe itching and low vision [16]. We estimated the 
impacts of onchocerciasis elimination on this burden, assuming that only people living in 
areas uncovered by CDTi would visit health facilities, as people living in CDTi project areas 
benefit annual or biannual treatment with ivermectin which relieves severe itching and stops 
the progression towards blindness [17]. We assumed that people with blindness would not 
visit health facility, as blindness is irreversible. To estimate the number of outpatient visits we 
multiplied the number of patients with severe itching or low vision with the health facility 
utilization rate. As a proxy for the health facility utilization rate, we used the average 
treatment coverage over 2010−2012, assuming people who complied with CDTi would be 
willing to seek care if there were no CDTi. Based on the predicted number of outpatient visits, 
we estimated the potential cost-savings for each country, by multiplying the number of visit 
by a country-specific outpatient cost per visit [18].  
The total number of outpatient visits under the control scenario would be 46.2 million over 
2013−2045, incurring $56.0 million ($27.2m–$71.8m) of outpatient visit costs. The 
elimination and eradication scenarios would lead to the reduction of the number of outpatient 
visits by 31.6 million and 42.3 million (68% and 91%) as compared to the control scenario, 
thereby reducing the burden on health systems by saving outpatient visit costs by $47.5 
million ($22.8m–$61.0m) and $52.1 million ($25.0m–$67.3m). 
Health information system (HIS), another building block of health systems, is related to the 
main difference of the elimination/eradication scenarios from the control scenario, namely 
intensive surveillance. Regular active surveillance under the elimination and eradication 
scenarios, which serves to track epidemiological trends, decide a proper time to stop CDTi, 
detect and provide early warning on possible recrudescence, would be feasible only when the 
HIS are strong, because well-established and effective HIS enables health workers to collect 
and analyze data on a regular basis, and convert them into information to support 
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policymakers’ decision. This implies strengthening the HIS would be essential to achieve 
elimination in endemic African countries. 
Assessment of the economic impacts 
The areas where onchocerciasis is endemic are among the poorest of the world. We estimated 
the potential economic benefits of eliminating onchocerciasis using two approaches: the 
human capital approach in which the economic value of health is measured in terms of 
productivity in the market-place; the full income approach in which the economic value of 
health goes beyond material well-being to include a monetary value of the welfare gains (or 
psychological value) that people place on increased life expectancy [19,20]. We also assessed 
the potential impacts of onchocerciasis elimination on financial protection of households by 
estimating the reduction in out-of-pocket payments. 
With the human capital approach, we estimated the productivity gains from the reduction in 
morbidity over 2013–2045, by multiplying the predicted number of patients with severe 
itching, low vision, and blindness with the country-specific employment rate and a proxy for 
income losses due to each symptom under each scenario. We assumed that patients aged from 
15 and above would have the same probability of being employed as general population 
unless they had onchocercal symptoms. We assumed patients aged from 15 to 64 years with 
severe itching would lose 13% of GDP per capita based on the study on the economic impacts 
of onchocercal skin diseases in Ethiopia  [21], and patients in the same age group with low 
vision and blindness would lose 38% and 79% of GDP per capita, respectively, based on the 
study on the socioeconomic impacts of onchocercal vision impairment in Guinea [22]. 
Patients aged less than 15 years were assumed to have no economic productivity. Patients 
aged 65 years and above were assumed to be half as productive as those aged from 15 to 64 
years based on the methods used by Frick, Smith, and colleagues [23,24]. We also estimated 
the productivity gains for informal care-takers (e.g., families and relatives), assuming that one 
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patient with low vision or blindness would need one adult care-taker. We multiplied the 
number of patients with low vision and blindness with a relevant proxy for their care-takers’ 
income losses under each scenario. For the proxy, we assumed the care-taker would lose 5% 
of GDP per capita if the patient has low vision, and 10% of GDP per capita if the patient is 
blind, based on the study by Smith, Shamanna, and colleagues [24,25]. Also, to estimate the 
productivity gains from the reduction in mortality over 2013–2045, we multiplied the 
predicted YLL with GDP per capita, considering blindness causes premature death at a fully 
productive age [26].  
With the full income approach, we evaluated welfare gains associated with the life-expectancy 
gains from eliminating onchocerciasis, by multiplying the predicted YLL with a proxy for the 
economic value of one life-year increase in sub-Saharan Africa. For the proxy, we used the 
result of the study by the Lancet Commission on Investing in Health, 4.2 times GDP per 
capita estimated for sub-Saharan Africa and 2.3 times GDP per capita for low and middle 
income countries[20]. The Lancet Commission used survival curves for different life tables to 
estimate the relationship between mortality and life expectancy, and estimated the economic 
value associated with a unit mortality rate based on studies on the value of a statistical life. 
The elimination and eradication scenarios would lead to the productivity gains of $4.6 billion 
($2.4bn−$6.2bn) and $5.0 billion ($2.7bn−$6.7bn), respectively, as compared to the control 
scenario, in which 96% is for patients and 4% for care-takers (Figure 7). The economic 
benefits measured in terms of welfare gains associated with the life-year gains from averted 
blindness would be, applying the value of a life-year for sub-Saharan Africa (4.2 times GDP 
per capita), $7.0 billion ($3.6bn–$9.4bn) for the elimination scenario and $7.4 billion 
($3.8bn–$9.9bn) for the eradication scenario over 2013–2045 as compared to the control 
scenario; and applying that for low and middle income countries (2.3 times GDP per capita), 
$3.9 billion ($2.0bn–$5.1bn) for the elimination scenario and $4.1 billion ($2.1bn–$5.4bn) for 
the eradication scenario (Figure 8). 
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Figure 7. Economic productivity gains under the elimination and eradication scenarios 
in endemic African regions over 2013–2045, baseline: control scenario 
 
(The ranges are from PSA.) 
 
Figure 8. Economic welfare gains due to the reduction of premature deaths under the 
elimination and eradication scenarios in endemic African regions over 2013–2045, 
baseline: control scenario 
 
(The ranges are from PSA.) 
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Weak health systems generally result in poor financial protection against households’ 
catastrophic health expenditure. To assess the benefits of onchocerciasis elimination in terms 
of financial protection of households, we estimated patients’ out-of-pocket (OOP) payments 
for visiting health facility due to severe itching and low vision for each scenario. We 
multiplied the previously estimated outpatient visit costs with the proportion incurred as OOP 
payments for which the proxy was OOP health expenditure as percentage of total health 
expenditure for each country, and added transportation costs which were assumed to be 17% 
of OOP payments based on a study by Saksena and colleagues [27].  
The total household OOP payments due to onchocerciasis would be $35.7 million ($16.7m–
$47.4m) over 2013−2045 under the control scenario (Figure 9). The elimination and 
eradication scenarios would lead to the reduction of the household OOP payments by $4.5 
million ($2,2m–$6.0m) and $2.2 million ($1.2m–$3.0m), respectively, as compared to the 
control scenario. 
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Figure 9. Total outpatient visit costs and out-of-pocket payments in endemic African 
regions over 2013–2045 
 
(The ranges are from PSA.) 
 
Investing in justice: ethics, equity, and fairness considerations 
Neglected tropical diseases such as onchocerciasis are concentrated among low-income 
countries and disadvantaged populations. Social justice consists in fairness and equity in the 
distribution of societal benefits and burdens. Nevertheless, it is challenging to account for the 
ethical importance of the benefits, burdens, and distributions,  that are salient in people’s 
experiences of the diseases and related interventions. Thus these aspects are not assessed in 
traditional approaches for health and economic evaluation.  
To evaluate the potential impacts of onchocerciasis elimination in terms of the inequalities in 
economic conditions at local level, we compared the night light level between meso-/hyper-
endemic areas and non-/hypo-endemic areas. We used night light data as a proxy for local 
income, because there were no data available on the local economic conditions of the endemic 
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areas. Recent studies showed that, despite several limitations,  the night light data can be used 
as a proxy for income at sub- and supranational levels in low income countries [28]. We 
identified meso-/hyper-endemic and non-/hypo-endemic areas using the APOC database 
which were created based on epidemiological surveys and using a geospatial analysis [29,30] 
(Figure 10). We obtained the 2013 night light map [31]. Using the night light map, we created 
a database that contains the light levels (dark−bright: 0−64) at the geographic unit of 0.1 by 
0.1 degrees, and identified if each unit area is meso-/hyper-endemic or non-/hypo-endemic by 
overlapping the endemicity map. We compared the average light level between meso-/hyper-
endemic and non-/hypo-endemic areas using Welch’s unequal variances t-test. 
Figure 10.Endemicity and night lights in Africa 
 
 
The statistical comparison of night light levels shows that the average night light level in 
meso-/hyper-endemic areas (M=0.15, SD=1.46) is significantly lower than that in non-/hypo-
endemic areas (M=0.18, SD=1.93); t(82,117)=2.97, p<0.05. This suggests that, within the 
APOC countries where most of the global cases are found, meso-/hyper-endemic areas are 
likely to have higher poverty levels than non-/hypo-endemic areas.  
24 
 
Poverty is not just about low income, but goes beyond to the deterioration of individual 
capabilities to lead their lives and accomplish what they value as human beings [32]. 
Onchocercal symptoms (severe itching and vision impairment including blindness) deteriorate 
patients’ well-being from psychological, psychosocial, and social aspects [33]. These 
symptoms undermine self-respect due to stigma, teasing, and negative stereotyping, and 
deprive of the opportunities of physical and educational activities and relationships with 
others because of ostracism or the avoidance of infected person. This indicates that the 
elimination and subsequent eradication of onchocerciasis would not only contribute to 
relieving income inequality, but also lead to ethical advantages and social justice. 
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Policy implications 
The eradication and elimination scenarios dominate the control scenario in terms of 
intervention costs and health benefits. They not only save the intervention costs, but also lead 
to the health, economic, social benefits, as compared to the control scenario (Table 2). 
Intensive investment in the early stage to scale up the interventions to hypo-endemic areas and 
operationally challenging areas, in addition to meso-/hyper-endemic areas, combined with 
strengthening the surveillance and response systems would eventually save financial and 
societal opportunity costs, and result in the reduction of morbidity and mortality due to 
onchocerciasis. In addition, this would generate substantial economic productivity and welfare 
gains, foster equity by preventing people living in endemic areas from missing social and 
economic opportunities, and relieve income inequality.  
The implementation of elimination and eradication strategies would affect and be affected by 
the conditions of health systems that should therefore be strengthened. Also the elimination 
and eradication of onchocerciasis are public goods that can only be achieved through the 
coordinated efforts of multiple countries [34,35]. To achieve the elimination and subsequent 
eradication of onchocerciasis, political, financial, and societal commitments across a whole 
spectrum of stakeholders, including community members, religious leaders, national 
policymakers, pharmaceutical companies, and global donors, will be essential [36]. 
Globally, the elimination and eradication of onchocerciasis would require cooperation among 
endemic countries, global donors, and pharmaceutical companies. Especially during the early 
stage of the implementation of elimination/eradication strategies, endemic countries would 
need higher financial costs, more human resources, and more medicines to stabilize new 
treatment projects in currently uncovered endemic areas and strengthen surveillance and 
response systems. Thus, global donors’ continuous funding and pharmaceutical companies’ 
drug donation will be critical. The centralized efforts led by international organizations would 
also be necessary to prevent potential holdout problems caused by unwilling or unable 
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countries, which could hinder elimination and eradication. In line with this, it has been argued 
that the explicit inclusion of NTDs elimination in the Sustainable Development Goals of the 
United Nations would further motivate the commitment of national and global policymakers 
and donors [37]. 
National governance and leadership will be critical to achieve the elimination and eradication 
of onchocerciasis. National policymakers would need to develop the long-term strategies 
targeting the elimination and eradication of onchocerciasis. Especially, the countries where 
co-endemicity with Loa loa hinders scaling up treatments would need to develop locally 
tailored approaches in addition to CDTi for those co-endemic areas, for example, a test-and-
treat approach and an anti-Wolbachia therapy with macrofilaricidal drugs. To implement the 
long-term strategies effectively, policymakers would need to regularly monitor and evaluate 
the performance of all the relevant components including health information systems, 
financing, scaling up interventions, human capacity building, andtimely drug supply (Figure 
11). The collaboration between endemic countries would be important, especially when 
endemic areas span across the border areas, as human and vector migration could cause 
recrudescence. 
Table2. Summary of key results 
  Control (baseline) Elimination Eradication 
Health benefits, 2013–2045 
DALYs averted – 
4.3 million 
(2.1m−5.5m) 
5.6 million 
(2.7m−7.2m) 
Intervention cost, 2013–2045 
Financial costs 
$640 million 
($572m−$711m)  
$650 million 
($574m−$751m)  
$649 million 
($566m−$745m)  
Economic costs 
$3.7 billion 
($3.3bn−$4.3bn) 
$2.2 billion 
($2.0bn−$2.7bn) 
$2.1 billion 
($1.8bn−$2.5bn)  
Economic benefits, 2013–2045 
Productivity gains – 
$4.6 billion 
($2.4bn−$6.2bn) 
$5.0 billion 
($2.7bn−$6.7bn) 
Welfare gains from life-years 
gains 
– 
$7.0 billion 
($2.9bn−$8.9bn) 
$7.4 billion 
($3.0bn−$9.4bn) 
Data format: mean (95% central ranges from probabilistic sensitivity analysis) 
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Note: Costs, DALYs, and economic impacts were discounted with 3% to the year 2013 to account for time 
preference 
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Figure 11. Policy implications for health systems 
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2 Introduction 
Epidemiology of onchocerciasis 
Infection and clinical symptoms 
Onchocercias is a parasitic disease caused by filariae, Onchocerca volvulus, that are 
transmitted by blackflies and only infect humans (Fig 12).Adult worms are found in nodules 
under the skin of infected persons and live up to 14 years. They produce thousands of 
microfilaria that cause inflammatory reactions, and consequently clinical symptoms. 
Microfilariae are ingested by blackflies during a blood meal on an infected person, develop 
into infective larvae inside blackflies, and are transmitted to another person during a 
subsequent blood meal. The most notable clinical symptoms are severe itching, skin lesions, 
and vision impairment including blindness. 
Figure 12. Main stages of the life-cycle of a filarial worm Onchocerca volvulus 
 
Onchocerciasis is endemic in parts of Africa, Latin America, and Yemen (Fig 13), but over 99% 
of all current cases are found in sub-Saharan Africa [1] where onchocercias is has historically 
been a serious public health problem and hindered socioeconomic development in endemic 
areas [38].  
(image: APOC/WHO, JAF 16.6 II) 
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Figure 13. Global endemicity of onchocerciasis 
 
 
History of treatment and prevention 
In Africa, morbidity caused by onchocerciasis was significantly reduced by the vector control 
activities of the Onchocerciasis Control Programme (OCP) in West Africa (1975–2002) and 
by the community-directed treatment with ivermectin (CDTi) under the African Programme 
for Onchocerciasis Control (APOC) in sub-Saharan Africa and parts of West Africa (1995–
present) [39]. In Latin America, the Onchocerciasis Elimination Program for the Americas 
(OEPA) implemented since 1993 has brought the disease close to elimination. Colombia and 
Ecuador announced the elimination of onchocerciasis after WHO verification in 2013 and 
2014, respectively [40,41]. Treatment has also been stopped in seven foci in Guatemala and 
Mexico where it has been replaced by surveillance to detect possible recrudescence [42]. 
Regional elimination in Latin America is expected to be achievable by 2020if the regular 
treatment of a sufficient proportion of the nomadic Yanomami in the border area between 
Brazil and Venezuela can be achieved [43].In Yemen, onchocerciasis is endemic in a limited 
number of communities. Elimination in the near future is considered technically feasible, and 
a national action plan aiming at elimination by 2015 was developed in 2010 [44]. Currently, 
(image: WHO, 2013) 
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political instability and security concerns that limit access to endemic areas hamper its 
implementation [45].  
Studies in Mali and Senegal have proved the feasibility of onchocerciasis elimination through 
ivermectin treatment in some hyper-endemic foci in West Africa [2,46]. This has provided 
additional momentum and arguments for a shift in the strategic goal from control to 
elimination also in Africa. 
 
Study rationale and design 
Research needs 
The decision to invest in elimination and eradication efforts should be informed by broad 
assessments considering biological and technical feasibility, financial and economic costs, 
health and economic gains, capacity of and impacts on health systems, and societal and 
political will to cooperate [47]. To assess these broad aspects, a working group at the Ernst 
Strüngmann Forum suggested developing and analyzing eradication/elimination investment 
cases (EIC) [47]. The EIC approach is an assessment addressing all three fundamental 
economics  questions: 1) the ‘‘What’’ question, that compares the feasibility and potential 
broad consequences of remaining in control mode and moving toward elimination and 
eradication; 2) the ‘‘How’’ question,’’ assessing which interventions or strategies should be 
adopted by which stakeholders, how much resources would be required, and how they could 
be mobilized; and 3) the ‘‘for Whom’’ question, assessing who would benefit from 
interventions in terms of health and economic gains and the likely impact on equity and 
fairness. Tediosi and colleagues have examined the approach with focus on three NTDs 
including onchocerciasis [48]. In this PhD thesis, the broad aspects associated with the 
investment in the elimination and eradication of onchocerciasis are examined. 
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Goal 
The overall goal of this research is to examine the feasibility of the elimination and eradiation 
of onchocercias is through the analysis of costs, health and economic benefits, potential 
impacts on health systems, and economic inequality, and provide an evidence base to national 
and global policymakers for informed decision making.  
Aims 
The aims of this PhD thesis are: 
 To develop scenarios of control, elimination, and eradiation  
 To estimate the timelines and needs of treatment for each scenario 
 To estimate financial and economic costs associated with each scenario 
 To evaluate health impacts associated with each scenario 
 To evaluate economic impacts associated with each scenario 
 To assess potential impacts on health systems from the goal shift from control to 
elimination and eradication 
 To evaluate economic inequality associated with onchocerciasis 
Objectives 
Objective 1: Control, elimination, and eradication scenarios 
 To describe all required activities and resources that are expected to lead to the goals 
of control, elimination, and eradication based on current standard practice, the results 
of large-scale studies, and available historical data and the consultation with a wide 
range of experts including epidemiologists, health economists, national and global 
policymakers, and public health experts 
Objective 2: The timelines and needs of treatment 
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 To identify endemic areas in Africa in need of treatment based on epidemiological 
mapping database 
 To predict expected start years of treatment for potential new projects based on the 
current epidemiology and political situation 
 To predict the required duration of treatment using a dynamical transmission model 
ONCHOSIM 
 To predict expected end years of treatment for ongoing and potential new projects  
 To predict the timelines of treatment phase at the national and regional levels for the 
control, elimination, and eradication scenarios 
Objective 3: Financial and economic costs 
 To predict financial and economic costs associated with the control, elimination, and 
eradication scenarios using project budgets with a micro-costing approach 
Objective 4: Health impacts 
 To evaluate the trend of prevalence of clinical symptoms and DALYs using a 
dynamical transmission model for the control, elimination, and eradication scenarios 
Objective 5: Economic impacts 
 To evaluate productivity losses/gains using a human capital approach and welfare 
impacts associated with premature death due to blindness using a full income approach 
for the control, elimination, and eradication scenarios 
Objective 6: Potential impacts on health systems 
 To assess potential impacts on the building blocks of health systems with focus on 
health workforce and the burden of outpatient visits  
Objective 7: Economic inequality 
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 To assess income inequality between meso-/hyper-endemic areas and non-/hypo-
endemic areas using night lights data as a proxy for local income levels 
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Abstract 
River blindness (onchocerciasis) causes severe itching, skin lesions, and vision impairment 
including blindness. More than 99% of all current cases are found in sub-Saharan Africa. 
Fortunately, vector control and community-directed treatment with ivermectin have 
significantly reduced morbidity. Studies in Mali and Senegal proved the feasibility of 
elimination with ivermectin administration. The treatment goal is shifting from control to 
elimination in endemic African regions. Given limited resources, national and global 
policymakers need a rigorous analysis comparing investment options. For this, we developed 
scenarios for alternative treatment goals and compared treatment timelines and drug needs 
between the scenarios. Control, elimination, and eradication scenarios were developed with 
reference to current standard practices, large-scale studies, and historical data. For each 
scenario, the timeline when treatment is expected to stop at country level was predicted using 
a dynamical transmission model, and ivermectin treatment needs were predicted based on 
population in endemic areas, treatment coverage data, and the frequency of community-
directed treatment. The control scenario requires community-directed treatment with 
ivermectin beyond 2045 with around 2.63 billion treatments over 2013-2045; the elimination 
scenario, until 2028 in areas where feasible, but beyond 2045 in countries with operational 
challenges, around 1.15 billion treatments; and the eradication scenario, lasting until 2040, 
around 1.30 billion treatments. The eradication scenario is the most favorable in terms of the 
timeline of the intervention phase and treatment needs. For its realization, strong health 
systems and political will are required to overcome epidemiological and political challenges.   
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Author summary 
River blindness (onchocerciasis) is transmitted by blackflies and causes severe itching, skin 
lesions, and vision impairment including blindness. More than 99% of all current cases are 
found in sub-Saharan Africa where the disease has historically hindered socioeconomic 
development in endemic areas. The treatment goal is shifting from control to elimination in 
Africa as morbidity has significantly decreased through vector control and community-
directed treatment with ivermectin. Studies in Mali and Senegal proved that elimination is 
feasible with ivermectin administration. Given limited resources, national and global 
policymakers need a rigorous analysis of investment options from epidemiological, economic, 
and societal aspects. For this, we developed control, elimination, and eradication scenarios 
and compared treatment timelines and drug needs over the next 30 years. We found that the 
elimination and eradication scenarios would require a shorter treatment phase and a smaller 
amount of ivermectin than the control scenario, mainly because community-directed treatment 
with ivermectin could be ended earlier thanks to regular active surveillance.  
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Introduction 
Elimination of neglected tropical diseases (NTDs) has recently emerged on the global health 
agenda and gained prominence with the release of the global plan to combat NTDs by the 
World Health Organization (WHO) [49]. In 2012,WHO issued a roadmap towards the 
elimination of 17 NTDs [4], and stakeholders from the public and private sectors pledged to 
contribute to the control, elimination, and eradication of ten NTDs through the London 
Declaration on NTDs [5]. The second WHO report on NTDs further elaborated the roadmap 
[45], and the London Declaration follow-up report showed the substantial progress that had 
already been achieved through the stakeholder partnership approach [50].  
One of the NTDs targeted for elimination is onchocerciasis (river blindness). This is a 
parasitic disease caused by filariae that are transmitted by blackflies. Severe itching, skin 
lesions, and vision impairment including blindness are its most notable symptoms. 
Onchocerciasis is endemic in parts of Africa, Latin America, and Yemen, but over 99% of all 
current cases are found in sub-Saharan Africa [1] where onchocerciasis has historically been a 
serious public health problem and hindered socioeconomic development in endemic areas [38]. 
However, many infections are asymptomatic, and vector control and community-directed 
treatment with ivermectin have significantly reduced morbidity. Specifically, the 
Onchocerciasis Control Program (OCP), which was implemented in West Africa from1975 to 
2002, and the African Programme for Onchocerciasis Control (APOC), which has supported 
onchocerciasis control activities in sub-Saharan countries since 1995 and continued the OCP’s 
activities where needed, have decreased the burden of disease to such an extent that it is no 
longer a public health problem in most endemic areas [39]. In Latin America, the 
Onchocerciasis Elimination Program for the Americas (OEPA) implemented since 1993 has 
brought the disease close to elimination. Colombia and Ecuador announced the elimination of 
onchocerciasis after WHO verification in 2013 and 2014, respectively [40,41]. Treatment has 
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also been stopped in seven foci in Guatemala and Mexico where it has been replaced by 
surveillance to detect possible recrudescence [42]. Regional elimination in Latin America is 
expected to be achievable by 2020 if the regular treatment of a sufficient proportion of the 
nomadic Yanomami in the border area between Brazil and Venezuela can be achieved [43]. In 
Yemen, onchocerciasis is endemic in a limited number of communities. Elimination in the 
near future is considered technically feasible, and a national action plan aiming at elimination 
by 2015 was developed in 2010 [44]. Currently, political instability and security concerns that 
limit access to endemic areas hamper its implementation [45].  
Studies in Mali and Senegal have proved the feasibility of onchocerciasis elimination through 
ivermectin treatment in some hyper-endemic foci in West Africa [2,46]. This has provided 
additional momentum and arguments for a shift in the strategic goal from control to 
elimination also in Africa. The decision to invest in elimination and eradication efforts should 
be informed by broad assessments considering biological and technical feasibility, financial 
and economic costs, health and economic gains, capacity of and impacts on health systems, 
and societal and political willingness to cooperate [47]. An approach to such an assessment 
has been proposed in the form of eradication investment cases in 2010 [51]. Tediosi and 
colleagues have examined the approach with focus on three NTDs including onchocerciasis 
[48]. With reference to this approach, we have developed and compared alternative scenarios, 
namely, staying in a control mode versus moving toward elimination and subsequent 
eradication.  
In the present paper, we describe the scenarios to achieve control, elimination, and eradication 
of onchocerciasis, predict the timeline of stopping treatment at country level, and estimate the 
number of required ivermectin treatments over the next 30 years with focus on Africa. 
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Methods 
Development of scenarios 
We developed scenarios, describing all required activities and resources that are expected to 
lead to the goals of control, elimination, and eradication, if effectively implemented and 
sustained as long as required, based on current standard practice, the results of large-scale 
studies, and available historical data. To clearly distinguish these alternative scenarios, we 
referred to the definitions of control, elimination, and eradication endorsed and recommended 
by the WHO Strategic and Technical Advisory Group for NTDs [52]. The ultimate goals of 
the scenarios were defined as follows:  
1) control scenario: continuing community-directed treatment with ivermectin (CDTi) to keep 
the prevalence under a locally acceptable level; 2) elimination scenario: scaling up CDTi to all 
endemic areas where feasible aiming at the reduction of disease incidence to zero; and 3) 
eradication scenario: including strategies and tailored interventions to overcome operational 
challenges in endemic areas with feasibility concerns in addition to CDTi with the aim of 
reducing the global disease incidence to zero (Table 3).   
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Table 3. Proposed scenarios of control, elimination, and eradication of onchocerciasis 
 
Control Elimination Eradication 
Ultimate goal 
Reduce disease prevalence to a 
locally acceptable level 
Reduce the incidence of infection 
to zero in a defined geographical 
area 
Reduce the worldwide incidence of 
infection to zero 
Target areas  
Endemicity Hyper, meso Hyper, meso, hypo Hyper, meso, hypo 
Feasibility 
concerns for 
CDTi1 
Partially targeted Partially targeted Targeted2 
Activities at project level 
Phase 1. Intervention  
1. Community-directed treatment with ivermectin (CDTi) 
Frequency Once a year Once or twice3 a year 
Treatment 
coverage 
65%+ 65%+ 
Start year of 
new projects4 
2014-2015 2014-2015: hyper-/meso-endemic 2014-2015: hyper-/meso-endemic 
 2016-2017: hypo-endemic 
2016-2017: hypo-endemic, with no 
feasibility concerns for CDTi 
  
2020-2021: hypo-endemic, with 
feasibility concerns for CDTi 
Duration 
25 years; another 25 years in case 
of insufficient treatment coverage 
Until the probability of local elimination is ≥ 99%5 
2. Surveillance 
Type 
Epidemiological 1A) Epidemiological  
 1B) Epidemiological and entomological  
Frequency 
Last year of MDA (25th, 50th year) 1A) Every 4 years from 9th year of MDA 
 1B) Last one year 
Site 
10 villages 1A) 10 villages  
 
1B) 20 villages (epidemiological surveys) and 4 catching sites 
(entomological) 
Phase 2. Confirmation of elimination  
Surveillance 
Type NA Epidemiological and entomological  
Frequency 
NA Epidemiological: last one year (3rd year) 
NA Entomological: last two years (2nd and 3rd year) 
Site NA 10 villages and 4 catching sites 
Phase 3. Post-elimination  
Surveillance 
Type NA Epidemiological and entomological 
Frequency 
NA Epidemiological: every 3 years 
NA Entomological: every 4 years 
Site NA 5 villages and 2 catching sites 
1 Political insecurity and co-endemicity with Loa loa. 
2 Hypo-endemic areas with feasibility concerns were included in the eradication scenario only. 
3 Twice a year in new projects in Ethiopia and Uganda where the respective ministries of health announced six-monthly CDTi 
in new projects to bring them in line with ongoing projects [53,54] 
4 Predicted considering APOC’s strategic plan to focus on the onchocerciasis elimination for the next decade 2016-2025 and 
the current epidemiological and political situation 
5 A dynamical transmission model ONCHOSIM [8] was used. 
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From an operational perspective, the control and elimination scenarios are designed to target 
endemic areas where interventions appear feasible without major challenges, whereas the 
eradication scenario is an optimal situation. To make the eradication scenario feasible, 
intensive efforts to improve operational capacity and to increase political willingness would 
be required to overcome epidemiological and political challenges. We assume effective 
treatment would be implemented through tailored approaches in those areas, and regular 
surveillance would be maintained during and after the intervention phase until eradication has 
been verified. 
Referring to the general principles for developing scenarios outlined by Tediosi and 
colleagues [48], the key components of scenarios were identified at project level. Scenarios 
were further revised by verifying the realism of assumptions in consultation with a technical 
advisory group consisting of policymakers, onchocerciasis epidemiologists, public health 
experts, health economists, and donors.  
Key components for developing the scenarios are defined as follows and the developed 
scenarios are described in Table3. 
 
Projects 
In all APOC areas, operational decisions regarding drug administration and monitoring are 
made at the level of projects whose geographic scope ranges from a single district to a whole 
country, and which is under the leadership of a project management team supported by the 
ministry of health, APOC, and NGOs [15]. For the purpose of modeling, all ongoing and 
potential new projects were identified and counted. First, a total of 112 projects were 
identified to be active in 16 APOC countries as of November 2013 based on the APOC 
treatment database (last update: 2012). Additional potential endemic areas in APOC countries 
that are not yet covered by systematic ivermectin treatment and hence not part of existing 
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projects were identified using the Rapid Epidemiological Mapping of Onchocerciasis (REMO) 
map [29] and broken down into 43 potential new projects considering administrative 
boundaries, endemicity, Loa loa(African eyeworm) co-endemicity, and operational feasibility. 
For endemic countries in former OCP countries, a provisional database had been set up with 
the information on geographical location, pre-control endemicity, latest available treatment 
coverage, and population at project level. Treatment areas were divided into hypothetical 
project areas based on administrative boundaries, treatment history, and available impact 
evaluation data. A total of 17 such projects in 10 endemic countries in West Africa were 
identified as ongoing as of November 2013. Two possibly endemic regions in Côte d’Ivoire 
and Ghana had reportedly implemented neither CDTi nor vector control; thus they were 
included as new projects in the database. 
 
Population 
The population for ongoing projects (as of November 2013) was derived from the APOC 
treatment database and the provisional database for former OCP countries. The information 
came from the census conducted by community drug distributors for estimating drug needs. 
For potential new projects, the population was estimated by multiplying the surface area (km
2
) 
of the project with the average population density (per km
2
) across other projects with census 
data within the country. Population over the next 30 years was adjusted for population growth 
rates [55]. 
 
Pre-control endemicity 
For APOC countries, endemicity was classified into four levels based on the highest pre-
control nodule prevalence among adult males in the project area, namely, non-endemic with 
less than 5% nodule prevalence, hypo-endemic between 5% and 20%, meso-endemic between 
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20% and 40%, and hyper-endemic with 40% and above. The pre-control geographic 
distribution of nodule prevalence in each project area was obtained from a map generated 
using a kriging analysis of REMO survey results [56]. For former OCP countries, endemicity 
was classified based on the highest pre-control microfilariae prevalence among the population 
aged 5 years and older, namely, non-endemic with less than 10% microfilariae prevalence, 
hypo-endemic between 10% to 40%, meso-endemic between 40% and 60%, and hyper-
endemic with 60% and above. The pre-control geographical distribution of microfilariae 
prevalence in each project area was obtained from a map generated using a kriging analysis of 
pre-control skin snip survey results. The corresponding ranges of microfilariae prevalence to 
nodule prevalence for the endemicity levels were estimated using a published relationship 
between microfilariae and nodule prevalences[57].  
 
Community-directed treatment with ivermectin 
CDTi was considered the primary treatment approach. Ivermectin is known as a safe drug to 
treat early onchocerciasis symptoms and prevent lasting symptoms from developing to 
blindness. WHO deemed that non-medical people could administer ivermectin after training 
[14,58,59], and APOC formally adopted CDTi in 1997 [60]. In this approach, community 
volunteers play a key role; they conduct a community census to determine the required 
amount of ivermectin, plan when and how to distribute ivermectin in their communities, 
administer the correct dose of ivermectin, manage adverse reactions, keep records, and report 
to health workers. 
 
Target projects 
Target projects were selected for each scenario based on the pre-control endemicity and 
considering the treatment goals. The control scenario included projects with meso- and hyper-
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endemicity considering the goal of keeping the prevalence under a locally acceptable level. 
The fact that surrounding hypo-endemic areas are not treated implies the possibility of 
recrudescence, yet was considered consistent with the aim of control as onchocerciasis is not a 
public health problem in hypo-endemic areas.  
The elimination scenario extended the target projects to include those in hypo-endemic areas. 
The target projects in hypo-endemic areas, however, were confined to those where CDTi is 
expected to be operationally feasible at present or in the near future. To assess the feasibility, 
we referred to the criteria defined by the International Task Force on Disease Eradication and 
agreed in the Ernst Strüngmann Forum [61]. First, for biological and epidemiological 
feasibility, we took into account co-endemicity with L. loa, as severe adverse reactions against 
ivermectin can occur in L. loa patients with heavy infection, and the availability of alternative 
treatment approaches to mitigate the risk. For social and political feasibility, we took into 
account the current political situation and previous project performance.  
The eradication scenario further extended the target areas to include all projects in hypo-
endemic areas assuming locally tailored approaches would be successfully employed in the 
areas with epidemiological and political feasibility concerns. 
 
Frequency of CDTi 
Annual CDTi was assumed considering CDTi had been conducted annually in most projects 
in Africa [39]. Exceptions were new projects in Ethiopia [53] and Uganda [54] where the 
respective ministries of health announced six-monthly CDTi in new projects to bring them in 
line with ongoing projects. 
 
Treatment coverage  
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Treatment coverage was defined as the proportion of the total population residing in a project 
area that was actually treated. APOC suggests that the treatment coverage needs to be higher 
than 65% for the program to achieve effective control of the disease [62]. The average 
treatment coverage over the last three years (2010-2012) was calculated based on the APOC 
treatment database and assumed to be stable at that level for the future duration of CDTi. If a 
project had, on average, not achieved the recommended coverage (65%), we assumed that 
future treatment coverage would be equal to the highest coverage that had been achieved over 
2010-2012. In case historical data were lacking, the national average treatment coverage over 
projects with available data was used. If there were no projects with available historical data 
within a country, the regional average (over national averages available) for the APOC 
regions was used. In the database for former OCP countries, only the latest treatment coverage 
data were available and were used as the expected treatment coverage. The treatment 
coverage data in the former OCP countries were higher than 65%, and we used the national 
average for new projects. 
 
Start year of CDTi 
The historical start years of ongoing projects were obtained from the APOC treatment 
database. For projects yet to be started, a start year was predicted based on APOC’s strategic 
plan to focus on onchocerciasis elimination for the next decade 2016-2025 [63], the current 
epidemiology, and the current political situation. A start year in 2014-2015 was assumed for 
projects in areas without feasibility concerns. For other projects with feasibility concerns, two 
phases were distinguished depending on the current epidemiology. Projects in meso- and 
hyper-endemic areas without feasibility concerns were assumed to start CDTi in 2016-2017, 
because these areas were expected to be given priority considering the regional momentum 
toward onchocerciasis elimination. Projects in hypo-endemic areas with feasibility concerns 
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were assumed to start in 2020-2021, as countries are not likely to postpone treatment by more 
than a decade if they actually aim at eradication. Within each of the three groups, the year 
when a project is expected to start CDTi was determined using a point system in which the 
earlier year is assigned if the project has a higher level of endemicity, a larger population size, 
and a higher expected treatment coverage, considering CDTi is expected to be more urgently 
needed if the disease is more prevalent and more people are exposed to the risk of infection, 
and also more feasible if the treatment compliance is expected to be higher compared to other 
projects. 
 
Duration of CDTi 
In the control scenario, the treatment goal is to control the disease as a public health problem 
by CDTi in all meso- and hyper-endemic areas where there is a high risk of disease. The 
required duration of CDTi was assumed to be 25 years considering that ONCHOSIM 
simulations predict that 25 years of annual ivermectin would achieve elimination in highly 
endemic areas (pre-control microfilariae per skin snip: 50 to 70 mf/s) and all areas with lower 
endemicity levels. Local elimination might occur within 25 years; however, the lack of regular 
surveillance to evaluate progress and verify elimination entails continued CDTi. This is the 
current practice in former OCP regions, that is, CDTi has been continued until now although 
the disease had been eliminated as a public health problem in most areas when OCP stopped 
in 2002. For 14% of the projects targeted in the control scenario, an additional 25 years of 
CDTi was assumed, referring to the results of APOC's most recent evaluations that showed 
unsatisfactory decline in infection levels in 14% of the evaluated projects (5 of 35) due to 
insufficient treatment coverage [64]. The projects requiring this additional CDTi effort were 
randomly selected regardless of the historical treatment coverage, because the APOC 
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evaluation revealed that some projects that had reported high treatment coverage had actually 
failed to maintain the coverage above 65%.  
In the elimination and eradication scenarios, the required duration of CDTi was predicted 
using ONCHOSIM which uses a stochastic model to simulate the life events of human 
individuals and inhabitant parasites and a deterministic model to simulate the fly dynamics 
and the development of parasites in the flies [8]. The model had been fitted to longitudinal 
data from Ghana [65,66], and the predicted trends of infection had been shown to be 
consistent with the actually observed trends in the study sites in Mali and Senegal [2,46,67]. 
The model estimated the years of CDTi required for achieving elimination with a probability 
of 99% by simulating the dynamics of transmission for different settings with regard to pre-
control endemicity and treatment coverage.  
 
End year when CDTi can be stopped 
The year when CDTi can be stopped was estimated by adding the required CDTi duration to 
the start year. If the predicted end year was before 2014, it was delayed to 2015 or 2016, as 
stopping treatment is likely to be cautiously ordered at present despite epidemiological and 
entomological evidence indicating that the threshold for safely stopping CDTi had been 
reached. To date, little practical experience has been collected in this domain, and restarting 
CDTi is considered more challenging than maintaining CDTi a few years beyond the actually 
required time. The number of years for which stopping CDTi was delayed was determined 
using a point system in which the end year was more delayed if the project had a higher level 
of pre-control endemicity, a larger population size, and a lower treatment coverage than other 
projects. The rational was that more solid evidence would be needed to stop CDTi if the pre-
control endemicity had been higher, more people were exposed to the risk of infection, and 
the treatment compliance had been lower than in other projects.  
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Surveillance 
Two types of surveillance were assumed: epidemiological surveillance to track infection 
levels in the population and entomological surveillance to evaluate the infectivity rate of 
blackflies.   
The control scenario included epidemiological surveillance only in the expected end year of 
CDTi to confirm that the infection level was low enough to stop CDTi. This reflects the 
practice under the control mode until recently in most endemic African regions, which do not 
have routine surveillance systems as the goal has been controlling the disease rather than 
eliminating it.  
For the elimination and eradication scenarios, surveillance strategies with three phases were 
defined based on the conceptual and operational framework of onchocerciasis elimination 
with ivermectin treatment developed by APOC [68] and in consultation with the technical 
advisory group. For detailed activities, we referred to a protocol for epidemiological 
surveillance developed by APOC and a guide for post treatment surveillance produced by 
OEPA [69]. In phase 1, the intervention phase, epidemiological surveys are scheduled every 4 
years, starting after 8 years of CDTi. The aim is to assess the impact of treatment and the 
prevalence decline towards elimination thresholds. In the expected final year of CDTi, 
entomological as well as epidemiological surveys are assumed in all endemic areas to confirm 
that elimination thresholds have been reached and CDTi can be safely stopped. Following the 
confirmation that the prevalence and the vector infectivity rate have reached the thresholds to 
stop CDTi, phase 2 starts. Its goal is to confirm local elimination and it lasts at least three 
years. In this phase, epidemiological surveys in the last year and entomological surveys in the 
last two years are planned to confirm that the infection prevalence and the vector infectivity 
rate continue to decrease toward zero and that no recrudescence has occurred. In phase 3, the 
post-elimination phase, surveillance consists of epidemiological surveys every 3 years and 
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entomological surveys every 4 years, but less intensive than in phase 2 (e.g., a smaller number 
of survey sites). The objective is to detect possible recrudescence until eradication has been 
verified. If surveillance detects recrudescence after CDTi had been stopped, phase 1 restarts 
with a focus on the area where the recrudescence had happened and adjacent areas. 
 
Number of required ivermectin treatments 
The number of required ivermectin treatments to achieve the goals of the control, elimination 
and eradication scenarios in endemic African regions was predicted by multiplying the 
estimated population living in endemic areas with the treatment coverage rate and the CDTi 
frequency per year for the required duration of treatment at project level. The capacity of drug 
manufacturers to supply the required number of ivermectin was assumed to be sufficient 
considering Merck’s commitment to donate ivermectin until elimination is achieved globally 
[70]. 
The time horizon for predicting the number of treatments was 2013 to 2045. The start year 
was set considering the most recent version of the APOC databases available for analysis was 
for 2012. The end year was chosen based on the prediction that the last project in the 
eradication scenario would stop CDTi in 2040, and that after stopping CDTi, at least three 
years would be required to confirm local elimination. In the control and elimination scenarios, 
the last projects were expected to continue CDTi beyond 2045.  
In the Table S1, the relevant data regarding the key components of the scenarios, which were 
used for estimating the timelines and the number of required ivermectin treatments, are 
presented at project level. 
 
Uncertainty analysis 
51 
 
Parameters used for the scenario analysis were subject to considerable uncertainty and the 
impact of the uncertainty was examined for the target population, the timeline when CDTi is 
expected to be stopped, and the number of required ivermectin treatments. The impact of a 
single parameter’s uncertainty was assessed with one-way deterministic sensitivity analysis 
(DSA). Considering the final estimates are driven by the joint effects of multiple parameters, 
multivariate probabilistic sensitivity analysis (PSA) was conducted with all the variables 
examined in the one-way DSA. 
The included parameters were population growth rate, treatment coverage, treatment duration, 
CDTi start and end years, and the assumptions for selecting target projects. For DSA, the 
parameter uncertainty ranges were determined based on available data, expert opinion or both. 
For PSA, statistical distributions were chosen considering the characteristics of parameters, 
and fitted to available data. Simulations were run 1,000 times for each scenario. 
 
Population growth rate 
For DSA, the range of national population growth rates from the UN database was used [55]. 
For PSA, a normal distribution was fitted, assuming the range of population growth rates to be 
the 95% confidence interval.  
 
Treatment coverage 
The range of uncertainty about treatment coverage was assumed to be ±10% of the expected 
coverage in DSA. For PSA, a beta distribution was selected considering treatment coverage is 
between zero and one, and fitted to the historical data over 2010-2012. In these sensitivity 
analyses, samples were bounded from 60% to 84%, because control and elimination is not 
expected to be achievable with treatment coverage less than 60%, and the maximum 
achievable coverage is 84% considering around 16% of the population in endemic regions is 
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not eligible for treatment because individuals are less than five years old, pregnant, or 
severely ill. 
Average treatment coverage data and distribution parameters are presented in the Table S2, 
and distribution graphs are shown in the Fig S1. 
 
CDTi duration  
For DSA and PSA, the CDTi duration was linked to the treatment coverage so that it changed 
automatically with the variation of treatment coverage. For the relationship between treatment 
coverage and CDTi duration, we used the results of ONCHOSIM [8] simulations fitted to the 
longitudinal data from Ghana [65,66]. For the control scenario, the CDTi duration changed 
only if the required duration predicted by the ONCHOSIM simulation was longer than 25 
years; otherwise 25 years of CDTi was assumed as previously described. 
 
Delay in starting and ending CDTi 
Starting and ending CDTi could be delayed as political turmoil or operational difficulties arise 
or become exacerbated. Also, CDTi might be stopped later than expected considering APOC 
has strict criteria for ending CDTi (e.g., prevalence of mf < 1% in 90% of surveyed villages) 
[68]. For DSA, the uncertainty range of the delay in starting and ending CDTi was assumed to 
be from 0 to 5 years. For PSA, a gamma distribution that has around 90% of samples between 
0 and 5 was selected (Fig S2).  
 
Selection of target projects 
In the control scenario, 14% of the target projects were assumed to need another 25-year of 
CDTi due to insufficient treatment coverage as previously described. In DSA, the proportion 
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of projects that were expected to have insufficient treatment coverage was varied between 0% 
and 14% under the control scenario, and in PSA a uniform distribution was used. 
The elimination and eradication scenarios included 18 potential new projects in hypo-endemic 
areas (Table S1). Onchocerciasis mapping based on REMO surveys has been largely 
completed in the APOC countries [29]. However, nodule palpation may give false positive 
results in non-endemic areas, while most REMO surveys were done more than 10 to 15 years 
ago before the start of CDTi. Recent parasitological surveys to determine the current infection 
status of hypo-endemic areas [71] have shown that, in many of these areas, onchocerciasis is 
no longer endemic. In order to take this into account, the number of new projects in hypo-
endemic areas was varied between 20% and 100% of the total number of potential new 
projects: the lower bound was based on the finding that one of five potential project areas was 
confirmed to be hypo-endemic, and the upper bound based on the possibility that all potential 
hypo-endemic areas could be confirmed to be endemic. For PSA, a uniform distribution was 
used.  
 
Results 
For each scenario, we predicted target areas in endemic African regions and population in 
those areas, the timeline when CDTi is expected to be stopped, and the number of required 
ivermectin treatments. 
 
Target areas and population 
The control scenario targeted hyper-and meso-endemic areas in all endemic African countries. 
Under the elimination scenario, CDTi was extended to hypo-endemic areas where CDTi is 
feasible in addition to hyper-and meso-endemic areas. Countries that include projects with 
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feasibility concerns have been identified to be the Central African Republic, the Democratic 
Republic of the Congo, and South Sudan due to political instability, and Gabon due to the 
high prevalence of L. loa in areas with a low prevalence of onchocerciasis. In these four 
countries, hypo-endemicity areas were therefore excluded from the elimination scenario. The 
eradication scenario targeted all hyper-, meso-, and hypo-endemic areas. The endemic 
countries in Africa were categorized into two control programs in which they participate or 
participated, APOC and OCP, respectively (Table 4). 
 
Table 4. Endemic countries in Africa 
Program Endemic countries 
APOC 
Angola, Burundi, Cameroon, the Central African Republic*, Chad, Congo, the Democratic 
Republic of the Congo*, Equatorial Guinea, Ethiopia, Gabon*, Liberia, Malawi, 
Mozambique**, Nigeria, South Sudan*, Sudan, Tanzania, Uganda (total 18 countries) 
Former OCP 
Benin, Burkina Faso, Côte d'Ivoire, Ghana, Guinea, Guinea Bissau, Mali, Senegal, Sierra 
Leone, Togo (total 10 countries) 
* countries with epidemiological or political insecurity issues 
** non-endemic with possible exception of small border areas with Malawi and Tanzania 
 
The control scenario included 27 countries, and potential new projects were predicted to cover 
around 3% of the total population in the entire target area, or 4.7 million of 144 million (Fig 
14). The elimination scenario included the same 27 countries, and new projects were predicted 
to cover at most 17% of the population in the entire target area (167 million). Depending on 
the number of new projects in potential hypo-endemic areas, the population in new project 
areas ranged from 12.1 million to 27.8 million (7% and 17%). The eradication scenario 
included one more country, Gabon, and the total population in the entire target area was 
estimated at around 176 million of which 21% at maximum live in new project areas with a 
range of 12.1 million to 36.5 million people (7% to 21%) depending on the number of new 
projects in potential hypo-endemic areas.  
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Figure 14. Total population living in ongoing and potential new project areas in endemic 
African countries (numbers, % of total population in endemic regions), 2014 
 
 
Expected year when CDTi can be stopped 
In the control scenario, most endemic countries outside West Africa were predicted to 
continue CDTi beyond 2045 (Fig 15). The most influential parameter determining the 
expected year of ending CDTi was the extension of treatment duration due to insufficient 
treatment coverage (Fig 16). For the elimination and eradication scenarios, the final year of 
CDTi represents the year of ending the intervention phase at country level assuming no 
recrudescence would occur. In the elimination scenario, all endemic countries except the four 
countries with feasibility concerns were expected to finish the intervention phase by 2028 at 
the latest and those four countries were expected to continue CDTi beyond 2045 (Fig 15). In 
the eradication scenario, all endemic countries were expected to reach the end of the 
intervention phase by 2040 assuming sufficient treatment would be delivered sustainably in 
the four countries with epidemiological and political concerns. For the elimination and 
eradication scenarios, one-way DSA (Fig 16) showed that any delay in starting and ending 
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CDTi and low treatment coverage would result in the intervention phase to end later than 
expected; on the contrary, high treatment coverage would expedite the progress of the 
intervention phase and lead to an earlier end of the intervention phase. 
 
Figure 15. Years when CDTi is expected to be stopped in endemic African regions 
 
 
Figure 16. One-way deterministic sensitivity analysis for the years when CDTi is 
expected to be stopped in endemic African regions 
 
(Note: CONTROL also applies to the countries with feasibility concerns in the elimination scenario. 
ELIMINATION excludes countries with feasibility concerns.) 
 
Number of required ivermectin treatments 
The need for ivermectin treatments was concentrated in the first half of the time horizon for 
the elimination and eradication scenarios, as 80% of all potential projects were stopped safely 
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by 2031 and 2025, respectively. In the control scenario, it took until 2038 for the same 
proportion of the total projects to stop CDTi (Fig 17). The cumulative number of required 
ivermectin treatments over 2013-2045 was estimated at 2.63 billion (95% central range: 2.41 
billion-2.99 billion) for the control scenario. Specifically, 1.48 billion (1.51bn-1.57bn) 
treatments were predicted to be required until 2025 and 1.15 billion (0.90bn-1.41bn) 
treatments over 2026-2045 (Table 5). According to the simulation of the elimination scenario, 
the required number of ivermectin treatments over the whole period was around 1.48 billion 
(1.42bn-1.79bn). Compared to the control scenario, the total number of required treatments in 
the elimination scenario was lower by 1.15 billion (44%): 0.45 billion (0.36bn-0.55bn) until 
2025 and 0.69 billion (0.38bn-0.92bn) from 2026 to 2045 (Table 5, Fig 18). The eradication 
scenario required an even smaller number of ivermectin treatments for the whole period, 1.30 
billion (1.18bn-1.51bn), which was 0.18 billion (0.03bn-0.49bn), or 12%, lower than that 
under the elimination scenario and 1.32 billion (0.97bn-1.75bn), or 50%, lower than that 
under the control scenario (Fig 18). In one-way DSA (Fig 19), the most influential parameter 
on the cumulative number of required ivermectin treatments was the delay in ending CDTi in 
all scenarios. For the control scenario, the second most influential parameter was the number 
of projects with extended CDTi duration due to insufficient treatment coverage. For the 
elimination and eradication scenarios, it was the number of potential new projects in hypo-
endemic areas.  
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Figure 17. Cumulative number of ivermectin treatments and annual number of projects 
with ongoing CDTi in endemic African regions, 2013-2045 
 
 
Table 5. Population in target areas and the cumulative number of required ivermectin 
treatments in endemic African regions 
 
Control Elimination Eradication 
2013-2025 
Population living in target areas, 2025 189,958,000 217,377,000 229,557,000 
Cumulative number of required 
ivermectin treatments 
1,480,765,000 1,027,466,000 1,041,229,000 
2026-2035 
Population living in target areas, 2035 238,794,000 273,380,000 289,519,000 
Cumulative number of required 
ivermectin treatments 
859,636,000 367,629,000 249,291,000 
2036-2045 
Population living in target areas, 2045 293,373,000 336,005,000 357,428,000 
Cumulative number of required 
ivermectin treatments 
287,319,000 86,630,000 12,681,000 
 
Figure 18. Difference in the cumulative number of ivermectin treatments between 
scenarios, 2013-2045 
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Figure 19. One-way deterministic sensitivity analysis for the cumulative number of 
ivermectin treatments over 2013-2045 
 
 
Discussion 
The key changes for shifting from the control mode to elimination and subsequent eradication 
are the scale-up of CDTi to hypo-endemic areas and the implementation of regular 
epidemiological and entomological surveys along with ongoing surveillance. For successful 
implementation of these, overcoming the existing feasibility issues related to the co-
endemicity with L. loa, the insecure political situation, and weak health systems will be 
critical. We found that, if this could be accomplished, regional elimination in Africa could be 
achieved as early as 2040, and consequently all endemic countries including Latin Americas 
and Yemen would be in the post-elimination phase until eradication has been verified. 
We found that achieving elimination would reduce treatment needs by 43% compared to the 
control mode for the period 2013-2045. The driver of this remarkable difference is that CDTi 
could be stopped for the majority of projects based on regular surveillance, while it would 
have to continue for at least 25 years under the control scenario. The eradication scenario is 
predicted to require an even smaller number of ivermectin treatments than the elimination 
scenario, as hypo-endemic areas with feasibility concerns were assumed to have a shorter 
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treatment period through effective treatment via tailored approaches as well as CDTi, whereas 
those areas would be under the control mode in the elimination scenario. This finding implies 
that saved ivermectin drugs could be used for other disease programs, for instance, mass drug 
administration (MDA) for lymphatic filariasis (LF).  
The uncertainty about the target population in the elimination and eradication scenarios was 
mainly driven by uncertainty in the number of potential new projects in hypo-endemic areas, 
as some of those areas might not be actually endemic. Parasitological surveys are therefore 
needed to determine the current infection status of those areas. Setting up a new project 
requires operational planning, human resource mobilization, and startup costs. To move 
towards elimination without delay and to save human and financial resources, the rapid 
mapping of potential hypo-endemic areas should be a priority to confirm areas to set up new 
projects and to develop elimination strategies for those areas. 
The main driver of the number of required ivermectin treatments was the delay in stopping 
CDTi. This finding implies that maintaining high treatment coverage to avoid the extension of 
treatment duration and continuous monitoring and evaluation to decide a proper time to stop 
CDTi would lead to faster elimination and prevent unnecessary efforts to deliver drugs.  
We assumed no recrudescence in our analysis. However, if recrudescence occurs, the duration 
of CDTi would need to be extended, local elimination would be delayed, and the number of 
required treatments would increase. Recrudescence might occur because of human or vector 
migration, interrupted drug distribution due to political instability, and residual transmission 
from not-treated endemic areas due to incomplete or inconsistent geographic coverage. 
We did not adjust for alternative treatment approaches for areas where L. loa is highly 
endemic but onchocerciasis is hypo-endemic. Suggested treatment approaches for these areas 
include anti-Wolbachia therapy with macrofilaricidal drugs, high doses of albendazole, and 
the test-and-treat strategy [72,73]. These approaches would expedite elimination and increase 
the demand for other drugs while reducing the need for ivermectin.  
61 
 
Our modeling did not incorporate the impact of changing the CDTi frequency on the 
treatment duration. It has been suggested to increase the frequency of CDTi to reduce the 
prevalence and transmission of onchocerciasis faster compared to the annual CDTi [64]. A 
recent study by Coffeng and colleagues shows that six-monthly ivermectin treatment could 
reduce the required treatment duration by 40% based on a dynamical transmission model [67]. 
In practice, increasing the CDTi frequency would require collaboration between policymakers, 
health workers, and community volunteers and new strategies on how to mobilize human and 
financial resources, given limited resources and competing health programs. Under the control 
scenario, annual CDTi could mean overtreatment for projects that had more than 15-20 years 
of treatment, for example, some areas in West Africa where ivermectin administration has 
been implemented since the 1990s.  For these areas, less frequent CDTi could be an 
alternative for morbidity control, which would require a smaller number of ivermectin and 
less human and financial resources. However, less frequent CDTi might lead to a loss of local 
expertise, human resources, and community compliance over the time interval without CDTi 
and, consequently, to the decrease of treatment coverage below the required level, which 
could expose the areas to the risk of recrudescence.  
We did not incorporate possible delays in ending CDTi due to co-endemicity with LF. In 
areas where LF is co-endemic with onchocerciasis, an assessment whether both diseases have 
reached the thresholds to stop treatment will be needed in order to stop CDTi. In practice, no 
delay is expected in most cases as MDA for LF, which relies on albendazole and ivermectin, 
usually requires fewer cycles to reach the point of transition to the post-treatment phase. 
However, LF mapping or anti-LF MDA have not started in about a third of the 35 endemic 
countries in Africa [74]. 
We did not take into account the possibility of drug resistance, as no confirmed cases of 
ivermectin resistance have been reported from endemic countries so far. However, if 
ivermectin resistance were to happen as suggested by Bourguinat and colleagues through 
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studies on the effects of ivermectin on the genetics of Onchocerca volvulus [75], the entire 
efforts for onchocerciasis treatment could be endangered, as current strategies heavily rely on 
ivermectin.  
The long time horizon of 2013-2045 poses challenges in predicting technological, political, 
and economic changes. New treatment and diagnostic tools could be game changers in 
achieving elimination. Ivermectin is a microfilaricidal drug which requires many years of 
treatment and has a risk of eliciting severe adverse reactions in L. loa patients. 
Macrofilaricidal drugs that are safe and effective for general population use, are easy to 
administer in communities, and have a shorter treatment period than ivermectin could 
substantially change treatment strategies and expedite elimination. Several macrofilaricidal 
drugs for human use have been or currently are under development, e.g., doxycycline [76], 
emodepside[77], moxidectin[78], and flubendazole[79]. The need for diagnostic techniques 
that are capable of detecting infections early, are easy to use in the field, and are affordable 
would greatly facilitate surveillance when early detection of new infections is paramount. The 
skin snip method, currently the most common diagnostic method, has low sensitivity for 
detecting very light infections, and can result in a delay in detecting recrudescence. Several 
diagnostic techniques, e.g., OV-16 (ELISA and Rapid Test) and the DEC patch test [80,81], 
that may prove more sensitive and practical, have been developed. Unexpected political unrest 
might hamper the elimination programs, as it interrupts interventions and weakens political 
support. Industrialization along with economic growth may have a significant impact. For 
instance, the construction of dams can flood existing breeding sites of blackflies or create new 
ones, and deforestation can greatly alter the composition or density of blackfly populations.  
Political will across the whole spectrum of stakeholders from global and national 
policymakers to community members will be particularly critical during the “last mile” 
towards elimination and subsequent eradication [36]. Countries sharing borders spanning 
endemic areas would need to effectively collaborate to enable prompt responses to or prevent 
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possible recrudescence. Regular meetings have been held between Guinea/Sierra 
Leone/Liberia, Togo/Benin, and Benin/Nigeria [82], and this proves such mechanism can 
work. Similar collaborative relationships would need to be fostered for other endemic 
countries. APOC has announced that it would transform to a new regional entity by 2016 that 
would  support integrated country-driven programs to eliminate onchocerciasis, LF, and other 
preventive chemotherapy NTDs (soil-transmitted helminthiasis, schistosomiasis, trachoma) in 
Africa [83,84]. Successful launching of this new regional entity might provide a more 
collaborative environment for sustainable interventions and post-treatment surveillance for 
NTDs in the region. Continuous support from community members is essential for 
onchocerciasis elimination in Africa. National policymakers would need to keep empowering 
community drug distributors, as their role is critical for successful CDTi and will continue to 
be so until eradication has been achieved.  
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Abstract 
Background Onchocerciasis (river blindness) is a parasitic disease transmitted by blackflies. 
Symptoms include severe itching, skin lesions, and vision impairment including blindness. 
More than 99% of all cases are concentrated in sub-Saharan Africa. Fortunately, vector 
control and community-directed treatment with ivermectin have significantly decreased 
morbidity, and the treatment goal is shifting from control to elimination in Africa.  
Methods We estimated financial resources and societal opportunity costs associated with 
scaling up community-directed treatment with ivermectin and implementing surveillance and 
response systems in endemic African regions for alternative treatment goals – control, 
elimination, and eradication. We used a micro-costing approach that allows adjustment for 
time-variant resource utilization and for the heterogeneity in the demographic, 
epidemiological, and political situation.  
Results The elimination and eradication scenarios, which include scaling up treatments to 
hypo-endemic and operationally challenging areas at the latest by 2021 and implementing 
intensive surveillance, would allow savings of $1.5 billion and $1.6 billion over 2013−2045 as 
compared to the control scenario. Although the elimination and eradication scenarios would 
require higher surveillance costs ($215 million and $242 million) than the control scenario 
($47 million), intensive surveillance would enable treatments to be safely stopped earlier, 
thereby saving unnecessary costs for prolonged treatments as in the control scenario lacking 
such surveillance and response systems. 
Conclusions The elimination and eradication of onchocerciasis are predicted to allow 
substantial cost-savings in the long run. To realize cost-savings, policymakers should keep 
empowering community volunteers, and pharmaceutical companies would need to continue 
drug donation. To sustain high surveillance costs required for elimination and eradication, 
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endemic countries would need to enhance their domestic funding capacity. Societal and 
political will would be critical to sustaining all of these efforts in the long term.
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Author summary 
River blindness (onchocerciasis) is a parasitic disease transmitted by blackflies. Symptoms 
include severe itching, skin lesions, and vision impairment including blindness. More than 99% 
of all cases are concentrated in sub-Saharan Africa. Fortunately, vector control and 
community-directed treatment with ivermectin have significantly decreased morbidity, and 
the treatment goal is shifting from control to elimination in Africa. To inform policymakers’ 
and donors’ decisions, we estimated financial resources and societal opportunity costs 
associated with alternative treatment goals – control, elimination, and eradication. We found 
that rapid scale-up of ivermectin treatment for elimination and eradication would result in 
substantial cost-savings in the long term as compared to staying in a control mode, because 
regular active surveillance would allow treatments to end earlier, thereby saving the economic 
costs of community volunteers and donated ivermectin. To realize cost-savings, policymakers 
should keep empowering community volunteers, and pharmaceutical companies would need 
to continue drug donation. To sustain high surveillance costs required for elimination and 
eradication, endemic countries would need to enhance their domestic funding capacity. 
Societal and political will would be critical to sustaining all of these efforts. 
68 
 
Introduction 
The treatment goal for onchocerciasis (river blindness) has shifted from control to elimination 
as shown by the World Health Organization’s (WHO’s) roadmap for neglected tropical 
diseases (NTDs) and the London Declaration on NTDs in 2012[5,85]. Onchocerciasis is a 
parasitic disease transmitted by blackflies, and notable symptoms include severe itching, skin 
lesions, and vision impairment including blindness. Those affected by onchocerciasis suffer 
negative socioeconomic consequences as a result of their symptoms [68]. The disease is 
endemic in parts of Africa, Latin America, and Yemen, and more than 99% of all cases are 
concentrated in sub-Saharan Africa [39]. In Africa, morbidity caused by onchocerciasis was 
significantly reduced by the vector control activities of the Onchocerciasis Control 
Programme (OCP) in West Africa (1975–2002) and by the community-directed treatment 
with ivermectin (CDTi) under the African Programme for Onchocerciasis Control (APOC) in 
sub-Saharan Africa and parts of West Africa (1995–present) [39]. Studies of foci in Mali, 
Senegal, and Uganda have proved that eliminating onchocerciasis through ivermectin 
administration is feasible for amenable epidemiological settings under effective treatments 
and surveillance [2,3].  
Onchocerciasis elimination and subsequent eradication will generate health benefits by 
reducing the incidence of infection to zero, first in a defined area and then globally. These 
benefits would be higher than those of staying in a control mode that keeps disease prevalence 
at a locally acceptable level. In addition to epidemiological evidence, national and global 
policymakers must consider economic, social, and political aspects when deciding whether to 
invest in elimination in settings with limited resources and competing health priorities. To 
assess these broad aspects, a working group at the Ernst Strüngmann Forum suggested 
developing and analyzing eradication/elimination investment cases[47]. Tediosi and 
colleagues examined the suggested approach focusing on three NTDs including 
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onchocerciasis [48]. Referring to this study, Kim and colleagues defined investment options 
for onchocerciasis as scenarios, and compared the respective timelines and needs for treatment 
in endemic African countries[6]. Each scenario consists of strategies of treatments and 
surveillance – epidemiological surveillance to track the infection levels in human and/or 
entomological surveillance to track the infectivity rates of blackflies.  
Control scenario: to reduce disease prevalence to a locally acceptable level (i.e., microfilaria 
prevalence≤40% or community microfilarialload≤5mf/s [68]), all endemic African countries 
implement annual CDTi in hyper- and meso-endemic areas, and after at least 25-years of 
CDTi, conduct epidemiological surveillance to confirm that CDTi can be safely stopped 
(former OCP projects having implemented regular surveillance continue their surveillance 
strategies). 
Elimination scenario: to reduce the incidence of infection to zero in a defined area, all 
endemic African countries except those with epidemiological and political challenges 
implement annual or biannual CDTi, and conduct regular active epidemiological and 
entomological surveillance to evaluate epidemiological trends, to decide a proper time to stop 
CDTi, and to detect and respond to possible recrudescence. 
Eradication scenario: to reduce the incidence of infection to zero in Africa, which would 
lead to global eradication, all endemic African countries implement not only annual or 
biannual CDTi but also locally tailored treatment strategies to deliver sustainable treatments 
to areas with operational challenges, and implement regular active epidemiological and 
entomological surveillance to evaluate epidemiological trends, to decide a proper time to stop 
CDTi, and to detect and respond to possible recrudescence. 
We estimated financial resources and societal opportunity costs for endemic African countries 
(Table 6) associated with the control, elimination, and eradication scenarios to support 
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policymakers’ and donors’ informed decisions and provide a basis for further economic 
evaluation of the elimination and eradication of onchocerciasis.  
Table 6. Endemic African countries: GDP per capita, health expenditure (total, out of 
pocket), population living in endemic areas 
Country Program 
GDP per capita, 
2012  
Total health 
expenditure (THE), 
2012 (% of GDP) 
Out-of-pocket 
health expenditure, 
2012 (% of THE) 
Population living in 
endemic areas, 2014 
Angola APOC $5,539 3.47% 26.69% 2,640,000 
Benin former OCP $751 4.49% 44.26% 3,585,000 
Burkina Faso former OCP $652 6.17% 36.36% 230,000 
Burundi APOC $251 8.13% 28.27% 1,613,000 
Cameroon APOC $1,220 5.13% 62.65% 9,040,000 
Central African Rep. APOC $479 3.76% 45.57% 2,150,000 
Chad APOC $1,035 2.81% 66.43% 2,182,000 
Congo, Dem. Rep. APOC $418 5.59% 32.48% 43,633,000 
Congo, Rep. APOC $3,154 3.16% 25.07% 1,475,000 
Côte d’Ivoire former OCP $1,244 7.06% 55.83% 2,359,000 
Equatorial Guinea APOC $22,391 4.74% 43.53% 88,000 
Ethiopia APOC $467 3.83% 41.22% 12,276,000 
Gabon APOC $10,930 3.47% 41.41% 85,000 
Ghana former OCP $1,646 5.17% 28.72% 2,535,000 
Guinea former OCP $493 6.30% 66.62% 3,332,000 
Guinea-Bissau former OCP $494 5.86% 43.18% 195,000 
Liberia APOC $414 15.53% 21.22% 3,169,000 
Malawi APOC $267 9.16% 12.58% 2,261,000 
Mali former OCP $696 5.82% 60.73% 5,146,000 
Mozambique APOC $570 6.42% 5.04% 67,000 
Nigeria APOC $2,742 6.07% 65.88% 55,255,000 
Senegal former OCP $1,023 4.96% 34.14% 187,000 
Sierra Leone former OCP $633 15.08% 76.23% 3,320,000 
South Sudan APOC $974 2.55% 56.70% 7,307,000 
Sudan APOC $1,695 7.25% 73.68% 657,000 
Tanzania APOC $609 6.99% 31.75% 3,536,000 
Togo former OCP $589 8.64% 41.08% 3,172,000 
Uganda APOC $551 7.97% 49.33% 4,473,000 
Average (SD)  $2,212 ($4,507) 6.27% (3.10%) 43.45% (18.25%) 
6,285,000 
(12,604,000) 
GDP per capita, 2012 (USD 2012) from World Bank [86]; 
Total health expenditure (THE), 2012 (% of GDP) from World Bank [87]; 
Out-of-pocket health expenditure, 2012 (% of THE) from WHO [88]; 
Population living in endemic areas (2014) from APOC treatment database (last update:2012) and UN (population growth 
rates 2013–2014) [9] 
SD: standard deviation 
 
Methods 
We estimated financial costs to predict how much the governments of endemic countries and 
donors would have to pay for implementing the required interventions for alternative 
treatment goals of control, elimination, and eradication, and economic costs to assess societal 
opportunity costs of donated services and goods. The time horizon of the analysis was from 
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2013 to 2045, based on the predicted timeline for reaching the post-elimination phase in 
endemic African regions [6].  
There are different methods for estimating health intervention costs, ranging from micro-
costing (bottom-up approach) to gross-costing (top-down approach) [89]. We used a micro-
costing method to more precisely estimate time-variant resource utilization depending on 
epidemiological trends and to incorporate the heterogeneity in the demographic, 
epidemiological, and political situation at project level. Fig 20 shows the six steps of the 
micro-costing approach calculating from the cost of a single cost item to the total financial 
and economic cost for a project.  
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Figure 20. Micro-costing method for estimating total costs for a project 
 
We defined the key activities and resources required for onchocerciasis elimination and 
eradication with reference to an APOC report of the technical consultative committee [90], an 
APOC protocol for epidemiological surveillance, and a guide for post-treatment 
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epidemiological and entomological surveillance (developed for the Onchocerciasis 
Elimination Program for the America) [69]. Based on the identified activities and resources, 
we defined cost items under five categories – CDTi, surveillance, capital costs, overhead and 
administrative costs, financial support for (post) conflict endemic areas – and their 
characteristics which include the type (financial or economic), the unit cost, and the time-
variant unit quantity (depending on relevant phases among the three phases of treatment, 
confirmation of elimination, and post-elimination). The details about each step of the micro-
costing approach and the characteristics of cost items are described in the Appendix 2. 
Data 
We obtained 2012 budgets from APOC, approved for onchocerciasis CDTi, that cover 67 of 
all 112 ongoing projects (as of November 2013) in sub-Saharan Africa. All budget documents 
include information on the unit cost and the unit quantity of each resource, demography, 
available human resources (community health workers, community volunteers), and funding 
from the ministry of health, APOC, and non-governmental organizations. These data were 
used as the main sources to estimate financial costs. To estimate economic costs, agriculture 
value added per worker was used as an opportunity cost of community volunteers’ unpaid 
time [91], considering most volunteers are farmers in remote rural areas [92]. The opportunity 
cost of donated ivermectin was $1.5054 per treatment (three 3mg-tablets), based on Merck’s 
suggested drug price of $1.5 per treatment before the donation was decided [7] and on the 
insurance and freight cost of $0.0018 per tablet [93].  
For projects with missing unit costs, we used the national average if relevant unit costs were 
available; otherwise, the regional average (Table7) across available national averages for 
endemic African countries. For the countries that did not have agriculture value added per 
worker, we used the regional average for sub-Saharan Africa [91]. For projects with missing 
data for the determinants of unit quantities (e.g., the ratio of health workers over population, 
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the ratio of volunteers over population), we used the national average if relevant data were 
available; otherwise, the regional average across available national averages for endemic 
African countries. Unit costs and the determinants of unit quantities at the country and 
regional levels are included in the Appendix 2. 
Table 7. Average unit costs across endemic African countries 
Cost items Average(SD)* Unit 
Category 1. Community-directed treatment with ivermectin 
Advocacy/sensitization/mobilization 
Advocacy $4,544.00 ($3,624.71) /project 
Sensitization $3,902.00  ($2,590.79) /project 
Mobilization $0.01 ($0.01) /person  
Support for mobilization from community volunteers% $1.68 ($3.12) /volunteer/day 
Development of IEC& material $2,250.00  ($1,715.51) /project 
Production of IEC& material $0.04 ($0.05) /person 
Supervision/monitoring/evaluation 
Supervision (first 6 years) $18,021.00  ($16,252.27) /project 
Assistance for supervisory visits (7th year+) $2,099.00  ($981.23) /project 
Monitoring $3,622.00  ($3,259.28) /CDTi round 
Evaluation $4,008.00  ($599.03) /CDTi round 
Review meeting $6,746.00  ($5,206.34) /project 
Data management $2,309.00  ($2,287.10) /project 
Community self-monitoring $0.02 ($0.02) /person 
Training 
Training of trainers and health workers $184.00  ($334.96) /health worker 
Training of community volunteers $8.00  ($6.31) /volunteer 
Training of community leaders $9.00  ($7.45) /community 
Drug distribution/management of severe adverse events 
Community registration $12.00  ($10.91) /community 
Census% $1.68 ($3.12) /volunteer/day 
1) In areas without epidemiological challenges 
∙ Delivery of ivermectin $1.51 ($0.00) /treatment 
∙ Ivermectin administration% $1.68 ($3.12) /volunteer/day 
2) In areas with epidemiological challenges (co-endemicity with Loa loa) 
∙ Diagnostic tools (annuitized) $120.00  ($0.00) /set 
∙ Delivery and administration of doxycycline@ $2.50 ($0.00) /6-week treatment 
Management of severe adverse events $2,993.00  ($3,888.44) /project 
Category 2. Surveillance 
Supervision/monitoring/evaluation 
Supervisory visit $2,099.00  ($981.23) /project 
Monitoring $3,622.00  ($3,259.28) /project 
Evaluation $4,008.00  ($599.03) /project 
Review meeting $6,746.00  ($5,206.34) /project 
Data management $2,309.00  ($2,287.10) /project 
Training 
Training of trainers and health workers $184.00  ($334.96) /health worker 
Training of community volunteers (fly/larva-catchers) $8.00  ($6.31) /volunteer 
Training of community leaders $9.00  ($7.45) /community 
Epidemiological survey sampling 
Surveillance trip transportation $21.00  ($16.11) /person/day/site 
Personnel $15.00  ($16.72) /person/day/site 
Field supplies (annuitized) $68.00  ($0.00) /set 
Entomological survey sampling 
Personnel $2.41 ($2.14) /person/day/site 
Field supplies (annuitized) $1.85 ($0.00) /set/person/day/site 
Delivery of samples 
Delivery of skin-snip samples from villages to laboratory  
Included in the surveillance 
trip transportation costs 
/site 
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Cost items Average(SD)* Unit 
Delivery of vector samples from catching site to health facility $7.95 ($5.25) /site 
Delivery of vector samples from health facility to MSDC $135.00  ($0.00) /project 
Epidemiological laboratory testing 
Personnel $15.00  ($16.72) /person/day/site 
Laboratory supplies (annuitized) $120.00  ($0.00) /set 
Entomological laboratory testing 
Personnel $9.00  ($0.00) /person/day/site 
Category 3. Capital costs 
Vehicle (annuitized) $3,919.00  ($661.27) /vehicle  
Motorcycle (annuitized) $503.00  ($155.89) /motorcycle 
Bicycle (annuitized) $21.00  ($6.12) /bicycle 
IT equipment and power supply equipment (annuitized) $2,695.00 ($119.06) /set 
Category 4. Overhead and administrative costs 
Maintenance of vehicle $280.00  ($85.71) /vehicle 
Maintenance of motorcycle $84.00  ($25.71) /motorcycle 
Office supplies, communication, top-ups (first 6 years), others $34,151.00 ($24,626.97) /project 
Category 5. Financial support for CDTi and surveillance in (post) conflict endemic areas 
Support for CDTi and surveillance in (post) conflict endemic areas# $1,052,363.00 (NA) /endemic African regions 
* Average unit costs across national averages for endemic African countries with budgets available 
% Agriculture value added per worker [91], 2012 GDP per capita [86] 
& IEC: Information/Education/Communication 
@ Data from Wanji et al. 2009 [94] 
# Based on the APOC budget plan for 2008-2015 and Sightsavers’s strategic plan for 2011-2021 [95,96] 
Note: all capital costs for non-disposable goods were annuitized with 3% over six years. 
 
Cost estimation 
Financial costs 
From an operational perspective, financial costs consist of those of CDTi and of surveillance. 
At project level, we multiplied the unit cost with the unit quantity for each cost item and every 
year. Costs of capital goods were annuitized over a useful time of each item with 3%. We 
assumed the useful time to be six years based on the capital-goods replacement policy 
specified in Burundi’s budget document. We aggregated the costs across cost items relevant to 
CDTi and surveillance separately. We split the capital and administrative costs (for the years 
when both CDTi and surveillance were conducted) and the financial support costs for (post) 
conflict areas (over the entire time horizon) equally between CDTi and surveillance. To 
estimate annual financial costs, we added the CDTi and surveillance costs (Fig 20).  
Economic costs 
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Economic costs consist of those of community volunteers, who play a central operational role 
in CDTi[92], and of ivermectin, the main drug for CDTi and donated by Merck. For each 
project, we estimated annual economic costs of community volunteers by multiplying the 
daily agriculture value added per worker with the number of required community volunteers 
(population multiplied by the ratio of volunteers over population), the required volunteering 
days, and the number of CDTi rounds per year. We used the multi-country survey by 
McFarland and colleagues [97] to identify the main activities of volunteers and the required 
days. Three main activities were administering ivermectin (17.8 days), supporting health 
workers for mobilization (5.5 days), and doing census to update the treatment registers (4.6 
days). As community mobilization would be required until elimination is confirmed, we 
included the economic costs of supporting health workers for mobilization in both phases for 
treatment and the confirmation of elimination.  
To estimate annual economic costs of donated ivermectin, we multiplied the drug and delivery 
cost per treatment with the number of required treatments (population multiplied by treatment 
coverage and the number of CDTi rounds per year). To estimate annual economic costs for a 
project, we summed the annual economic costs of community volunteers and donated 
ivermectin (Fig 20).  
Total costs 
To estimate annual total costs, we summed annual financial and economic costs. To estimate 
total costs over the entire time horizon, we summed annual costs from 2013 to 2045 with 
discounting (Fig 20). The discount rate to account for time preference was 3%.  
All costs were reported in 2012 US dollars (USD). Local currency before 2012 was inflated 
using country-specific inflation rates [98] and converted to USD using exchange rates [99].  
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Uncertainty analysis 
We conducted sensitivity analysis to assess the robustness of results to parametric 
uncertainties. The parameters included either cost items for which unit costs were missing for 
more than one third of total projects or total countries with available budgets. Also the 
parameters included the time-variant determinants of unit quantities: population living in 
endemic areas, the number of required treatments (determined by population, treatment 
coverage linked to required treatment duration, and possible delay in starting and ending 
treatments), the number of required community volunteers (determined by population and the 
ratio of community volunteers over population), and the number of required community 
health workers (determined by population and the ratio of community health workers over 
population). For probabilistic sensitivity analysis (PSA), we attached statistical distributions 
to the cost items and the determinants of unit quantities, and fitted to relevant data. We 
conducted one-way sensitivity analysis to examine the impact of parameters related to CDTi 
performance, the cost items with high uncertainty, and discount rates on total costs. We also 
simulated multivariate PSA to examine the joint effects of uncertainties about all selected 
variables on total costs. Appendix 2 describes the methodological details of the sensitivity 
analysis. 
 
Results 
Total costs 
Total financial and economic costs would be concentrated in the early stage during which 
treatments are scaled up to remaining endemic areas, and decrease as the treatment phase 
nears the end (Fig 21). In endemic African regions, total financial and economic costs over the 
period 2013−2045 would be $4.3 billion (95% central range: $3.9 billion[bn]−$5.0bn) for the 
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control scenario, $2.9 billion ($2.6bn−$3.4bn) for the elimination scenario, and $2.7 billion 
($2.4bn−$3.2bn) for the eradication scenario. That is, switching from control to elimination 
and eradication would lead to cost-savings of $1.5 billion ($1.0bn−$1.9bn) and $1.6 billion 
($1.2bn−$2.1bn), respectively (Fig S3). The eradication scenario would lead to cost-savings 
of $144 million (-$25 million[M]−$462M) as compared to the elimination scenario.  
Figure 21. Annual and cumulative financial and economic costs over 2013−2045 for the 
control, elimination, and eradication scenarios 
 
Unit financial and economic cost per treatment for the control scenario would decrease from 
$2.5 to $0.9 over 2013–2045. For the elimination scenario, it would decrease from $2.5 to 
$1.3 until 2035, and increase to $1.6 afterwards. For the eradication scenario, it would 
decrease from $2.5 to $1.5 over 2013–2030, and increase to $3.9 afterwards until the end of 
the treatment phase in endemic African regions (Fig 22). 
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Figure 22. Unit costs per treatment per period for the control, elimination, and 
eradication scenarios, both financial and economic and only financial 
 
Financial costs 
Total financial costs over the period 2013−2045 would be $640 million ($572M−$711M) for 
the control scenario, $650 million ($574M−$751M) for the elimination scenario, and $649 
million ($566M −$745M) for the eradication scenario (Fig 23). That is, the total financial 
costs associated with the elimination and eradication scenarios are slightly lower than those 
associated with the control scenario; however, these cost differences are not robust to 
sensitivity analysis (Fig S4). The main difference between scenarios is the proportion of 
surveillance costs in total costs. Total surveillance costs over 2013–2045 would increase from 
7% ($47M) of total financial costs under the control scenario to 33% ($215M) and 37% 
($242M) under the elimination and eradication scenarios, respectively (Fig 23). 
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Figure 23. Cumulative financial costs of CDTi and surveillance over 2013−2045 for the 
control, elimination, and eradication scenarios 
 
Unit financial cost per treatment for the control scenario would decrease from $0.4 to $0.1 
over 2013−2045. For the elimination scenario, it would stay between $0.4 and $0.5 until 2035, 
and increase to $0.9 afterwards. For the eradication scenario, it would stay between $0.4 and 
$0.5 until 2030, and increase to $3.1 as the treatment phase nears the end in endemic African 
regions (Fig 22). 
Economic costs 
Economic costs would be six times higher than financial costs under the control scenario and 
three times higher under the elimination and eradiation scenarios. Total economic costs over 
2013−2045 would be $3.7 billion ($3.3bn−$4.3bn) for the control scenario, $2.2 billion 
($2.0bn−$2.7bn) for the elimination scenario, and $2.1 billion ($1.8bn−$2.5bn) for the 
eradication scenario (Fig 24). That is, the total economic costs associated with the elimination 
and eradication scenarios are lower than those associated with the control scenario by $1.5 
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billion ($1.1bn−$1.9bn) and $1.6 billion ($1.2bn−$2.1bn), respectively (Fig S5). Donated 
ivermectin and community volunteers would account for 75% and 25% of the total economic 
costs over 2013−2045 in all scenarios. 
Figure 24. Cumulative economic costs of donated ivermectin and community volunteers’ 
unpaid time over 2013−2045 for the control, elimination, and eradication scenarios 
 
Uncertainty analysis 
One-way sensitivity analysis (Fig 25) shows that, among the parameters related to CDTi 
performance, the delay in ending CDTi (after the infection levels reach the threshold for 
stopping CDTi) is the most influential parameter, leading total costs to increase by $2 billion 
(undiscounted) over 2013−2045 in all scenarios. Among the cost items with high uncertainty 
(based on the number of missing data), the most influential one is the salary top-ups for 
stabilizing new projects in the elimination and eradication scenarios, leading total costs 
(undiscounted) to range from $3.807 billion to $3.847 billion, and from $3.460 billion to 
$3.498 billion, respectively. Increasing the discount rate from 0% to 6% would decrease total 
costs over 2013−2045 by 46% from $6.1 billion to $3.3 billion for the control scenario, by 39% 
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from $3.8 billion to $2.3 billion for the elimination scenario, and by 35% from $3.5 billion to 
$2.2 billion for the eradication scenario.  
Figure 25. One-way sensitivity analysis for cumulative financial and economic costs over 
2013−2045 
 
 
Discussion 
The elimination and eradication scenarios are predicted to generate substantial cost-savings in 
the long run compared to the control scenario. The main factors contributing to cost-savings 
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are the reduction in economic costs of community volunteers and donated ivermectin due to a 
shorter treatment phase as a result of regular active surveillance. This finding implies that the 
saved volunteers’ time and ivermectin can be used for other health programs. Willing 
volunteers and their well-established networks, which have enabled successful 
implementation of CDTi in Africa, could contribute to improving access to primary health 
care in remote rural areas with insufficient human resources. In addition, the saved ivermectin 
drugs could be used for other disease programs, for example, anti-LF mass drug 
administration. To realize these possibilities, policymakers would need to keep empowering 
community volunteers through training and societal or economic appreciation. Also, 
pharmaceutical companies’ continuous commitment to donating drugs would be needed. 
The main operational difference between the elimination/eradication scenarios and the control 
scenario is regular active surveillance. Our analysis suggests that the cumulative financial 
costs for surveillance over 2013−2045 in the elimination and eradication scenarios would be 
five times higher those in the control scenario. This implies that endemic countries would 
need to improve their domestic funding capacity to sustain high surveillance costs to achieve 
elimination, as the post-treatment surveillance period could last beyond 2045 [6] and external 
funding would be temporary. The development and operationalization of new affordable and 
effective diagnostic tools, for example, OV-16 (ELISA and Rapid Test) and the DEC patch 
test under development [80,81], might lead to the savings of surveillance costs. 
The financial unit cost per treatment in the elimination and eradication scenarios would 
increase by factors of respective two and eight as the regional intervention phase nears the end. 
This increase is driven by the reduction in the number of people in need of treatment and 
steady or increasing costs for surveillance and capital goods. Additionally, in the last stage, 
the majority of people in need of treatments are expected to live in areas with epidemiological 
and political challenges [6]. This implies that, in the last mile towards elimination and 
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eradication, political, financial, and societal commitment across a whole spectrum of 
stakeholders will be essential to meet high unit costs and to deliver treatments in challenging 
areas; otherwise, the last mile could become the hardest [36]. Studies based on social choice 
theory and game theory [34,35,100,101] show that the elimination and eradication of 
infectious diseases are public goods that can only be achieved through the coordinated efforts 
of multiple countries. These studies suggest that high benefit-cost ratios associated with 
elimination and/or eradication could incentivize endemic countries to pursue elimination 
and/or eradication, and global donors to finance endemic countries lacking the financial 
capacity. Equity and social justice arguments for elimination and/or eradication [33,102] could 
also complement and strengthen those provided by economic rationality. The role of global 
stakeholders can play a decisive role to overcome national challenges. A study by Shaffer 
suggests that, to prevent potential holdout problems caused by unwilling or unable countries, 
which could hinder elimination and eradication, the centralized efforts led by international 
organizations would be necessary [103]. In line with this, it has been argued that the explicit 
inclusion of NTDs elimination in the Sustainable Development Goals (SDGs) of the United 
Nations (UN) [37,104] would further motivate the commitment of national and global 
policymakers and donors. Societal commitment at local level will be also essential, because 
delivering treatments to operationally challenging areas would require successful drug 
administration by community volunteers and communities’ compliance to treatments. To 
promote such commitment by communities, endemic countries’ continuous investments in 
enhancing the operational capacity of community volunteers and in mobilizing communities 
will be needed.  
The uncertainty analysis showed that the delay in ending CDTi would have the highest impact 
among those related to CDTi performance on total costs. Thus, planning to move towards the 
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post-treatment phase, along with regular monitoring and evaluation to define the proper time 
of stopping treatments, would be important to avoid the delay in ending CDTi.  
The uncertainty analysis also showed that the salary top-ups for stabilizing new projects 
would have the most influence of all cost items on total costs. Many new projects are in 
potential hypo-endemic areas where parasitological surveys are still needed to confirm 
endemicity[71]. This suggests that complete epidemiological mapping should be a priority to 
choose areas to start new projects and to predict required human resources for those projects. 
The results presented in this study should be interpreted considering the limitations of the 
approach and data used. To calculate financial costs for projects without available budgets, we 
relied on national or regional average unit costs which might only approximately represent the 
actual costs in those projects. For economic costs, we assumed agriculture value added per 
worker as an opportunity cost of community volunteers’ unpaid time. However, other studies 
used different proxies such as national minimum wage and GNI per capita [97,105]. We did 
not use national minimum wage, as it was unavailable for 11 of 28 endemic countries [106]. 
We did not use GNI per capita, as it does not represent the income level in remote rural areas. 
In the opportunity cost of donated ivermectin, we did not include tax deduction provided to 
donating manufacturers [7], as the relevant detailed information is proprietary and unavailable.  
There were some other factors that could affect resource utilization, but were not included in 
the analysis. We assumed no recrudescence, because it was difficult to predict when 
recrudescence would happen. If that were to happen, costs would increase because the 
treatment phase would have to be restarted. We did not consider the potential impact of new 
diagnostic and treatment tools, because it was difficult to predict when they would be 
developed and operationalized. If new effective and affordable tools are operationalized, the 
strategies of treatment and surveillance could change, thereby influencing costs. We assumed 
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no unexpected political unrest that could interrupt interventions, and would increase costs to 
restart the interventions. 
Despite these limitations, to our knowledge and based on literature review (see Appendix 2), 
our study is the most up-to-date cost analysis of potential regional elimination strategies in 
Africa. National and global policymakers and donors could use our cost analysis to make 
informed policy decisions and to predict the funding needs for implementing elimination 
programs in Africa. Our cost estimates could also be used by policymakers and researchers to 
compare costs and potential benefits associated with potential elimination strategies in Africa.  
 
Acknowledgements 
We thank the APOC director and his team who kindly shared 2012 approved budgets for 
onchocerciasis projects. We also thank David Bishai (Johns Hopkins University) for his 
advice on the analysis, Amena Briet (Swiss TPH) for the help with the final revision, and all 
members of the technical advisory group for their valuable comments on the analysis. 
87 
 
5 Value of investing in the elimination and eradication of 
onchocerciasis in Africa: the health and economic benefits and 
the impacts on health systems 
 
Young Eun Kim
1,2
, Wilma A. Stolk
3
, Marcel Tanner
1,2
, Fabrizio Tediosi
1,2*
 
 
1 Swiss Tropical and Public Health Institute, Basel, Switzerland 
2 University of Basel, Basel, Switzerland 
3 Erasmus MC, University Medical Center Rotterdam, The Netherlands 
 
 
Email addresses 
YEK: young.kim@unibas.ch 
WS: w.stolk@erasmusmc.nl 
MT: marcel.tanner@unibas.ch 
FT: fabrizio.tediosi@unibas.ch 
 
 
*Correspondence to:  
FabrizioTediosi 
Swiss Tropical and Public Health Institute 
Socinstrasse 57, 4002 Basel, Switzerland 
Email: fabrizio.tediosi@unibas.ch 
Telephone: +41 61 284 8719 
  
88 
 
Abstract 
Background Onchocerciasis (river blindness) is endemic mostly in remote and rural areas in 
sub-Saharan Africa. The treatment goal for onchocerciasis has shifted from control to 
elimination in Africa. For informed decision-making, national and global policymakers need 
evidence on costs, benefits, and risks of investing in elimination initiatives. We evaluated the 
health benefits from the elimination and eradication of onchocerciasis and the potential 
economic and health systems impacts. 
Methods We evaluated health benefits associated with the elimination and eradication 
scenarios using a dynamical transmission model. The impact on workforce and outpatient 
services and the associated costs to both health systems and households were evaluated. We 
also predicted the potential economic impact first in terms of productivity gains using a 
human capital approach and second in terms of welfare gains associated with prevented 
premature deaths using a full income approach. 
Results The elimination and eradication of onchocerciasis would avert 4.3 million and 5.6 
million disability-adjusted life years respectively over 2013–2045. Also the number of 
required community volunteers would be reduced by 45% (10.7 million) and 52% (12.4 
million);and the number of required community health workers by 56% (1.3 million) and 60% 
(1.4 million). The number of outpatient visits would be reduced by 68% (31.6 million) and 92% 
(42.3 million) leading to the savings of outpatient visit costs by $47.5 million and $52.1 
million and the savings of out-of-pocket payments by $31.2 million and $33.5 million. The 
elimination and eradication of onchocerciasis would generate economic benefits, $4.6 billion 
and $5.0 billion respectively in terms of productivity gains and 7.0 billion and $7.4 billion in 
terms of welfare gains.  
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Conclusions The elimination and eradication of onchocerciasis would lead to health and 
economic benefits and relieve the burden on health systems by saving health workforce and 
reducing the number of outpatient visits. This indicates that intensive investment in the early 
stage to scale up the interventions to hypo-endemic areas and operationally challenging areas, 
in addition to meso-/hyper-endemic areas, combined with strengthening the surveillance and 
response systems would eventually save financial and societal opportunity costs, and result in 
the reduction of morbidity and mortality due to onchocerciasis. In addition, this would 
generate substantial economic productivity and welfare gains, foster equity by preventing 
people living in endemic areas from missing social and economic opportunities. 
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Introduction 
Onchocerciasis (river blindness) is a parasitic disease transmitted by blackflies. Notable 
symptoms include severe itching, skin lesions, and vision impairment including blindness. 
The disease is endemic in parts of Africa, Latin America, and Yemen, and more than 99% of 
all cases are found in sub-Saharan Africa [1]. Onchocerciasis in Africa has affected the poor 
population in remote and rural areas, resulting in a negative socioeconomic impact on them. 
Fortunately, morbidity has been significantly decreased in Africa through the vector control 
activities in West Africa under the Onchocerciasis Control Programme (OCP) over 
1975−2002 and through the community-directed treatment with ivermectin (CDTi) in sub-
Saharan Africa and parts of West Africa under the African Programme for Onchocerciasis 
Control (APOC) since 1995 until the present [39]. A study in Mali, Senegal, and Uganda 
proved that onchocerciasis elimination is feasible through ivermectin administration [2,3]. The 
successful control programs and the proved feasibility of elimination have provided national 
and global policymakers and donors with a justification to pursue the elimination of 
onchocerciasis. The treatment goal in Africa has shifted from control to elimination as shown 
by the WHO roadmap for neglected tropical diseases (NTDs) and the London declaration on 
NTDs [4,5]. 
The assessment of the potential impacts of onchocerciasis elimination strategies can provide 
valuable information to national and global policymaker and donors. This assessment should 
consider not only epidemiological evidence but also costs, benefits, and risks, given limited 
resources and competing health priorities. In a recent manuscript, we  developed  control, 
elimination, and eradication scenarios for onchocerciasis that describe required activities to 
achieve the relevant goals, and estimated the timelines of a treatment phase and the number of 
required ivermectin treatments [6].  In another manuscript, we estimated financial and 
economic costs associated with the control, elimination, and eradication scenarios [107]. In 
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this manuscript, we assess the potential value of onchocerciasis elimination and eradication in 
terms of health benefits, health systems impacts, and economic returns to people living in 
endemic areas.  
 
Methods 
The time horizon for our analysis was from 2013 to 2045 based on the predicted timeline of 
the treatment phase in endemic African regions[6]. Health and economic benefits were 
discounted at 3% to account for time preference. Economic benefits were expressed in 2013 
US dollar. 
Scenarios of onchocerciasis elimination and eradication 
To estimate the potential value of investing in onchocerciasis elimination, we used the control, 
elimination, and eradication scenarios (Box 2) developed by Kim and colleagues [6]. The 
elimination and eradication scenarios describe the strategies of treatments and surveillance – 
epidemiological surveillance to assess the infection levels in humans and entomological 
surveillance to evaluate the infectivity rates in blackflies. The control scenario is the 
counterfactual that represents the general practice conducted in Africa under the aim of 
control and against which we assessed the impacts of achieving elimination and eradication. 
The main difference of the elimination and eradication scenarios from the control scenario is 
that treatments are scaled up from meso-/hyper-endemic areas to hypo-endemic and 
operationally challenging areas, accompanied by regular active surveillance. With the scale-
up of treatments, the population living in target areas (2014) would increase from around 140 
million to 170 million−180 million. In most endemic African regions under APOC, 
operational and financial decisions for treatments have been made for a geographical 
implementation unit called project. Each scenario has the database for target areas composed 
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of the list of target projects. The details on the scenarios and population at project level are 
described in Kim et al. 2015 [6]. 
Box2. Brief description of scenarios 
Control scenario: to keep the disease prevalence at a locally acceptable level, annual CDTi is 
implemented for at least 25 years, and afterwards epidemiological surveillance is conducted to 
evaluate whether CDTi can be stopped. 
 
Elimination scenario: to reduce the incidence of infection to zero in a defined area, annual or 
biannual CDTi is implemented, and regular epidemiological and entomological surveillance is 
implemented to track epidemiological trends, to decide a proper time to stop CDTi, and to 
early detect and respond to possible recrudescence.  
 
Eradication scenario: to reduce the incidence of infection to zero in Africa, which would 
lead to global eradication, tailored treatment approaches in addition to CDTi are implemented 
to deliver sustainable treatments to all endemic areas including challenging areas with 
epidemiological and political concerns. Regular epidemiological and entomological 
surveillance is implemented to track epidemiological trends, to decide a proper time to stop 
CDTi, and to early detect and respond to possible recrudescence. 
 
Assessment of health impacts 
To evaluate health impacts from onchocerciasis elimination and eradication, we compared the 
number of cases of severe itching, low vision, and blindness and disability-adjusted life years 
(DALYs) between the control, elimination, and eradication scenarios. To predict the 
prevalence trends of the three symptoms for the period 2013−2045, we ran the simulation 
using a dynamical transmission model (ONCHOSIM [8]), by incorporating the onchocerciasis 
type (savanna or forest), the pre-control endemicity level, the history of treatment coverage, 
and the start year of CDTi at project level, all of which were available from APOC databases. 
The endemicity level (none, hypo, meso, hyper)was defined based on pre-control nodule 
prevalence among adult males for APOC countries and, for former OCP countries, based on 
pre-control microfilariae prevalence among people aged five years and above. For the entire 
time horizon, we assumed that treatment coverage would be stable at the level of average 
treatment coverage over 2010−2012 for APOC countries and, for former OCP countries 
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lacking relevant history data, at the most recent treatment coverage level. If the average 
treatment coverage was below 65%, the required minimum for effective control [10], we used 
the highest treatment coverage achieved during 2010−2012 as the expected treatment 
coverage. For potential new projects, we used the national average treatment coverage and, if 
there was no relevant data, we used the regional average (across available national averages in 
either APOC or former OCP regions). The start years of CDTi were available for all ongoing 
projects (as of November 2013). For potential new projects, we used the predicted start years 
based on donors’ strategic plans and epidemiological and political situations in Kim et al. 
2015 [6]. 
We estimated the number of cases by multiplying the predicted prevalence of each symptom 
for the period 2013−2045 by population living in endemic areas at project level. Population 
for 2011 was available for all projects from APOC REMO (Rapid Epidemiological Mapping 
of Onchocerciasis) database, and we adjusted for country-specific population growth rates 
[55]. 
To compute DALYs, we estimated the years lost due to disability (YLD) by multiplying the 
number of prevalent cases of each symptom by a relevant disability weight, namely, 0.108 for 
severe itching, 0.033 for low vision, and 0.195 for blindness over 2013−2045[11]. And we 
calculated the years of life lost (YLL) by assigning eight years of life-expectancy loss for each 
blindness incidence assuming that blindness causes premature death [12]. 
Assessment of the impacts on health systems 
Eliminating onchocerciasis in endemic African countries would have an impact on health 
systems that are generally weak and characterized by a shortage of health workforce 
especially in remote and rural areas [13]. We assessed the impacts with focus on the 
implications in terms of health workforce and the burden caused by outpatient services. 
94 
 
1) Impact on health workforce 
CDTi has been the primary approach for onchocerciasis treatment and prevention in endemic 
African countries [108]. In CDTi, community volunteers play a central operational role by 
deciding when and how to distribute drugs, administering drugs, managing adverse reactions, 
keeping records, and reporting to health workers [14]. Community health workers train 
community volunteers, monitor and evaluate CDTi performance, and report to health workers 
at higher levels to support informed decision-making [15]. We estimated the number of 
community volunteers and community health workers required to implement CDTi under 
each scenario, by multiplying population living in endemic areas and the respective ratio of 
community volunteers and community health workers over population, adjusting for the 
required CDTi duration. We used population from APOC REMO database adjusted for 
population growth rates over 2013−2045 [55]. The ratios of community volunteers and of 
community health workers over population were available from 2012 budget documents for 
67 of total 112 ongoing (as of November 2013) APOC projects in sub-Saharan Africa. We 
assumed the ratios would be stable until CDTi is ended. For projects without relevant ratios, 
we used the national average ratio and, if there was no national average data, we used the 
regional average ratio (across available national averages among endemic African countries). 
The required CDTi durations for projects were different depending on the surveillance 
strategy of each scenario, mainly because regular surveillance would lead to a shorter period 
of CDTi by tracking infection levels and deciding a proper time to stop treatments. The 
required durations of CDTi for projects were predicted based on ONCHOSIM simulations in 
Kim et al. 2015 [6]. 
2) Impact on outpatient services and associated costs and out-of-pocket payments 
To assess the impact of onchocerciasis elimination on the burden on health systems associated 
with outpatient services, we predicted the number of outpatient visits in endemic areas where 
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CDTi is not implemented for each scenario over 2013−2045. We multiplied the predicted 
number of patients with severe itching and low vision by the health facility utilization rate. As 
a proxy for the health facility utilization rate, we used the average treatment coverage of CDTi 
over 2010–2012 (Table8), assuming people who complied with CDTi would be willing to 
seek care if there is no CDTi. We assumed that people with blindness would not visit health 
facility because blindness is irreversible.  
Table 8. Average treatment coverage over 2010−2012 as a proxy for health facility 
utilization rate 
Country Average treatment coverage (SD) 
APOC countries  
Angola 67.45% (10.66%) 
Burundi 77.02% (3.58%) 
Cameroon 77.94% (4.60%) 
Central African Rep. 80.37% (2.74%) 
Chad 81.00% (0.10%) 
Congo, Dem. Rep. 70.53% (13.39%) 
Congo, Rep. 81.42% (2.43%) 
Equatorial Guinea 70.95% (0.07%) 
Ethiopia 78.80% (4.10%) 
Gabon* 76.42% (6.20%) 
Liberia 77.38% (9.81%) 
Malawi 82.75% (0.48%) 
Mozambique* 76.42% (6.20%) 
Nigeria 79.87% (3.91%) 
South Sudan 60.14% (12.43%) 
Sudan 81.50% (2.71%) 
Tanzania 80.50% (1.21%) 
Uganda 75.17% (11.18%) 
Average 76.42% (6.20%) 
Former OCP countries
#
  
Benin 48.10% (NA) 
Burkina Faso 83.60% (NA) 
Côte d’Ivoire 83.60% (NA) 
Ghana 72.60% (NA) 
Guinea 72.60% (NA) 
Guinea-Bissau 72.60% (NA) 
Mali 72.60% (NA) 
Senegal 77.40% (NA) 
Sierra Leone 80.30% (NA) 
Togo 77.40% (NA) 
Average 74.08% (10.14%) 
*Data were missing. We used the average for APOC countries. 
#History data were unavailable for former OCP countries. The data are the most recent available ones as of November 2013. 
SD: standard deviation 
 
We then estimated potential outpatient service costs by multiplying a country-specific 
outpatient service cost per visit, available in WHO-CHOICE (CHOsing Interventions that are 
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Cost Effective) database (Table 9), by the predicted number of outpatient visits over 
2013−2045.  
Table 9.Outpatient service costs per visit and out-of-pocket payments as percentage of 
total health expenditure for endemic African countries 
Country Outpatient cost per visit, 2013
a
 
Out-of-pocket payments as % of total 
health expenditure, 2012
b
 
Angola $6.93 26.69% 
Benin $1.26 44.26% 
Burkina Faso $1.10 36.36% 
Burundi $0.37 28.27% 
Cameroon $1.90 62.65% 
Central African Rep. $0.76 45.57% 
Chad $1.18 66.43% 
Congo, Dem. Rep. $0.44 32.48% 
Congo, Rep. $3.72 25.07% 
Côte d`Ivoire $1.84 55.83% 
Equatorial Guinea $30.94 43.53% 
Ethiopia $0.62 41.22% 
Gabon $11.46 41.41% 
Ghana $1.26 28.72% 
Guinea $0.96 66.62% 
Guinea-Bissau $0.50 43.18% 
Liberia $0.55 21.22% 
Malawi $0.31 12.58% 
Mali $1.21 60.73% 
Mozambique $0.75 5.04% 
Nigeria $3.92 65.88% 
Senegal $1.58 34.14% 
Sierra Leone $0.77 76.23% 
South Sudan
c
 $2.94 56.70% 
Sudan $2.94 73.68% 
Tanzania $0.92 31.75% 
Togo $1.13 41.08% 
Uganda $1.07 49.33% 
Average (SD) $2.98 ($5.96) 43.45% (18.25%) 
a Data in 2008 local currency from WHO [109]; Adjusted for country-specific inflation over 2009–2013[98] and converted to 2013 USD 
using market exchange rate [99]; Outpatient visit costs exclude drug and laboratory diagnosis. 
b Data from WHO [88].  
c Outpatient service cost per visit was estimated before Sudan was divided, so we used the same as that for Sudan. 
 
In sub-Saharan Africa it is estimated that 23%−40% of total households face catastrophic 
health expenditure [110–112]. The prevalence of out-of-pocket payments is highly correlated 
with catastrophic health expenditure and impoverishment [113,114]. To evaluate the impact 
on the financial protection of households of onchocerciasis elimination and eradication, we 
estimated outpatient service costs paid out of pocket by patients under each scenario, by 
multiplying the predicted outpatient service costs by the percentage of total health expenditure 
paid out of pocket (Table 2) that is inflated by 17% to include transportation costs (based on 
2010 World Health Report [27]).  
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Assessment of economic impacts 
We estimated the potential economic benefits of onchocerciasis elimination and eradication 
using two alternative approaches: one to estimate the economic productivity gains associated 
with the reduction in the prevalence of onchocercal symptoms and another to estimate the 
economic welfare gains associated with additional life-years from prevented premature deaths 
and encompassing broader impacts than labor productivity [19,115]. 
1) Economic productivity gains 
We estimated the economic productivity gains from the reduction in morbidity over 2013–
2045, by multiplying the predicted number of patients with severe itching, low vision, and 
blindness by a country-specific employment rate and a proxy for income losses for each 
symptom under each scenario. We assumed that patients aged from 15 and above would have 
the same probability of being employed as general population (Table10) unless they had 
onchocercal symptoms. We assumed patients aged from 15 to 64 years with severe itching 
would lose 13% of GDP per capita based on the study on the economic impact of onchocercal 
skin diseases in Ethiopia  [21], and patients in the same age group with low vision and 
blindness would lose 38% and 79% of GDP per capita, respectively, based on the study on the 
socioeconomic impact of onchocercal vision impairment in Guinea [22]. Patients aged less 
than 15 years were assumed to have no economic productivity. Patients aged 65 years and 
above were assumed to be half as productive as those aged from 15 to 64 years referring to the 
methods used by Frick, Smith, and colleagues [23,24]. We also estimated the productivity 
gains for informal care-takers (e.g., families and relatives), assuming that one patient with low 
vision and blindness needs one adult care-taker. We multiplied the number of patients with 
low vision and blindness and a relevant proxy for their care-takers’ income losses under each 
scenario. As a proxy, we assumed the care-taker would lose 5% of GDP per capita if the 
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patient has low vision, and 10% of GDP per capita if the patient is blind, referring to the study 
by Smith, Shamanna, and colleagues [24,25]. 
To estimate the economic productivity gains from the reduction in mortality over 2013–2045, 
we multiplied the predicted YLL by GDP per capita, considering blindness causes premature 
death at a fully productive age [26].   
Table 10. GDP per capita and employment rate for endemic African countries 
Country GDP per capita, 2013
a
 Employment rate, 2013
b
 
Angola $5,668 65.24% 
Benin $805 72.17% 
Burkina Faso $684 80.81% 
Burundi $267 76.90% 
Cameroon $1,315 67.49% 
Central African Rep. $333 72.72% 
Chad $1,046 66.59% 
Congo, Dem. Rep. $3,172 66.15% 
Congo, Rep. $1,521 66.10% 
Côte d`Ivoire $454 64.61% 
Equatorial Guinea $20,572 79.76% 
Ethiopia $498 78.93% 
Gabon $11,571 48.88% 
Ghana $1,850 66.11% 
Guinea $527 70.70% 
Guinea-Bissau $504 68.10% 
Liberia $454 59.22% 
Malawi $226 76.69% 
Mali $715 60.59% 
Mozambique $593 77.21% 
Nigeria $3,006 51.89% 
Senegal $1,072 68.62% 
Sierra Leone $809 65.15% 
South Sudan $1,045 64.67%
c
 
Sudan $1,753 45.37% 
Tanzania $695 85.98% 
Togo $636 75.41% 
Uganda $572 74.56% 
Average (SD) $2,234 ($4,252) 68.45% (9.52%) 
a Data from World Bank [116] 
b Adjusted for labor force participation rate, i.e., (1-unemployment rate)*( % of population ages 15 and older that is economically 
active); Unemployment rate from World Bank [117]; Labor force participation rate from World Bank [118] 
c Data were missing. We used data for sub-Saharan Africa from World Bank [117,118] 
 
2) Economic welfare gains  
We estimated economic welfare gains associated with life-year gains from onchocerciasis 
elimination and eradication, by multiplying the predicted YLL by the economic value of one 
additional life-year. We used two alternatives for the value of a life-year, 4.2 times GDP per 
capita estimated for sub-Saharan Africa and 2.3 times GDP per capita for low and middle 
income countries in the study by the Lancet Commissionon Investing in Health[20]. This 
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study used willingness-to-pay studies that survey how much a person is willing to give up 
consumption opportunities to avoid mortality risk to measure the comprehensive impacts of 
disease beyond labor productivity. As the economic value of a life-year in this study was 
discounted at 3% over 12 years, we applied the discount rate to our estimates for the period 
beyond the first 12 years in our time horizon. 
Uncertainty analysis 
We conducted sensitivity analysis to examine the robustness of results to parametric 
uncertainties and assumptions. We conducted one-way deterministic sensitivity analysis (DSA) 
to examine the impact of a single parameter’s uncertainty on the results and to determine 
which parameters are the key drivers. We also conducted probabilistic sensitivity analysis 
(PSA) to assess the robustness of the results to the joint uncertainties about all selected 
parameters. For the PSA, we applied statistical distributions to parameters considering 
parametric characteristics and fitted to available data. Parameters against which we assessed 
the robustness of the results are as follows. 
Health impacts: the expected treatment coverage linked to the required duration of 
treatment, the level of infection and morbidity in hypo-endemic areas relative to meso-
endemic areas, the reduction of life expectancy per blindness incidence, and the 
population growth rate 
Health workforce: the ratio of community volunteers over population, the ratio of 
community health workers over population, the population growth rate, and the possible 
delay in starting and ending CDTi 
Outpatient services and associated costs and out-of-pocket payments: the number of 
patients with severe itching and low vision, the health facility utilization rate, the 
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outpatient cost per visit, the proportion of outpatient visit costs paid out of pocket by 
patients, and the transportation cost 
Economic productivity gains: GDP per capita, the employment rate, the proportion of 
GDP per capita associated with the productivity losses due to severe itching, low vision, 
and blindness 
Economic welfare gains: the predicted YLL 
Further methodological details on PSA, including statistical distributions and data used for 
each parameter, are described in Appendix 3. 
Results 
Health impacts 
The elimination and eradication scenarios would lead to the decrease in the prevalence of the 
onchocercal symptoms and to the consequent reduction of DALYs.  
The prevalence of severe itching in endemic African regions would decrease from 30/1,000 to 
7/1,000 for the control scenario, to 2/1,000 for the elimination scenario, and to less than 
1/1,000 for the eradication scenario over 2013−2045 (Figure 26).The number of patients with 
severe itching would be 231.3 million (95% central range from PSA: 218.4M–295.7M)over 
2013–2045under the control scenario. Switching to the elimination and eradication scenarios 
would lead to the reduction of the number of patients with severe itching by 15% and 
20%respectively, that is, 34.2 million (14.2M−39.9M) and 46.4 million (20.2M−55.8M). The 
prevalence of low vision would decrease from 51/10,000 to 6/10,000 for the control scenario, 
to 4/10,000 for the elimination scenario, and to 3/10,000 for the eradication 
scenario(Figure26). The number of patients with low vision under the control scenario would 
be 33.1 million(31.7M−36.9M) over 2013–2045. Switching to the elimination and eradication 
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scenarios would lead to the reduction of the number of patients with low vision by 4% and 5% 
respectively, that is, 1.5 million (0.2M−1.3M) and 1.8 million (0.4M−1.7M).  The prevalence 
of blindness would decrease from 17/10,000 to 2/10,000 for the control scenario, and to less 
than 1/10,000 for the elimination and eradication scenarios (Figure26). The number of 
patients with blindness under the control scenario would be 11.3 million(10.8M−12.8M) over 
2013–2045. Switching to the elimination and eradication scenarios would lead to the 
reduction of the number of patients with blindness by 6% and 7% respectively, that is, 670 
thousand (34.6k−528.9k) and 778 thousand (87.4k−670.0k). The faster decrease in the 
prevalence of severe itching than that of low vision and blindness is because ivermectin 
treatment can relieve severe itching by killing 99% of microfiliae[68], whereas vision 
impairment is irreversible. 
The elimination and eradication scenarios would avert DALYs by 33%, 4.3 million 
(2.1M−5.5M), and 43%, 5.6 million (2.7M−7.2M), respectively over 2013−2045 as compared 
to the control scenario (Figure 27). 
 
Figure 26. Prevalence of severe itching, low vision, and blindness in endemic African 
regions over 2013-2045 
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Figure 27. Cumulative DALYs averted in endemic African regions over 2013-2045 
 
(Note: The ranges are from PSA. DALYs are discounted with 3%.) 
 
Impacts on health systems 
1) Impact on health workforce 
The total number of required community volunteers for implementing CDTi in endemic 
African regions would be 23.9 million (18.6M−30.4M) over 2013−2045 for the control 
scenario, 13.2 million (10.5M−19.1M) for the elimination scenario, and 11.6 million 
(9.2M−17.5M) for the eradication scenario (Figure28). That is, switching from the control 
scenario to the elimination and eradication scenarios would lead to the reduction of the 
number of required community volunteers by 45% and 52% respectively, that is, 10.7 million 
(5.9M−14.1M) and 12.4 million (6.9M−15.7M).  
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Figure 28.Saved community volunteers and community health workers in endemic 
African regions over 2013-2045, baseline: control scenario 
 
(The ranges are from PSA.) 
 
The total number of required community health workers for implementing CDTi in endemic 
African regions would be 2.3 million (1.6M−3.2M) over 2013−2045 for the control scenario, 
1.0 million (0.8M−1.7M) for the elimination scenario, and 900 thousands (0.7M−1.6M) for 
the eradication scenario (Figure28). Switching to the elimination and eradication scenarios 
from the control scenario would lead to the reduction of required community health workers 
by 56% and 60% respectively, that is, 1.3 million (0.5M−1.9M) and 1.4 million (0.6M−2.0M). 
2) Impact on outpatient services and associated costs and out-of-pocket payments 
The elimination and eradication of onchocerciasis would reduce the burden on health systems 
associated with patients’ visits to health facility due to severe itching and low vision. The 
number of outpatient visits due to those symptoms in endemic African regions would be 46.2 
million (25.7M–58.9M) over 2013−2045 under the control scenario, generating $56.0 million 
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($26.7M–$74.1M) of outpatient service costs which would result in $35.7 million ($17.0M–
$49.4M) of out-of-pocket payments by patients. Switching to the elimination and eradication 
scenarios would decrease the number of outpatient visits by 68% and 92%, that is, 31.6 
million (17.6M–40.3M) and 42.3 million (17.6M–40.3M) (Figure 4). This reduction would 
save outpatient service costs by $47.5 million ($22.4M−$63.3M) and $52.1 million 
($24.3M−$69.5M) respectively and out-of-pocket payments by $31.2 million ($14.6M–
$43.5M) and $33.5 million ($15.7M–$46.4M). 
Figure 29.The savings of outpatient service costs and out-of-pocket payments for 
outpatient visits and the reduced number of outpatient visits in endemic African regions 
over 2013-2045, baseline: control scenario 
 
(The ranges are from PSA.) 
 
Economic impacts 
1) Economic productivity gains 
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The economic benefits measured in terms of productivity gains would be $4.6 billion 
($2.3bn–$6.3bn) for the elimination scenario and $5.0 billion ($2.4bn–$6.8bn) for the 
eradication scenario over 2013–2045 as compared to the control scenario (Figure30). The 
economic productivity gains associated with the reduction in severe itching cases would 
account for 55% of the total; and the reduction in low vision and blindness for 35% and 10% 
respectively. The majority of the productivity gains, 96%, would be associated with patients 
treated and the rest 4% with their care-takers. 
Figure 30.Economic productivity gains in endemic African regions over 2013-2045, 
baseline: control scenario 
 
(The ranges are from PSA.) 
 
2) Economic welfare gains  
The economic benefits measured in terms of welfare gains associated with the life-year gains 
from averted blindness would be, applying the value of a life-year for sub-Saharan Africa (4.2 
times GDP per capita), $7.0 billion ($3.6bn–$9.4bn) for the elimination scenario and $7.4 
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billion ($3.8bn–$9.9bn) for the eradication scenario over 2013–2045as compared to the 
control scenario; and applying that for low and middle income countries (2.3 times GDP per 
capita), $3.9 billion ($2.0bn–$5.1bn) for the elimination scenario and $4.1 billion ($2.1bn–
$5.4bn) for the eradication scenario (Figure 31). 
Figure 31.Economic welfare gains in endemic African regions over 2013-2045, baseline: 
control scenario 
 
(The ranges are from PSA.) 
 
Uncertainty analysis 
The one-way DSA indicates the results are the most sensitive to the following parameters: 
Health impacts: the level of infection and morbidity in hypo-endemic areas relative to 
meso-endemic areas (Figure S7) 
Health workforce: the ratio of community volunteers over population, the ratio of 
community health workers over population (Figure S8, S9) 
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Outpatient services and associated costs and out-of-pocket payments: the number of 
patients with severe itching (FigureS10, S11) 
Economic productivity gains: the number of patients with severe itching (Figure S12) 
Economic welfare gains: the years of life lost due to blindness (Figure S13) 
As the discount rate decreases from 6% to 0%, the results vary from 70% (minimum) to 150% 
(maximum) of the point estimates (Figure S7, S10–S13). 
The 95% central ranges generated from the PSA and reported with the point estimates for all 
results previously (summary in Table 11) indicate that the health and economic benefits and 
the reduction of the burden on health systems from onchocerciasis elimination and eradication 
are robust to the joint uncertainties of relevant parameters.  
Table 11. Summary of key results 
  Elimination vs Control (baseline) Eradication vs Control (baseline) 
Health benefits, 2013–2045   
DALYs averted 4.3 million (2.1m−5.5m) 5.6 million (2.7m−7.2m) 
   
Health systems impacts, 2013–2045   
Health workforce saved   
1) Community volunteers 10.7 million (5.9m−14.1m) 12.4 million (6.9m−15.7m) 
2) Community health workers 1.3 million (0.5m−1.9m) 1.4 million (0.6m−2.0m) 
Outpatients services    
1) Number of outpatients visits reduced 31.6 million (17.6m–40.3m) 42.3 million (17.6m–40.3m) 
2) Outpatient service cost savings $47.5 million ($22.4m−$63.3m) $52.1 million ($24.3m−$69.5m) 
3) Out-of-pocket payment savings $31.2 million ($14.6m–$43.5m) $33.5 million ($15.7m–$46.4m) 
   
Economic benefits, 2013–2045   
Productivity gains $4.6 billion ($2.4bn−$6.2bn) $5.0 billion ($2.7bn−$6.7bn) 
Welfare gains   
Value of a life-year: 4.2 times GDP PC $7.0 billion ($3.6bn–$9.4bn) $7.4 billion ($3.8bn–$9.9bn) 
Value of a life-year: 2.3 times GDP PC $3.9 billion ($2.0bn–$5.1bn) $4.1 billion ($2.1bn–$5.4bn) 
Data: mean (95% central ranges from PSA) 
 
Discussion 
Our study shows that the elimination and eradication scenarios, scaling up treatments from 
meso-/hyper-endemic areas to hypo-endemic areas including those with political insecurity 
and co-endemicity with Loa loa and implementing regular epidemiological and entomological 
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surveillance, would lead to the health and economic benefits and reduce the burden on health 
systems in terms of health workforce and outpatient services. We found that the decrease of 
the prevalence of severe itching would be the main driver of DALYs averted, the savings of 
outpatient service costs and out-of-pocket payments, and the economic productivity gains 
over 2013–2045 under the elimination and eradication scenarios as compared to the control 
scenario, and the reduction of blindness cases would generate life-year gains, thereby leading 
to the economic welfare gains. This study also shows that onchocerciasis elimination and 
eradication would save human resources needed for implementing CDTi, namely community 
volunteers and community health workers. 
Our results should be interpreted considering the limitations of our methodologies. To 
calculate DALYs we used the most recent disability weights from the 2010 global burden of 
disease (GBD) study. The disability weight of blindness has been controversial as it decreased 
by 70% as compared to that in the previous 2004 GBD study (from 0.6 to 0.195). The 
important difference of the 2010 GBD study from the 2004 GBD study is that disability 
weights were measured in terms of health loss, rather than socioeconomic welfare 
loss[11,119]. Thus, the interpretation of averted DALYs needs to be restricted to health gains. 
To calculate YLL we assigned eight years of life-years lost to each blindness incidence. 
However, this could be overestimation assuming life expectancy for general population would 
be stable, because regular annual or biannual ivermectin administration would postpone the 
incidence of blindness to a later age. To estimate the required number of health workforces for 
CDTi, we assumed the current availability of community volunteers and community health 
workers would be sustained until CDTi is safely stopped. However, the availability of these 
health workforces could change depending on political situations and policies and budgets for 
supporting their activities. Also the delay in stopping CDTi due to managerial issues could 
require more workforces than expected. To estimate outpatient service costs we assumed the 
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same proportion of people who complied with CDTi would visit health facility if there is no 
CDTi. However, in real settings, poor road networks and a long distance to health facility 
could hamper people’s access to health facility. To estimate out-of-pocket payments we 
assumed that the proportion of health expenditure paid out of pocket by patients would be 
stable over the entire time horizon; however, it could change depending on how much 
financial protection mechanisms are improved against catastrophic health expenditure. To 
evaluate economic productivity gains we used GDP per capita as a proxy for individual 
productivity. The actual income of people living in endemic areas could be much lower than 
GDP per capita. However, we assumed that the potential productivity of individuals is not 
different between endemic and non-endemic areas. To estimate economic welfare gains we 
used two alternatives 4.2 times and 2.3 times GDP per capita as the value of one additional 
life-year in endemic African regions. However, if the demographic and epidemiological 
settings in endemic African regions change with industrialization over the period 2013−2045, 
the economic value of a life-year would change towards that for high income countries which 
is lower than the two alternatives. In the analysis of economic impacts, we assumed no per 
capita GDP growth for conservative estimation, and this limited the predicted economic 
benefits.  
The elimination and eradication scenarios dominate the control scenario in terms of 
intervention costs and benefits. The cost analysis by Kim and colleagues shows that an 
intensive investment in the early stage to scale up CDTi under the elimination and eradication 
scenarios would lead to the decrease of total financial and economic costs associated with 
treatments and surveillance, and eventually save costs over the period 2013−2045 as 
compared to the control scenario [107]. This result, combined with our results on health and 
economic benefits, indicates that the eradication scenario, followed by the elimination 
scenario, is the most economically favorable among the three scenarios.  
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Shifting the treatment goal from control to elimination and eradication would affect and be 
affected by health systems (Figure 34) which therefore should be strengthened. The mandated 
and critical activity to achieve the elimination and eradication of onchocerciasis is regular 
epidemiological and entomological surveillance which tracks the infection levels in humans 
and blackflies and enables prompt response to recrudescence in the post-treatment phase. 
Only if health information systems are effective and efficient, regular active surveillance 
would be feasible. Strengthening health information systems would require sustainable 
financing, another building block of health systems. Financial costs associated with 
surveillance and response systems are estimated to increase five times over the period 2013–
2045 under the elimination and eradication scenarios than the control scenario [107]. This 
implies that the governments of endemic countries would need to develop financing plans and 
enhance their domestic funding capacity, as surveillance would need to be sustained over the 
long term and external funding would be temporary. Scaling up treatments to achieve 
onchocerciasis elimination and eradication would affect mainly two building blocks of health 
systems, health workforce and medicine, as it would require more community volunteers and 
community health workers and more ivermectin and alternative macrofilaricidal medicines 
(for co-endemic areas with L.loa). However, the elimination and eradication would eventually 
save health workforce and medicine, because the duration of CDTi would be shorter than 
under the control mode [6]. Considering sub-Saharan African countries are expected to face a 
substantial deficit of health workforce by 2030 (WHO report [120]), the saved health 
workforce could be useful for other health care programs. Also the saved ivermectin could be 
used to treat other diseases such as lymphatic filariasis. Governance and leadership will be 
critical to achieve onchocerciasis elimination and eradication which are public goods that can 
be attained only through the collaboration between all stakeholders at community, national, 
regional, and global levels [36,101]. To foster the commitment from communities, national 
policymakers would need to invest in enhancing the capacity of community volunteers and 
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community health workers and mobilizing communities. At national level, policymakers 
would need to develop a long-term strategic policy for the elimination and eradication of the 
disease. To implement the policy effectively, policymakers would need to regularly monitor 
and evaluate the performance of all relevant components including health information systems, 
financing, scaling up treatments, timely drug supply, and human capacity building. Regional 
collaboration between endemic countries would be important when endemic areas span across 
the border areas, as human and vector migration could cause recrudescence. The cooperation 
with global donors and pharmaceutical companies would be needed especially in the early 
stage of elimination and eradication strategies. In this period, endemic countries would need 
higher financial costs, more health workforces, and more medicines as discussed previously. 
Thus, global donors’ continuous funding and pharmaceutical companies’ drug donation will 
be important.  
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Figure 32.Health systems impacts associated with the elimination and eradication of onchocerciasis 
113 
 
6 Income inequality associated with onchocerciasis endemicity 
Background 
Neglected tropical diseases including onchocerciasis are concentrated among low-income 
countries and disadvantaged populations. Social justice consists in fairness and equity in the 
distribution of societal benefits and burdens. Nevertheless, it is challenging to account for the 
ethical importance of the benefits, burdens, and distributions, that are salient in people’s 
experiences of the diseases and related interventions. Thus these aspects are not assessed in 
traditional approaches for health and economic evaluation.  
In this study, to evaluate the potential impacts of onchocerciasis elimination in terms of the 
inequalities in economic conditions at local level, we compared the night light level between 
meso-/hyper-endemic areas and non-/hypo-endemic areas. We used night light data as a proxy 
for local income, because there were no data available on the local economic conditions of the 
endemic areas. Recent studies showed that, despite several limitations,  the night light data 
can be used as a proxy for income at sub- and supranational levels in low income countries 
[28].  
Methods 
We identified meso-/hyper-endemic and non-/hypo-endemic areas using the APOC database 
which were created based on epidemiological surveys and using a geospatial analysis [29,30] 
(Fig 35). We obtained the 2013 night light map [31] and removed the flaring from national 
gas from the map, as gas flare is not related to economic activities [28]. Using the night light 
map (Fig 35), we created a database that contains the light levels (dark−bright: 0−64) at the 
geographic unit of 0.1 by 0.1 degrees, and identified if each unit area is meso-/hyper-endemic 
or non-/hypo-endemic by overlapping the endemicity map. We compared the average light 
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level between meso-/hyper-endemic and non-/hypo-endemic areas using Welch’s unequal 
variances t-test. 
Figure 33.Endemicity and night lights in Africa 
 
 
Results 
The statistical comparison of night light levels shows that the average night light level in 
meso-/hyper-endemic areas (M=0.15, SD=1.46) is significantly lower than that in non-/hypo-
endemic areas (M=0.18, SD=1.93); t(82,117)=2.97, p<0.05. This suggests that, within the 
APOC countries where most of the global cases are found, meso-/hyper-endemic areas are 
likely to have higher poverty levels than non-/hypo-endemic areas.  
Conclusion 
We found that meso-/hyper-endemic areas are likely to poorer than non-/hypo-endemic areas 
assuming night light data as a proxy for local income level. Poverty is not just about low 
income, but goes beyond to the deterioration of individual capabilities to lead their lives and 
accomplish what they value as human beings [32]. Specifically, onchocercal symptoms 
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deteriorate patients’ well-being from psychological, psychosocial, and social aspects [33]. 
These symptoms undermine self-respect due to stigma, teasing, and negative stereotyping, and 
deprive of the opportunities of physical and educational activities and relationships with 
others because of ostracism or the avoidance of infected person. This indicates that the 
elimination and subsequent eradication of onchocerciasis would not only contribute to 
relieving income inequality, but also lead to ethical advantages and social justice.  
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7 Discussion 
Overall significance of research 
This research shows that the elimination and eradication of onchocerciasis will be 
economically dominant over the control of the disease, and also contribute to the social justice 
by relieving economic inequality and preventing social stigma and psychological negative 
impacts on infected persons. The analysis used large datasets on epidemiological mapping, 
the history of treatment coverage(1995–2012) for all 112 ongoing projects as of November 
2013 in sub-Saharan Africa, approved budgets for 67 projects, and night light data for 
endemic African regions. The analysis was not only based on these data, but also used 
rigorous methods: dynamical transmission modelling for the epidemiological analysis, a 
micro-costing method for the cost analysis, human capital and full-income approaches for the 
economic impact analysis, and the spatial analysis of night light data. According to the 
literature review, this research is the first economic evaluation of potential regional 
elimination strategies for onchocerciasis in Africa. The results could be used as a guide for 
national and global policymakers’ informed decision making.  
Key findings 
Control, elimination, and eradication scenarios (objective 1) 
The key changes for shifting from the control mode to elimination and subsequent eradication 
are the scale-up of CDTi to hypo-endemic areas including areas with epidemiological and 
political concerns and the implementation of regular epidemiological and entomological 
surveys along with ongoing surveillance (Chapter 3). For successful implementation of these, 
overcoming the existing feasibility issues related to the co-endemicity with L. loa, the 
insecure political situation, and weak health systems will be critical. 
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The timelines and needs of treatment (objective 2) 
As Chapter 3 describes, this study found that regional elimination in Africa could be achieved 
as early as 2040, and consequently all endemic countries including Latin Americas and 
Yemen would be in the post-elimination phase until eradication has been verified. Also this 
study found that achieving elimination would reduce treatment needs by 43% compared to the 
control mode for the period 2013-2045. The driver of this remarkable difference is that CDTi 
could be stopped for the majority of projects based on regular surveillance, while it would 
have to continue for at least 25 years under the control scenario. The eradication scenario is 
predicted to require an even smaller number of ivermectin treatments than the elimination 
scenario, as hypo-endemic areas with feasibility concerns were assumed to have a shorter 
treatment period through effective treatment via tailored approaches as well as CDTi. This 
finding implies that saved ivermectin drugs could be used for other disease programs, for 
instance, mass drug administration(MDA) for lymphatic filariasis (LF). The main driver of 
the number of required ivermectin treatments was the delay in stopping CDTi. This finding 
implies that maintaining high treatment coverage to avoid the extension of treatment duration 
and continuous monitoring and evaluation to decide a proper time to stop CDTi would lead to 
faster elimination and prevent unnecessary efforts to deliver drugs.  
Financial and economic costs (objective 3) 
The elimination and eradication scenarios are predicted to generate substantial cost-savings in 
the long run compared to the control scenario (Chapter 4). The main factors contributing to 
cost-savings are the reduction in economic costs of community volunteers and donated 
ivermectin due to a shorter treatment phase as a result of regular active surveillance. This 
finding implies that the saved volunteers’ time and ivermectin can be used for other health 
programs. Willing volunteers and their well-established networks, which have enabled 
successful implementation of CDTi in Africa, could contribute to improving access to primary 
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health care in remote rural areas with insufficient human resources. To realize these 
possibilities, policymakers would need to keep empowering community volunteers through 
training and societal or economic appreciation. Also, pharmaceutical companies’ continuous 
commitment to donating drugs would be needed. 
The cost analysis also suggests that the cumulative financial costs for surveillance over 
2013−2045 in the elimination and eradication scenarios would be five times higher those in 
the control scenario. This implies that endemic countries would need to improve their 
domestic funding capacity to sustain high surveillance costs to achieve elimination. 
The uncertainty analysis showed that the delay in ending CDTi would have the highest impact 
among those related to CDTi performance on total costs. Thus, planning to move towards the 
post-treatment phase, along with regular monitoring and evaluation to define the proper time 
of stopping treatments, would be important to avoid the delay in ending CDTi. The 
uncertainty analysis also showed that the salary top-ups for stabilizing new projects would 
have the most influence of all cost items on total costs. Many new projects are in potential 
hypo-endemic areas where parasitological surveys are still needed to confirm endemicity [39]. 
This suggests that complete epidemiological mapping should be a priority to choose areas to 
start new projects and to predict required human resources for those projects. 
Health, economic, and health systems impacts (objective 4–6) 
As Chapter 5 describes, this study shows that the elimination and eradication scenarios, 
scaling up treatments to hypo-endemic areas including those with political insecurities and co-
endemicity with Loa loa in addition to meso-/hyper-endemic areas and implementing regular 
epidemiological and entomological surveillance, would lead to health and economic benefits 
and have impacts on health systems. The analysis found that the decrease of the prevalence of 
severe itching would be the main driver of DALYs averted, the savings of outpatient visit 
costs, and economic productivity gains over 2013–2045 under the elimination and eradication 
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scenarios as compared to the control scenario. As CDTi is scaled up, the prevalence of severe 
itching would decrease faster than those of low vision and blindness, because ivermectin 
treatment can relieve severe itching by killing 99% of microfiliae[68], whereas vision 
impairment is irreversible. Also the life-expectancy gains as a result of prevented blindness 
would lead to substantial welfare gains. This study also found that regular surveillance, 
another main component of the elimination and eradication scenarios besides the scale-up of 
CDTi, would be the main driver of the reduction of required community volunteers and 
community health workers for implementing CDTi, as regular surveillance would enable to 
decide a proper time to stop CDTi and save the workforces from unnecessarily prolonged 
CDTi.  
Economic inequality (objective 7) 
The analysis of economic inequality using night light data as a proxy for local income levels 
(Chapter 6) found that, within the APOC countries where most of the global cases are found, 
meso-/hyper-endemic areas are likely to have higher poverty levels than non-/hypo-endemic 
areas. Poverty is not just about low income, but goes beyond to the deterioration of individual 
capabilities to lead their lives and accomplish what they value as human beings [32]. This 
indicates that the elimination and subsequent eradication of onchocerciasis would not only 
contribute to relieving income inequality, but also lead to ethical advantages and social justice. 
Overall implications 
Economic efficiency and social justice 
The elimination and eradication scenarios dominate the control scenario in terms of 
intervention costs and benefits. The cost analysis shows that an intensive investment in the 
early stage to scale up CDTi under the elimination and eradication scenarios would lead to the 
decrease of total financial and economic costs associated with treatments and surveillance, 
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and eventually save costs over the period 2013−2045 as compared to the control scenario. 
This result, combined with the results on health and economic benefits, indicates that the 
eradication scenario, followed by the elimination scenario, is the most economically favorable 
as compared to the control scenario. Also the value of investing in elimination and eradication 
of the disease would go beyond the economic efficiency to alleviating socioeconomic 
inequalities, because onchocercal symptoms undermine self-respect due to stigma, teasing, 
and negative stereotyping [33]. Thus, elimination and eradication of onchocerciasis would be 
a social intervention that could increase opportunities of self-realization, alleviate poverty, 
and eventually promote socioeconomic equity. 
Health systems 
Shifting the treatment goal from control to elimination and eradication would affect and be 
affected by all building blocks of health systems – health information systems, financing, 
service delivery, human resources, medical technologies/products, governance/leadership – 
which therefore should be strengthened.  
First, health information systems, which serve to collect and analyze data and generate 
information for informed decision-making, would be essential to achieve the elimination and 
eradication of onchocerciasis. Regular epidemiological and entomological surveillance would 
be critical to track the infection levels in humans and blackflies and to promptly respond to 
recrudescence in the post-treatment phase, and these functions would be feasible only if 
health information systems are effective and efficient.  
Strengthening health information system would require sustainable financing. Financial costs 
associated with surveillance and response systems over the period 2013–2045 under the 
elimination and eradication scenarios are estimated to be five times higher than that under the 
control scenario. This implies that the governments of endemic countries would need to 
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develop financing plans and strengthen their domestic funding capacity, as surveillance would 
need to be sustained over the long term and external funding would be temporary. 
Scaling up treatments to hypo-endemic areas to achieve elimination and eradication would 
mainly affect two building blocks of health systems, human resources and medicines, by 
requiring more community volunteers and community health workers and more ivermectin 
and alternative macrofilaricidal medicines (for co-endemic areas with L.loa). However, the 
elimination and eradication of onchocerciasis would eventually reduce the burden on these 
two building blocks, because human resources and medicines would be saved in the long run 
as treatments are stopped earlier than under the control mode [6]. To realize this, 
policymakers would need to invest in enhancing the capacity of community volunteers and 
community health workers for the effective and sustainable implementation of CDTi.  
Governance and leadership will be critical to achieve the elimination and eradication of 
onchocerciasis, which are public goods that can be achieved only through the coordinated 
efforts among all stakeholders at national, regional, and global levels. National policymakers 
would need to develop the long-term strategic policy for the elimination and eradication of the 
disease. To implement the policy, policymakers would need to regularly monitor and evaluate 
the performance of all the relevant components including health information systems, 
financing, scaling up treatments, human capacity building, and timely drug supply. Regional 
collaboration between endemic countries would be also important when endemic areas span 
across the border areas, as human and vector migration could cause recrudescence. The 
elimination and eradication of onchocerciasis would also require cooperation from global 
donors and pharmaceutical companies. Especially during the early stage of elimination and 
eradication strategies, endemic countries would need higher financial costs, more human 
resources, and more medicines. In this period, global donors’ continuous funding and 
pharmaceutical companies’ drug donation will be needed.  
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Future research 
Integrated interventions for onchocerciasis and LF  
Some NTDs are endemic in the same or adjacent areas, and interventions are delivered with a 
similar time schedule and/or use the same medicines. For example, endemic areas of 
onchocerciasis and LF overlap in some African regions, and interventions for both diseases 
use the same medicine, ivermectin. There would be potential benefits from the integration of 
interventions of onchocerciasis and LF; however, there also would be challenges and risks. A 
future research topic could be the feasibility of the integration of onchocerciasis and LF 
interventions. Specifically, the research can include the epidemiological mapping of 
onchocerciasis and LF, the assessment of operational and managerial challenges against the 
integration, and the evaluation of costs, benefits, and impacts on health systems.  
Global collaboration towards onchocerciasis elimination 
The elimination and eradication of infectious diseases require collaboration among a wide 
range of stakeholders at community, national, regional, and global levels. Every stakeholder 
has a different level of interests depending on expected costs and benefits associated with 
elimination efforts. The elimination of infectious diseases will be possible only if all 
stakeholders are willing to collaborate. A future research topic could be the evaluation of the 
feasibility of onchocerciasis elimination and eradication from a perspective of social choice 
and game theory. Specifically, this evaluation could focus on the identification of countries 
with the least interests in the elimination of onchocerciasis based on the predicted costs and 
benefits in this PhD research and the development and evaluation of potential policies to 
incentivize those countries.  
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Final conclusions 
As the elimination of NTDs gained prominence in the global health agenda, there has been a 
need for the rigorous analysis of costs and benefits associated with the investment in 
elimination strategies and interventions. This research developed the investment case for 
onchocerciasis elimination and eradication in which potential elimination strategies were 
developed, and costs, benefits, and impacts on health systems were evaluated. The results 
could provide an evidence base for national and global policymakers’ informed decisions. The 
methodologies could be applied to other future investment cases. This research also provides 
an insight on future research topics such as the integrated NTD interventions and the 
stakeholders’ willingness to collaborate towards the elimination of infectious diseases.  
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Appendix 1. Supplementary Information for Chapter 3 
 
Control, elimination, and eradication of river blindness: scenarios, 
timelines, and ivermectin treatment needs in Africa 
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Table S1. Population, onchocerciasis endemicity, feasibility concern for community-directed treatment with ivermectin (CDTi), start year 
and frequency of CDTi, treatment coverage, and predicted end year of CDTi for ongoing (as of November 2013) and potential new projects 
Country Project 
APOC/ 
former OCP 
Population 
20141 
Pre-control 
endemicity2 
Feasibility 
concern 
CDTi start 
year3 
CDTi 
frequency 
per annum4 
Treatment 
coverage5 
CDTi end year 
Control 
scenario6 
Elimination 
scenario7 
Eradication 
scenario 
Angola Bengo APOC 26,658 Hypo None 2010 1 75% 2034-2059 2018 2018 
Angola Benguela APOC 50,992 Hypo None 2012 1 67% 2036-2061 2020 2020 
Angola Cuanza Norte APOC 26,058 Hypo None 2011 1 67% 2035-2060 2017 2017 
Angola Huila APOC 239,930 Meso None 2010 1 70% 2034-2059 2018 2018 
Angola KuandoKubango APOC 413,646 Meso None 2009 1 76% 2033-2058 2015 2015 
Angola LundaNorte APOC 309,045 Meso None 2009 1 62% 2033-2058 2017 2017 
Angola Lundasul APOC 260,377 Meso None 2009 1 69% 2033-2058 2017 2017 
Angola Moxico 1 APOC 272,116 Meso None 2011 1 67% 2035-2060 2018 2018 
Angola NY Benguela APOC 114,544 Hyper None 2014 1 67% Not targeted 2025 2025 
Angola NY Cuanza Norte APOC 18,688 Hypo None 2014 1 67% Not targeted 2022 2022 
Angola NY Huila APOC 23,189 Meso None 2014 1 67% Not targeted 2022 2022 
Angola NY LundaNorte APOC 67,327 Hypo None 2014 1 67% Not targeted 2022 2022 
                                                 
12012 population (source: APOC treatment database) was adjusted for population growth rates (UN (2013) World Population Prospects: The 2012 Revision. http://esa.un.org/wpp/Excel-
Data/population.htm Accessed on 23 May 2014) 
2APOC countries: non-endemic with highest nodule prevalence in adult males < 5%, hypo-endemic between 5% and 20%, meso-endemic between 20% and 40%, and hyper-endemic with 40% and 
above 
Former OCP countries: non-endemic with <10% microfilariae prevalence in ages 5+, hypo-endemic between 10% to 40%, meso-endemic between 40% and 60%, and hyper-endemic with 60% and 
above 
3Ongoing projects (as of November 2013): The first year with treatment coverage greater than 60% was used, as effective control of the disease requires the treatment coverage of 60% and above.  
New projects: The start year was predicted based on APOC’s strategic plan to focus on the onchocerciasis elimination for the next decade 2016-2025, the current epidemiology, and the current 
political situation. 
4 Six-monthly: only new projects in Ethiopia and Uganda where respective ministries of health announced six-monthly drug administration in new projects to bring them in line with ongoing 
projects 
5 APOC countries: average over 2010-2012 at project/country/regional levels, former OCP countries: latest available data or average at country level 
6 The lower bound is the expected end year without the assumption of possible CDTi extension for another 25 years due to insufficient treatment coverage, and the upper bound with the assumption. 
This assumption was applied to APOC countries except Equatorial Guinea that is known to have almost eliminated the disease and Mozambique that is endemic in limited border areas where less 
than 70,000 people live. The former OCP countries were also excluded from this assumption considering the level of transmission has decreased significantly due to CDTi implemented since the 
1990s and the recent regional treatment coverage was around 80% on average. 
7The control scenario was applied to projects with feasibility concerns. For these projects, the lower bound of the CDTi end year was expected without the assumption of possible CDTi extension for 
another 25 years due to insufficient treatment coverage, and the upper bound with the assumption. 
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Country Project 
APOC/ 
former OCP 
Population 
20141 
Pre-control 
endemicity2 
Feasibility 
concern 
CDTi start 
year3 
CDTi 
frequency 
per annum4 
Treatment 
coverage5 
CDTi end year 
Control 
scenario6 
Elimination 
scenario7 
Eradication 
scenario 
Angola NY Moxico 1 APOC 347,350 Hypo None 2014 1 67% Not targeted 2022 2022 
Angola P5Angola APOC 264,252 Hypo None 2015 1 67% Not targeted 2023 2023 
Angola Uige APOC 191,005 Meso None 2014 1 67% Not targeted 2023 2023 
Angola Zaire APOC 14,407 Hypo None 2014 1 67% Not targeted 2021 2021 
Benin Benin former OCP 3,585,280 Hyper None 1990s 1 48% 2016 2016 2016 
Burkina Faso BF Bougouriba former OCP 77,626 Hyper None 1990s 1 84% 2016 2016 2016 
Burkina Faso BF LerabaComoe former OCP 152,125 Hyper None 2010 1 84% 2034 2021 2021 
Burundi Bururi APOC 387,223 Meso None 2008 1 75% 2032-2057 2014 2014 
Burundi Cibitoke-Bubanza APOC 924,648 Meso None 2006 1 79% 2030-2055 2014 2014 
Burundi Rutana APOC 301,453 Hypo None 2008 1 77% 2032-2057 2016 2016 
Cameroon Adamaoua 1 APOC 506,733 Hyper None 2008 1 74% 2032-2057 2021 2021 
Cameroon Adamaoua 2 APOC 460,444 Hyper None 2004 1 77% 2028-2053 2016 2016 
Cameroon Centre 1 APOC 467,973 Hyper None 2003 1 78% 2027-2052 2024 2024 
Cameroon Centre 2 APOC 110,151 Hyper None 2005 1 77% 2029-2054 2018 2018 
Cameroon Centre 3 APOC 355,666 Hyper None 2004 1 77% 2028-2053 2017 2017 
Cameroon East APOC 129,904 Hyper None 2007 1 78% 2031-2056 2018 2018 
Cameroon Far North APOC 307,244 Meso None 2007 1 80% 2031-2056 2016 2016 
Cameroon Littoral 1 APOC 307,171 Hyper None 2007 1 78% 2031-2056 2026 2026 
Cameroon Littoral 2 APOC 163,866 Hyper None 2003 1 78% 2027-2052 2020 2020 
Cameroon Northern APOC 688,951 Hyper None 2004 1 78% 2028-2053 2021 2021 
Cameroon Northwest APOC 895,057 Hyper None 2005 1 78% 2029-2054 2017 2017 
Cameroon P20Cameroon APOC 164,900 Hyper None 2015 1 78% 2039-2064 2022 2022 
Cameroon P5Cameroon_forest APOC 335,977 Hypo None 2014 1 78% Not targeted 2020 2020 
Cameroon P5Cameroon_forest_noloa APOC 110,356 Hypo None 2014 1 78% Not targeted 2020 2020 
Cameroon P5Cameroon_savannah APOC 1,194,396 Hypo None 2014 1 78% Not targeted 2020 2020 
Cameroon South APOC 327,119 Hyper None 2006 1 78% 2030-2055 2019 2019 
Cameroon South West 1 APOC 428,877 Hyper None 2005 1 78% 2029-2054 2020 2020 
Cameroon South West 2 APOC 291,874 Hyper None 2004 1 78% 2028-2053 2019 2019 
Cameroon Western APOC 1,793,241 Hyper None 2003 1 80% 2027-2052 2024 2024 
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Country Project 
APOC/ 
former OCP 
Population 
20141 
Pre-control 
endemicity2 
Feasibility 
concern 
CDTi start 
year3 
CDTi 
frequency 
per annum4 
Treatment 
coverage5 
CDTi end year 
Control 
scenario6 
Elimination 
scenario7 
Eradication 
scenario 
CAR8 CAR combined project APOC 1,943,659 Hyper (post) conflict 2003 1 80% 2027-2052 2027-2052 2024 
CAR P20CAR APOC 63,224 Hyper (post) conflict 2016 1 80% 2040-2065 2040-2065 2034 
CAR P5CAR APOC 143,609 Hypo (post) conflict 2020 1 80% Not targeted Not targeted 2026 
Chad Chad APOC 2,181,933 Hyper None 2001 1 81% 2025-2050 2015 2015 
Congo Congo 1 APOC 904,556 Hyper None 2007 1 81% 2031-2056 2016 2016 
Congo P20Congo APOC 39,517 Hyper None 2014 1 81% 2038-2063 2026 2026 
Congo P5Congo APOC 530,726 Hypo None 2014 1 81% Not targeted 2020 2020 
Côte d’Ivoire Bandama former OCP 1,008,980 Hyper None 1990s 1 73% 2020 2020 2020 
Côte d`Ivoire CI Comoe former OCP 622,485 Hyper None 1990s 1 73% 2035 2023 2023 
Côte d`Ivoire CI Lower Sassandra former OCP 350,025 Hyper None 2014 1 73% 2038 2028 2028 
Côte d`Ivoire CI Upper Sassandra former OCP 377,662 Hyper None 1990s 1 73% 2020 2020 2020 
DRC9 Bandundu APOC 6,436 Hyper (post) conflict 2005 1 82% 2029-2054 2029-2054 2021 
DRC Bas-Congo Kinshasa APOC 1,523,869 Hyper (post) conflict 2008 1 71% 2032-2057 2032-2057 2023 
DRC Butembo-Beni APOC 946,872 Hyper (post) conflict 2011 1 56% 2035-2060 2035-2060 2031 
DRC Equateur-Kiri APOC 1,258,400 Hyper (post) conflict 2009 1 79% 2033-2058 2033-2058 2022 
DRC Ituri-Nord APOC 1,273,305 Hyper (post) conflict 2009 1 71% 2033-2058 2033-2058 2030 
DRC Ituri-Sud APOC 1,163,935 Hyper (post) conflict 2012 1 71% 2036-2061 2036-2061 2036 
DRC Kasai APOC 10,917,310 Hyper None 2009 1 75% 2033-2058 2031 2031 
DRC Kasongo APOC 1,367,616 Hyper (post) conflict 2009 1 71% 2033-2058 2033-2058 2022 
DRC Katanga-Nord APOC 635,388 Hyper (post) conflict 2009 1 71% 2033-2058 2033-2058 2030 
DRC Katanga-Sud APOC 703,780 Hyper (post) conflict 2009 1 71% 2033-2058 2033-2058 2030 
DRC Lualaba APOC 228,284 Hyper (post) conflict 2008 1 80% 2032-2057 2032-2057 2024 
DRC Lubutu APOC 339,104 Hyper (post) conflict 2009 1 61% 2033-2058 2033-2058 2028 
DRC Masisi-Walikale APOC 1,062,822 Hyper (post) conflict 2010 1 71% 2034-2059 2034-2059 2032 
DRC Mongala APOC 1,477,897 Hyper (post) conflict 2009 1 78% 2033-2058 2033-2058 2030 
DRC NY Katanga-Nord APOC 461,048 Meso (post) conflict 2014 1 71% Not targeted 2038-2063 2021 
DRC NY Lualaba APOC 997,775 Hyper (post) conflict 2014 1 71% Not targeted 2038-2063 2031 
                                                 
8 Central African Republic 
9 Democratic Republic of the Congo 
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Country Project 
APOC/ 
former OCP 
Population 
20141 
Pre-control 
endemicity2 
Feasibility 
concern 
CDTi start 
year3 
CDTi 
frequency 
per annum4 
Treatment 
coverage5 
CDTi end year 
Control 
scenario6 
Elimination 
scenario7 
Eradication 
scenario 
DRC NY Masisi-Walikale APOC 55,387 Hyper (post) conflict 2014 1 71% 2038-2063 2038-2063 2027 
DRC NY Rutshuru-Ngoma APOC 8,621 Meso (post) conflict 2014 1 71% 2038-2063 2038-2063 2023 
DRC NY Sankuru APOC 476,028 Hyper (post) conflict 2014 1 71% Not targeted 2038-2063 2027 
DRC NY Ueles APOC 161,944 Hyper (post) conflict 2014 1 71% 2038-2063 2038-2063 2035 
DRC P20DRC APOC 2,387,370 Hyper (post) conflict 2016 1 71% 2040-2065 2040-2065 2037 
DRC P5DRC APOC 7,591,705 Hypo (post) conflict 2020 1 71% Not targeted Not targeted 2027 
DRC Rutshuru-Ngoma APOC 669,404 Hyper (post) conflict 2009 1 74% 2033-2058 2033-2058 2018 
DRC Sankuru APOC 1,082,968 Hyper (post) conflict 2007 1 82% 2031-2056 2031-2056 2028 
DRC Tshopo APOC 1,617,757 Hyper (post) conflict 2010 1 63% 2037-2062 2037-2062 2037 
DRC Tshuapa APOC 1,441,333 Hyper (post) conflict 2010 1 66% 2034-2059 2034-2059 2033 
DRC Ubangi-Nord APOC 811,591 Hyper (post) conflict 2011 1 71% 2037-2062 2037-2062 2037 
DRC Ubangi-Sud APOC 1,368,969 Hyper (post) conflict 2011 1 71% 2035-2060 2035-2060 2023 
DRC Ueles APOC 1,596,501 Hyper (post) conflict 2006 1 71% 2030-2055 2030-2055 2028 
Equatorial Guinea Bioko APOC 88,252 Hyper None 2007 1 71% 2031 2020 2020 
Ethiopia Assosa APOC 579,207 Meso None 2014 2 79% Not targeted 2021 2021 
Ethiopia Bench-Maji APOC 765,856 Hyper None 2005 1 79% 2029-2054 2017 2017 
Ethiopia East Wellega APOC 937,884 Meso None 2006 1 79% 2030-2055 2015 2015 
Ethiopia Gambella APOC 112,052 Hyper None 2006 1 78% 2030-2055 2015 2015 
Ethiopia HoroGuduru APOC 54,995 Meso None 2014 2 79% Not targeted 2021 2021 
Ethiopia Illubabor APOC 793,275 Hyper None 2004 1 82% 2028-2053 2017 2017 
Ethiopia Jimma APOC 936,393 Meso None 2004 1 83% 2028-2053 2015 2015 
Ethiopia Kaffa-Sheka APOC 1,329,915 Hyper None 2003 1 79% 2027-2052 2015 2015 
Ethiopia Kamashi APOC 494,563 Hyper None 2014 2 79% 2038-2063 2023 2023 
Ethiopia Metekel APOC 169,262 Meso None 2007 1 74% 2031-2056 2015 2015 
Ethiopia North Gondar APOC 328,659 Meso None 2004 1 74% 2028-2053 2015 2015 
Ethiopia NY East Wellega APOC 300,211 Hyper None 2014 2 79% 2038-2063 2022 2022 
Ethiopia NY West Wellega APOC 304,914 Meso None 2014 2 79% Not targeted 2021 2021 
Ethiopia P20Ethiopia APOC 348,726 Hyper None 2014 2 79% 2038-2063 2022 2022 
Ethiopia P5Ethiopia APOC 3,682,280 Hypo None 2014 2 79% Not targeted 2020 2020 
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Country Project 
APOC/ 
former OCP 
Population 
20141 
Pre-control 
endemicity2 
Feasibility 
concern 
CDTi start 
year3 
CDTi 
frequency 
per annum4 
Treatment 
coverage5 
CDTi end year 
Control 
scenario6 
Elimination 
scenario7 
Eradication 
scenario 
Ethiopia West Shewa APOC 60,625 Hypo None 2014 2 79% Not targeted 2019 2019 
Ethiopia West Wellega APOC 1,076,961 Hyper None 2006 1 79% 2030-2055 2015 2015 
Gabon P5Gabon APOC 85,468 Hypo 
Loa 
loacoendemicity 2021 1 76% Not targeted Not targeted 2027 
Ghana Ghana Center former OCP 91,065 Hyper None 1990s 1 77% 2020 2020 2020 
Ghana Ghana North former OCP 1,229,326 Hyper None 1990s 1 77% 2018 2018 2018 
Ghana Ghana South CI border former OCP 709,561 Hypo None 2010 1 77% 2034 2015 2015 
Ghana Ghana South Rx former OCP 431,415 Hypo None 2010 1 77% 2034 2015 2015 
Ghana Ghana Tano new Rx former OCP 74,115 Hypo None 2015 1 77% 2039 2020 2020 
Guinea Guinea border former OCP 2,384,879 Hyper None 1990s 1 81% 2020 2020 2020 
Guinea Guinea Main former OCP 946,807 Hyper None 1990s 1 81% 2016 2016 2016 
Guinea-Bissau Guinea Bissau former OCP 194,915 Hyper None 1990s 1 75% 2016 2016 2016 
Liberia Northwestern APOC 1,878,803 Meso None 2009 1 77% 2033-2058 2016 2016 
Liberia Southeastern APOC 528,362 Meso None 2006 1 83% 2030-2055 2016 2016 
Liberia Southwestern APOC 761,649 Meso None 2007 1 77% 2031-2056 2014 2014 
Malawi Malawi Extension APOC 1,282,457 Meso None 2004 1 82% 2028-2053 2016 2016 
Malawi ThyoloMwanza APOC 978,116 Meso None 2004 1 83% 2028-2053 2015 2015 
Mali Mali former OCP 5,145,734 Hyper None 1990s 1 82% 2016 2016 2016 
Mozambique P20Mozambique APOC 17,030 Meso None 2015 1 76% 2039 2023 2023 
Mozambique P5Mozambique APOC 49,746 Hypo None 2015 1 76% Not targeted 2022 2022 
Nigeria Adamawa APOC 1,861,788 Hyper None 2001 1 80% 2025-2050 2015 2015 
Nigeria AkwaIbom APOC 31,875 Meso None 2006 1 84% 2030-2055 2016 2016 
Nigeria Bauchi APOC 1,907,526 Meso None 2009 1 79% 2033-2058 2015 2015 
Nigeria Benue APOC 3,761,997 Hyper None 2007 1 77% 2031-2056 2019 2019 
Nigeria Borno APOC 1,499,554 Meso None 2006 1 83% 2030-2055 2015 2015 
Nigeria Cross River APOC 1,359,649 Hyper None 1999 1 81% 2023-2048 2015 2015 
Nigeria Edo Delta APOC 1,748,040 Hyper None 1999 1 80% 2023-2048 2015 2015 
Nigeria Ekiti APOC 2,359,828 Meso None 2004 1 76% 2028-2053 2015 2015 
Nigeria Enugu Anambra Ebony APOC 2,597,471 Hyper None 1999 1 80% 2023-2048 2015 2015 
Nigeria FCT APOC 551,432 Meso None 2004 1 82% 2028-2053 2016 2016 
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Country Project 
APOC/ 
former OCP 
Population 
20141 
Pre-control 
endemicity2 
Feasibility 
concern 
CDTi start 
year3 
CDTi 
frequency 
per annum4 
Treatment 
coverage5 
CDTi end year 
Control 
scenario6 
Elimination 
scenario7 
Eradication 
scenario 
Nigeria Gombe APOC 2,072,712 Hyper None 2006 1 82% 2030-2055 2017 2017 
Nigeria Imo Abia APOC 1,431,900 Hyper None 1999 1 80% 2023-2048 2017 2017 
Nigeria Jigawa APOC 388,171 Hypo None 2004 1 74% 2028-2053 2015 2015 
Nigeria Kaduna APOC 3,016,022 Meso None 2010 1 80% 2034-2059 2018 2018 
Nigeria Kano APOC 1,076,195 Hyper None 2000 1 81% 2024-2049 2016 2016 
Nigeria Kebbi APOC 226,137 Hypo None 2006 1 78% 2030-2055 2016 2016 
Nigeria Kogi APOC 1,943,133 Hyper None 1999 1 82% 2023-2048 2015 2015 
Nigeria Kwara APOC 1,642,329 Hyper None 2000 1 81% 2024-2049 2015 2015 
Nigeria Niger APOC 2,887,036 Meso None 2004 1 79% 2028-2053 2015 2015 
Nigeria Ogun APOC 374,030 Meso None 2003 1 82% 2027-2052 2015 2015 
Nigeria Ondo APOC 1,487,782 Meso None 2001 1 81% 2025-2050 2015 2015 
Nigeria Osun APOC 1,755,255 Meso None 2009 1 79% 2033-2058 2016 2016 
Nigeria Oyo APOC 1,197,059 Meso None 2011 1 80% 2035-2060 2018 2018 
Nigeria P20Nigeria APOC 241,777 Hyper None 2014 1 80% 2038-2063 2026 2026 
Nigeria P5Nigeria APOC 5,847,463 Hypo None 2014 1 80% Not targeted 2020 2020 
Nigeria P5Nigeria APOC 2,362,136 Hypo None 2014 1 80% Not targeted 2020 2020 
Nigeria Plateau Nassarawa APOC 1,664,490 Meso None 2000 1 82% 2024-2049 2015 2015 
Nigeria Plateau Nassarawa LF APOC 1,685,205 Hyper None 2000 1 80% 2024-2049 2015 2015 
Nigeria Taraba APOC 1,810,936 Hyper None 2009 1 82% 2033-2058 2020 2020 
Nigeria Yobe APOC 669,776 Meso None 2002 1 78% 2026-2051 2015 2015 
Nigeria Zamfara APOC 310,839 Hypo None 1999 1 78% 2023-2048 2016 2016 
Senegal Senegal former OCP 187,405 Hyper None 1990s 1 79% 2015 2015 2015 
Sierra Leone Sierra Leone former OCP 3,319,643 Hyper None 2008 1 77% 2032 2021 2021 
South Sudan East Bahr El Ghazal APOC 619,344 Hyper (post) conflict 2011 1 60% 2035-2060 2035-2060 2020 
South Sudan East Equatoria APOC 1,100,863 Hyper (post) conflict 2009 1 67% 2033-2058 2033-2058 2019 
South Sudan P20SouthSudan APOC 31,012 Hyper (post) conflict 2017 1 60% 2041-2066 2041-2066 2040 
South Sudan P5SouthSudan APOC 853,648 Hypo (post) conflict 2021 1 60% Not targeted Not targeted 2029 
South Sudan Upper Nile APOC 576,858 Meso (post) conflict 2010 1 56% 2034-2059 2034-2059 2018 
South Sudan West Bahr El Ghazal APOC 3,338,305 Hyper (post) conflict 2011 1 60% 2035-2060 2035-2060 2035 
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Country Project 
APOC/ 
former OCP 
Population 
20141 
Pre-control 
endemicity2 
Feasibility 
concern 
CDTi start 
year3 
CDTi 
frequency 
per annum4 
Treatment 
coverage5 
CDTi end year 
Control 
scenario6 
Elimination 
scenario7 
Eradication 
scenario 
South Sudan West Equatoria APOC 787,420 Hyper (post) conflict 2009 1 71% 2033-2058 2033-2058 2026 
Sudan P5Sudan APOC 227,384 Hypo None 2014 1 82% Not targeted 2020 2020 
Sudan Sudan APOC 214,782 Hypo None 2008 1 82% 2032-2057 2016 2016 
Sudan Sudan Abu Hamed APOC 214,782 Hypo None 2008 1 82% 2032-2057 2016 2016 
Tanzania Kilosa APOC 551,542 Meso None 2004 1 80% 2028-2053 2015 2015 
Tanzania Mahenge APOC 551,412 Hyper None 2003 1 80% 2027-2052 2022 2022 
Tanzania Morogoro APOC 394,691 Meso None 2006 1 80% 2030-2055 2015 2015 
Tanzania P5Tanzania APOC 1,000,102 Hypo None 2015 1 81% Not targeted 2021 2021 
Tanzania Ruvuma APOC 435,723 Hyper None 2002 1 81% 2026-2051 2023 2023 
Tanzania Tanga APOC 341,837 Meso None 2004 1 81% 2028-2053 2016 2016 
Tanzania Tukuyu APOC 125,098 Meso None 2001 1 80% 2025-2050 2015 2015 
Tanzania Tunduru APOC 135,650 Hyper None 2005 1 82% 2029-2054 2017 2017 
Togo Togo former OCP 3,171,784 Hyper None 1992 1 83% 2016 2016 2016 
Uganda P5Uganda APOC 271,652 Hypo None 1990s 2 75% Not targeted 2022 2022 
Uganda Phase 1 APOC 425,538 Hyper None 2001 1 75% 2025-2050 2015 2015 
Uganda Phase 2 APOC 827,960 Hypo None 2000 1 75% 2024-2049 2016 2016 
Uganda Phase 3 APOC 1,527,173 Hyper None 2003 1 75% 2027-2052 2027 2027 
Uganda Phase 4 APOC 864,444 Hyper None 1999 1 75% 2023-2048 2015 2015 
Uganda Phase 5 APOC 556,618 Hyper None 2012 2 75% 2036-2061 2023 2023 
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Table S2. Summary of treatment coverage and distribution parameters for probabilistic 
sensitivity analysis 
Country Average
10 Standard deviation 
Beta distribution11 
Alpha Beta 
APOC countries 
Angola 67% 0.11 12.36 5.97 
Burundi 77% 0.04 105.52 31.48 
Cameroon 78% 0.05 62.60 17.72 
Central African  Republic 80% 0.03 167.75 40.98 
Chad 81% 0.00 124,658.19 29,240.81 
Congo 81% 0.02 207.63 47.39 
Democratic Republic of the Congo 71% 0.13 7.47 3.12 
Equatorial Guinea 71% 0.00 292,469.03 119,749.47 
Ethiopia 79% 0.04 77.58 20.87 
Liberia 77% 0.10 13.31 3.89 
Malawi 83% 0.00 5,112.61 1,065.77 
Nigeria 80% 0.04 83.33 21.00 
South Sudan 60% 0.12 8.72 5.78 
Sudan 82% 0.03 167.06 37.92 
Tanzania 81% 0.01 868.01 210.26 
Uganda 75% 0.11 10.48 3.46 
APOC 76% 0.06 35.04 10.81 
 
Country Latest
12 Standard deviation13 
Beta distribution 
Alpha Beta 
Former OCP countries 
Benin 48% 0.05 51.42 55.48 
Burkina Faso 84% 0.08 15.56 3.05 
Côte d’Ivoire 84% 0.08 15.56 3.05 
Ghana 73% 0.07 26.67 10.07 
Guinea 73% 0.07 26.67 10.07 
Guinea-Bissau 73% 0.07 26.67 10.07 
Mali 73% 0.07 26.67 10.07 
Senegal 77% 0.08 21.83 6.37 
Sierra Leone 80% 0.08 18.90 4.64 
Togo 77% 0.08 21.83 6.37 
Former OCP 74% 0.10 13.09 4.58 
 
 
  
                                                 
10The average treatment coverage over 2010-2012  
11 Parameters of Beta(α, β) were estimated using a method of moments: 
 ̂   ̅ (
 ̅(   ̅ )
 ̅
  )   ̂  (   ̅) (
 ̅(   ̅)
 ̅
  )      ̅   ̅(   ̅)   
       ̅                   ̅                       
12
A provisional database for the former OCP countries had only the latest treatment coverage. 
13
 The standard deviation was assumed to be 10% of the treatment coverage. 
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Figure S1. Beta distributions for treatment coverage for endemic African countries 
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Figure S2. Probability and cumulative density graphs for the gamma distribution 
applied to the delay in starting and ending CDTi 
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Appendix 2. Supplementary Information for Chapter 4 
 
Financial and economic costs of the elimination and eradication of 
onchocerciasis (river blindness) in Africa 
 
Methodological details on the micro-costing method, the uncertainty 
analysis, and the literature review 
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I. Micro-costing method 
1. Geographic unit for costing: project 
A unit for micro-costing was a project, considering budgets and operational decisions for community-
directed treatment with ivermectin (CDTi) are made at project level in endemic African regions [15]. 
We used data available in Kim et al. (S1 Table in [6]) to identify the list of projects and the 
demographic and epidemiological characteristics of each project. The data set included population 
living in endemic areas, pre-control endemicity, feasibility concerns, CDTi start year, CDTi rounds 
per year, expected treatment coverage, and predicted CDTi end year for the control, elimination, and 
eradication scenarios.   
 
2. Cost estimation for a project 
To estimate total costs for a project, we used a micro-costing method with six steps.  
Step 1. Identification of ingredients 
 
We defined the key activities and resources required for onchocerciasis elimination and eradication 
under five categories (Table S3) with reference to an APOC report of the technical consultative 
committee [90], an APOC protocol for epidemiological surveillance, and a guide for post-treatment 
epidemiological and entomological surveillance (developed for the Onchocerciasis Elimination 
Program for the Americas) [69] . Based on the key activities and resources, we identified 54 cost items, 
and defined their characteristics including the type (financial/economic), the unit cost, and the unit 
quantity. As resource utilization, represented by the unit quantity, changes depending on 
epidemiological trends, we defined relevant phases for each cost item, among the phase 1 for 
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treatment, the phase 2 for the confirmation of elimination, and the phase 3 for post-elimination 
surveillance (Table S4).  
Table S3. Key activities and required resources 
Item Definition Resources 
Category 1 Community-directed treatment with ivermctin (CDTi) 
Advocacy/sensitization/mobilization 
Advocacy 
Hold meetings at regional/province/state level to 
create and sustain awareness 
Per diem, travel expenses, facility rent, 
printing 
Sensitization and mobilization 
Educate, sensitize, and mobilize communities to 
achieve high treatment coverage 
Community volunteers, per diem, travel 
expenses, media announcement costs, 
mobilization material (town criers, 
banners, printing) 
Development and production of 
Information/Education/Communication 
(IEC) material 
Develop (every five years) and print (every year) 
training manuals and IEC material 
Per diem, travel expenses, printing 
Supervision/monitoring/evaluation 
Supervision (first 6 years) 
Supervise at district/health facility/community 
level to ensure smooth start of CDTi 
Per diem, travel expenses 
Assistance for supervisory visits (7th year 
and onward) 
Regular visits to districts, health facilities and 
communities by coordinators, epidemiologists, 
data managers, and accountants 
Per diem, travel expenses 
Monitoring and evaluation Track and evaluate CDTi performance Per diem, travel expenses 
Review meeting Hold regular meetings at state and district levels Per diem, travel expenses 
Data management Build database, enter, and validate data Per diem, travel expenses 
Community self-monitoring 
Track CDTi performance,  report to  health 
workers 
Community volunteers, travel expenses 
Training 
Training of trainers and health workers Develop capacity of trainers and health workers 
Per diem, travel expenses, facility rent, 
printing, stationery 
Training of community volunteers 
(community drug distributors) 
Train community volunteers to implement CDTi 
Per diem, travel expenses, printing, 
stationery 
Training of community leaders 
Educate community leaders on the concept of 
and the need for CDTi 
Per diem, travel expenses, printing, 
stationery 
Drug distribution/management of severe adverse events 
Community registration Register communities  Community volunteers, registration forms 
Census Conduct census Community volunteers 
Delivery of drugs Deliver drugs from manufacturer to country 
Drug purchase cost, shipping cost 
(insurance, freight) 
Drug administration  in areas without 
highly endemic Loa loa 
Community-directed treatment with ivermectin Community volunteers 
Drug administration  in areas with highly 
endemic Loa loa 
A test-and-treat approach with doxycycline 
Diagnostic tools for microscopic testing
i
, 
health workers 
Management of severe adverse events 
Purchase drugs, treat minor adverse events, refer 
people with severe adverse events to health 
facilities  
Community volunteers, drugs 
Category 2 Surveillance 
Supervision/monitoring/evaluation 
Supervisory visit 
Regular visit to sentinel sites by coordinators, 
epidemiologists, entomologists, data managers, 
and accountants 
Per diem, travel expenses 
Monitoring and evaluation Track and evaluate surveillance performance  Per diem, travel expenses 
Review meeting Hold regular meetings at state and district levels Per diem, travel expenses 
Data management Build database, enter and validate data Per diem, travel expenses 
Training 
Training of trainers and health workers 
Develop capacity of trainers and health workers 
for epidemiological and entomological 
surveillance 
Per diem, travel expenses, facility rent, 
printing, stationery 
Training of fly/larva-catchers Train fly/larva-catchers 
Per diem, travel expenses, printing, 
stationery 
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Item Definition Resources 
Training of community leaders 
Educate community leaders on the concept of 
and the need for surveillance 
Per diem, travel expenses, printing, 
stationery 
Sampling  
Epidemiological sampling by health 
workers 
Conduct skin snip 
Per diem and travel expenses for skin-
snipper, laboratory technician, and census 
clerk, field supplies
ii
 
Entomological sampling by fly/larva-
catchers 
Collect aquatic (to determine catching sites) and 
adult stages of black flies 
Perdiem for fly/larva-catchers, field 
supplies
iii
 
Delivery of samples 
Delivery of samples to laboratory Carry skin-snip samples to laboratory Travel expenses for the survey team 
Delivery of samples to laboratory 
Send fly/larva samples to MDSC(Multi Disease 
Surveillance Center) in Burkina Faso
iv
 
Transportation expenses, courier service 
fee 
Laboratory testing 
Epidemiological laboratory testing Test skin-snip samples in laboratory 
Salary for laboratory technicians, 
laboratory supplies
v
 
Entomological laboratory testing Test fly/larva samples Salary for MDSC laboratory technicians
vi
 
Category 3 Capital goods
vii
 
Vehicle Vehicle with 6 years of useful time Vehicle 
Motorcycle Motorcycle with 6 years of useful time Motorcycle 
Bicycle Bicycle with 6 years of useful time Bicycle 
IT equipment IT equipment with 6 years of useful time 
Computer, fax, printer, photocopier, 
scanner, projector, camera, TV, DVD 
reader 
Power supply equipment 
Power supply equipment with 6 years of useful 
time 
Generator, uninterruptible power supply 
Category 4 Administrative costs 
Maintenance of vehicle Maintenance of vehicles Technician’s service fee 
Maintenance of motorcycle Maintenance of motorcycles Technician’s service fee 
Office supplies Stationery Stationery 
Communication Telephone, internet, courier Fee for telephone, internet, and courier 
Salary top-ups (first 6 years) 
Provide salary top-ups to health workers for the 
first 6 years to stabilize new projects 
Salary top-ups 
Other administration Other administrative costs Bank charges, other administrative costs 
Category 5 Financial support for treatment and surveillance in (post) conflict endemic areas 
Financial support for treatment and 
surveillance in (post) conflict endemic 
areas 
Strengthen infrastructure, human capacity, and 
monitoring and evaluation system, treat 
internally displaced people 
Funding for the relevant activities 
i,v 1ml size test tube, binocular microscope, blood slids, hypodermic syringe and needle, micro pipette with disposable tips, microtitration 
trays, saline solution, slide trays; the useful time of non-disposable items is assumed to be six years. 
ii 2 liters of distilled water, 200 glass slides, 3 instrument trays, 4 slide trays each holding 3 glass slides, liquid detergent, butane burning 
stove, dropper bottle, aluminium pressure sterilizer, cotton swabs soaked with alcohol, curved tweezer, holth punch, lancets, scissors, 
sterilizer forcepts; the useful time of non-disposable items is assumed to be six years. 
iii aspirators, bottles; the useful time of these supplies is assumed to be six years. 
iv,vi Exceptional countries were Ethiopia, Uganda, and Sudan that were identified to conduct entomological tests in their own laboratories. 
vii Six years of useful time is assumed following the replacement policy specified in a Burundi’s budget document 
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Table S4. Characteristics of cost items: unit cost, unit quantity, relevant phase, and type 
ID Cost item Unit cost Unit quantity 
Phase
i
 Financial/ 
economic 1 2 3 
Category 1  Community-directed treatment with ivermectin 
Advocacy/sensitization/mobilization 
1 Advocacy 
Costs for resources per 
project 
1  v v  Financial 
2 Sensitization 
Costs for resources per 
project 
1  v v  Financial 
3 Mobilization 
Costs for resources per 
person 
Population in a project area v v  Financial 
4 
Support for mobilization from 
community volunteers 
Opportunity cost per 
volunteer-day 
5.5days[97]*No. of 
volunteers*CDTi rounds/year 
v v  Economic 
5 Development of IEC material 
Costs for resources per 
project  
1 v v  Financial 
6 Production of IEC material 
Costs for resources per 
person 
Population in a project area v v  Financial 
Supervision/monitoring/evaluation 
7 Supervision (first 6 years) 
Costs for resources per 
project 
1  v   Financial 
8 
Assistance for supervisory visits (7th 
year+) 
Costs for resources per 
project 
1  v v  Financial 
9 Monitoring 
Costs for resources per CDTi 
round 
Number of CDTi rounds per year v v  Financial 
10 Evaluation 
Costs for resources per CDTi 
round 
Number of CDTi rounds per year v v  Financial 
11 Review meeting 
Costs for resources per 
project 
1  v v  Financial 
12 Data management 
Costs for resources per 
project 
1  v v  Financial 
13 Community self-monitoring 
Costs for resources per 
person 
Population in a project area v v  Financial 
Training 
14 Training of trainers and health workers 
Costs for resources per 
health worker 
No. of health workers v   Financial 
15 Training of community volunteers 
Costs for resources per 
volunteer 
No. of volunteers v   Financial 
16 Training of community leaders 
Costs for resources per 
community 
No. of communities v   Financial 
Drug distribution 
17 Community registration 
Costs for resources per 
community 
No. of communities  v   Financial 
18 Census 
Opportunity cost per 
volunteer-day 
4.6days[97]*No. of 
volunteers*CDTi rounds/year 
v   Economic 
 Drug delivery and administration in areas without highly endemic Loa loa (19, 20) 
19 Delivery of ivermectin 
Opportunity cost per 
treatment  
No. of treatments v   Economic 
20 Ivermectin administration  
Opportunity cost per 
volunteer-day 
17.8days[97]* No. of 
volunteers*CDTi rounds/year 
v   Economic 
 Drug delivery and administration in areas with highly endemic Loa loa (21, 22) 
21 Diagnostic tools 
Purchase cost per set of 
diagnostic tools (annuitized) 
1 v   Financial 
22 
Delivery and administration of 
doxycycline 
Costs per 6-week treatment No. of treatments v   Financial 
23 Management of severe adverse events 
Costs for resources per 
project 
1  v   Financial 
Category 2 Surveillance
ii
 
Supervision/monitoring/evaluation 
24 Supervisory visit 
Costs for resources per 
project 
1 v v v Financial 
25 Monitoring 
Costs for resources per 
project 
1 v v v Financial 
26 Evaluation 
Costs for resources per 
project 
1 v v v Financial 
27 Review meeting 
Costs for resources per 
project 
1 v v v Financial 
28 Data management 
Costs for resources per 
project 
1 v v v Financial 
Training 
29 Training of trainers and health workers Costs for resources per No. of health workers v v v Financial 
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ID Cost item Unit cost Unit quantity 
Phase
i
 Financial/ 
economic 1 2 3 
health worker 
30 Training of fly/larva catchers 
Costs for resources per 
flycatcher 
No. of fly/larva -catchers (4 per 
catching site)*No. of catching sites 
 v v Financial 
31 Training of community leaders 
Costs for resources per 
community 
No. of communities v v v Financial 
Sampling and laboratory testing 
 Epidemiological survey sampling 
32 Surveillance trip transportation 
Transportation costs per 
person-day per site 
No. of survey 
workers(3)*2days*No. of survey 
sites 
v v v Financial 
33 Personnel 
Personnel costs per person-
day per site 
No. of survey 
workers(3)*2days*No. of survey 
sites 
v v v Financial 
34 Field supplies 
Purchase cost per set of 
supplies (annuitized) 
1 v v v Financial 
 Entomological survey sampling 
35 Personnel  
Personnel costs per person-
day per site 
No. of fly/larva catchers(4)*16days 
(4 days/month and 4 months)*No. 
of catching sites  
 v v Financial 
36 Field supplies 
Purchase cost per set of 
supplies per person-day 
(annuitized) 
No. of fly/larva 
catchers(4)*16days (4 days/month 
and 4 months)*No. of catching 
sites 
 v v Financial 
 Delivery of samples 
37 
Delivery of samples from villages to 
laboratory 
Transportation costs per site No. of survey sites v v v Financial 
38 
Delivery of samples  from catching site 
to health facility 
Transportation costs per site 
No. of fly/larva catchers(4)*4 (1 
delivery/month and 4 months)*No. 
of catching sites 
 v v Financial 
39 
Delivery of samples  from health facility 
to MSDC 
Courier fee per parcel 1  v v Financial 
 Epidemiological laboratory testing 
40 Personnel 
Personnel costs per person-
day per site 
No. of technicians (1)* 2days*No. 
of survey sites 
v v v Financial 
41 Laboratory supplies 
Purchase cost per set of 
supplies (annuitized) 
1 v v v Financial 
 Entomological laboratory testing 
42 Personnel 
Personnel costs per 
technician-day per site 
No. of technicians (6)
iii
*22days for 
testing*No. of catching sites 
 v v Financial 
Category 3 Capital goods
iv
 
43 Vehicle  
Purchase cost per vehicle 
(annuitized) 
1 v v v Financial 
44 Motorcycle 
Purchase cost per motorcycle 
(annuitized) 
No. of districts v v v Financial 
45 Bicycle 
Purchase cost per bicycle 
(annuitized) 
No. of communities v v v Financial 
46 IT equipment 
Purchase cost per set of 
equipment (annuitized) 
1  v v v Financial 
47 Power supply equipment 
Purchase cost per set of 
equipment (annuitized) 
1  v v v Financial 
Category 4 Administrative  costs 
48 Maintenance of vehicle 
Maintenance costs per 
vehicle 
No. of vehicles v v v Financial 
49 Maintenance of motorcycle 
Maintenance costs per 
motorcycle 
No. of motorcycles v v v Financial 
50 Office supplies 
Costs for resources per 
project 
1 v v v Financial 
51 Communication 
Costs for resources per 
project 
1 v v v Financial 
52 Salary top-ups (first 6 years) 
Costs for resources per 
project 
1 v   Financial 
53 Other administration 
Costs for resources per 
project 
1 v v v Financial 
Category 5 Financial support for MDA and surveillance in (post) conflict endemic areas 
54 
Support for CDTi and surveillance in 
(post) conflict endemic areas 
Costs for resources for entire 
(post) conflict areas 
1 v v v Financial 
i Phase 1: intervention; Phase 2: confirmation of elimination; Phase 3: post-elimination 
ii We assumed that supervisory visit, monitoring, evaluation, review meeting, data management, and training (ID:24-31) would be done only 
in the years when either epidemiological or entomological surveillance is conducted. 
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ID Cost item Unit cost Unit quantity 
Phase
i
 Financial/ 
economic 1 2 3 
iii 5 technicians per month = 10,000 flies per catching site/100 flies per technician-day/22 working days per month; 1 additional technician 
per month for larva-testing to identify species. 
iv Capital costs for diagnostic and laboratory testing tools are excluded; instead included in CDTi and surveillance cost items. 
 
As the main sources to estimate unit costs, we used approved budgets for 67 of ongoing 112 
onchocerciasis projects (as of November 2013) in sub-Saharan Africa (Table S5), which were made 
available by APOC. The capital costs were annuitized with 3% over the useful time that was assumed 
to be six years based on the capital-goods replacement policy specified in Burundi’s budget documents. 
For projects without available budgets, we used the national average unit costs or, if there was no 
national average, the regional average across available national averages for endemic African 
countries (Table S5). For economic unit costs, we used agriculture value added per worker as an 
opportunity cost of community volunteers’ unpaid time, considering most of volunteers are farmers in 
remote rural areas. For three countries for which agriculture value added was unavailable, we used the 
regional average for sub-Saharan Africa (developing only) (Table S6). As an opportunity cost of 
donated ivermectin, we used $1.5054 per treatment based on the suggested drug price ($1.5 per 
treatment) by Merck before their ivermectin donation was decided [121] and the freight and insurance 
cost ($0.0054 per treatment) [93]. To estimate the unit quantity for each cost item, we identified the 
determinants of unit quantities. The determinants were population living in a project area, the number 
of CDTi rounds per year, the number of treatments, the number of volunteers, the number of 
volunteering days, the number of health workers, the number of districts, the number of communities, 
the number of survey sites, the number of survey team members, the number of survey days, the 
number of fly-catching sites, the number of fly-catchers, the number of catching days, and the number 
of laboratory technicians (Table S4). Among these, time variant determinants were population living 
in a project area, the number of treatments, the number of volunteers, and the number of health 
workers. To adjust for time variation, we adjusted population living in a project area for population 
growth rates over 2013−2045[55]. We estimated the number of treatments by multiplying the 
population adjusted for growth rates with the expected treatment coverage and the CDTi rounds per 
year. To estimate the number of volunteers for CDTi, we multiplied the population adjusted for 
population growth rates with the ratio of volunteers for the years of the treatment phase. To estimate 
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the number of health workers, we multiplied the population adjusted for population growth rates with 
the ratio of health workers for the treatment phase and, in the post-treatment phase, for the years when 
surveillance is conducted. Projects without budgets available had no information on the ratio of 
volunteers over population, the ratio of health workers over population, the population per district, and 
the population per community. For these projects, we used the national averages or, if there was no 
national average, the regional average across available national averages for endemic African 
countries (Table S7). 
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Table S5. Unit costs for the countries with budgets available, average (standard deviation) 
ID Cost items Unit Angola Burundi Cameroon 
Central 
African 
Republic 
Chad Congo 
Eq. 
Guinea
+
 
Ethiopia Liberia Malawi Nigeria 
South 
Sudan 
Tanzania Uganda Average
*
 
 
Number of projects with budgets/total (as of 
November 2013) 
7/8 3/3 15/15 1/1
#
 1/1
%
 1/1 1/1 2/9 3/3 2/2
@
 18/28 5/5 3/7 5/5  
Category 1. Community-directed treatment with ivermectin 
Advocacy/sensitization/mobilization 
1 Advocacy /project 
$7,312 
($4,788) 
$4,611 
($4,840) 
$6,930 
($5,371) 
NA 
$5,059 
($1,533) 
$6,328 
($0) 
$1,700 
($0) 
$1,097 
($234) 
$2,638 
($1,525) 
$259 
($192) 
$4,037 
($3,895) 
NA 
$13,216 
($1,505) 
$1,336 
($1,231) 
$4,544 
($3,624) 
2 Sensitization /project 
$7,772 
($5,466) 
$6,436 
($4,619) 
$5,143 
($6,267) 
$677 ($0) 
$4,368 
($2,556) 
$8,688 
($0) 
$1,440 
($0) 
$2,520 
($1,624) 
$4,566 
($2,985) 
$672 
($237) 
$5,088 
($4,480) 
$3,356 
($1,010) 
$3,094 
($786) 
$805 
($475) 
$3,902 
($2,591) 
3 Mobilization /person  
$0.016 
($0.019) 
$0.007 
($0.005) 
$0.014 
($0.024) 
$0.010 
($0.010) 
$0.046 
($0.027) 
$0.002 
($0.000) 
NA 
$0.010 
($0.002) 
$0.008 
($0.009) 
$0.001 
(>$0.000) 
$0.006 
($0.005) 
$0.010 
($0.006) 
$0.035 
($0.011) 
$0.003 
($0.001) 
$0.013 
($0.013) 
4 
Support for mobilization 
from community volunteers
a
 
/volunteer/day 
$2.105  
(NA) 
$0.390 
(NA) 
$0.921 
(NA) 
$0.998 
(NA) 
$0.570 
(NA) 
$0.409 
(NA) 
$12.327 
(NA) 
$0.869 
(NA) 
$0.616 
(NA) 
$0.294 
(NA) 
$2.317 
(NA) 
$0.536 
(NA) 
$0.643 
(NA) 
$0.548 
(NA) 
$1.682 
($3.124) 
5 Development of IEC material /project NA NA NA NA NA NA NA 
$2,200 
($1,697) 
$4,532 
($99) 
NA 
$1,889 
($1,566) 
NA NA $382 ($0) 
$2,250 
($1,716) 
6 Production of IEC material /person 
$0.177 
($0.241) 
NA 
$0.043 
($0.049) 
NA NA 
$0.015 
($0.000) 
NA 
$0.009 
($0.003) 
$0.028 
($0.020) 
$0.039 
($0.048) 
$0.008 
($0.007) 
$0.023 
($0.009) 
NA 
$0.006 
($0.004) 
$0.039 
($0.053) 
Supervision/monitoring/evaluation 
7 Supervision (first 6 years) /project 
$11,269 
($10,754) 
$2,945 
($2,406) 
$36,398 
($42,103) 
$1,444 
($1,178) 
$23,152 
($1,972) 
NA NA 
$42,949 
($24,934) 
$7,074 
($3,407) 
$7,822 
($9,155) 
$8,367 
($8,325) 
$10,930 
($7,595) 
$49,520 
($15,981) 
$14,384 
($0) 
$18,021 
($16,253) 
8 
Assistance for supervisory 
visits (7th year+) 
/project 
$4,000 
($1,414) 
$3,001 
($2,434) 
$2,460 
($1,098) 
NA 
$635 
($352) 
$2,489 
($0) 
$1,450 
($0) 
NA NA 
$1,253 
($655) 
$1,702 
($1,480) 
$1,500 
($0) 
NA 
$2,498 
($566) 
$2,099 
($981) 
9 Monitoring /CDTi round 
$5,203 
($4,630) 
$1,617 
($19) 
$10,482 
($7,449) NA 
$1,468 
($676) NA NA 
$375 
($177) 
$1,735 
($17) 
$4,963 
($5,201) 
$3,135 
($4,353) NA NA NA 
$3,622 
($3,259) 
10 Evaluation /CDTi round 
NA 
$3,585 
($0) NA NA NA NA NA NA NA 
$4,432 
($4,309) NA NA NA NA 
$4,008 
($599) 
11 Review meeting /project 
$5,293 
($4,031) 
$4,037 
($0) 
$16,796 
($24,483) 
NA 
$7,787 
($3,049) 
NA 
$1,419 
($0) 
$13,600 
($936) 
$2,573 
($889) 
$3,986 
($3,978) 
$7,375 
($6,721) 
$3,488 
($561) 
$13,409 
($1,214) 
$1,191 
($0) 
$6,746 
($5,206) 
12 Data management /project 
$1,400 
($0) 
$6,793 
($9,598) 
$5,574 
($7,273) 
NA 
$175 
($207) 
$1,463 
($0) 
$800 ($0) NA NA 
$1,344 
($540) 
$975 
($2,220) 
NA NA 
$2,258 
($2,210) 
$2,309 
($2,287) 
13 Community self-monitoring /person 
$0.049 
($0.060) 
$0.004 
($0.002) 
$0.014 
($0.006) 
NA 
$0.066 
($0.019) 
$0.002 
($0.000) 
NA 
$0.025 
($0.018) 
$0.002 
($0.001) 
$0.006 
($0.005) 
$0.006 
($0.006) 
$0.005 
($0.002) 
NA 
$0.004 
($0.004) 
$0.017 
($0.022) 
Training 
14 
Training of trainers and 
health workers 
/health worker 
$132 
($57) 
$47 ($31) $140 ($123) $53 ($0) $81 ($0) $16 ($0) NA $1,179 
($275) 
$48 ($19) $1 ($0) $8 ($6) $107 
($24) 
$579 
($109) 
$6 ($1) $184 
($335) 
15 
Training of community 
volunteers 
/volunteer $20 ($7) $3 ($1) $9 ($7) NA $11 ($8) $2 ($0) $5 ($0) $18 ($1) $4 ($2) $2 ($2) $3 ($3) $8 ($5) $13 ($6) $1 ($2) $8 ($6) 
16 
Training of community 
leaders 
/community $15 ($13) $18 ($5) $9 ($5) NA $5 ($0) $12 ($0) NA $23 ($17) NA 
$0.350 
($0.003) 
$5 ($6) $4 ($3) NA $2 ($1) $9 ($7) 
Drug distribution 
17 Community registration /community $11 ($11) $37 ($0) $14 ($11) $4 ($7) $8 ($2) $1 ($0) $15 ($0) $12 ($1) $3 ($1) $4 ($5) $9 ($28) $34 ($15) $10 ($5) $2 ($0) $12 ($11) 
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ID Cost items Unit Angola Burundi Cameroon 
Central 
African 
Republic 
Chad Congo 
Eq. 
Guinea
+
 
Ethiopia Liberia Malawi Nigeria 
South 
Sudan 
Tanzania Uganda Average
*
 
18 Census
b
 /volunteer/day 
$2.105  
(NA) 
$0.390 
(NA) 
$0.921 
(NA) 
$0.998 
(NA) 
$0.570 
(NA) 
$0.409 
(NA) 
$12.327 
(NA) 
$0.869 
(NA) 
$0.616 
(NA) 
$0.294 
(NA) 
$2.317 
(NA) 
$0.536 
(NA) 
$0.643 
(NA) 
$0.548 
(NA) 
$1.682 
($3.124) 
 Drug delivery and administration in areas without epidemiological challenges (19, 20) 
19 Delivery of ivermectin /treatment 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
(NA) 
$1.505 
($0.000) 
20 Ivermectinadministration
c
 /volunteer/day 
$2.105  
(NA) 
$0.390 
(NA) 
$0.921 
(NA) 
$0.998 
(NA) 
$0.570 
(NA) 
$0.409 
(NA) 
$12.327 
(NA) 
$0.869 
(NA) 
$0.616 
(NA) 
$0.294 
(NA) 
$2.317 
(NA) 
$0.536 
(NA) 
$0.643 
(NA) 
$0.548 
(NA) 
$1.682 
($3.124) 
 Drug delivery and administration in areas with epidemiological challenges
d
 (21, 22) 
21 Diagnostic tools (annuitized) /set 
$120 
(NA) 
$120 
(NA) 
$120 (NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 (NA) $120 (NA) $120 ($0) 
22 
Delivery and administration 
of doxycycline 
/6-week 
treatment 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
(NA) 
$2.500 
($0.000) 
23 
Management of severe 
adverse events 
/project 
$1,360 
($381) 
$1,070 
($840) 
$5,329 
($8,271) 
NA NA $175 ($0) 
$1,275 
($0) 
$2,465 
($0) 
$13,195 
($4,185) 
NA 
$3,245 
($2,266) 
$544 
($345) 
NA 
$1,277 
($0) 
$2,993 
($3,888) 
Category 2. Surveillance 
Supervision/monitoring/evaluation 
24 Supervisory visit /project 
$4,000 
($1,414) 
$3,001 
($2,434) 
$2,460 
($1,098) 
NA 
$635 
($352) 
$2,489 
($0) 
$1,450 
($0) 
NA NA 
$1,253 
($655) 
$1,702 
($1,480) 
$1,500 
($0) 
NA 
$2,498 
($566) 
$2,099 
($981) 
25 Monitoring /project 
$5,203 
($4,630) 
$1,617 
($19) 
$10,482 
($7,449) NA 
$1,468 
($676) NA NA 
$375 
($177) 
$1,735 
($17) 
$4,963 
($5,201) 
$3,135 
($4,353) NA NA NA 
$3,622 
($3,259) 
26 Evaluation /project 
NA 
$3,585 
($0) NA NA NA NA NA NA NA 
$4,432 
($4,309) NA NA NA NA 
$4,008 
($599) 
27 Review meeting /project 
$5,293 
($4,031) 
$4,037 
($0) 
$16,796 
($24,483) 
NA 
$7,787 
($3,049) 
NA 
$1,419 
($0) 
$13,600 
($936) 
$2,573 
($889) 
$3,986 
($3,978) 
$7,375 
($6,721) 
$3,488 
($561) 
$13,409 
($1,214) 
$1,191 
($0) 
$6,746 
($5,206) 
28 Data management /project 
$1,400 
($0) 
$6,793 
($9,598) 
$5,574 
($7,273) 
NA 
$175 
($207) 
$1,463 
($0) 
$800 ($0) NA NA 
$1,344 
($540) 
$975 
($2,220) 
NA NA 
$2,258 
($2,210) 
$2,309 
($2,287) 
Training 
29 
Training of trainers and 
health workers 
/health worker 
$132 
($57) 
$47 ($31) $140 ($123) $53 ($0) $81 ($0) $16 ($0) NA $1,179 
($275) 
$48 ($19) $1 ($0) $8 ($6) $107 
($24) 
$579 
($109) 
$6 ($1) $184 
($335) 
30 Training of fly-catchers
e
 /fly-catcher $20 ($7) $3 ($1) $9 ($7) NA $11 ($8) $2 ($0) $5 ($0) $18 ($1) $4 ($2) $2 ($2) $3 ($3) $8 ($5) $13 ($6) $1 ($2) $8 ($6) 
31 
Training of community 
leaders 
/community $15 ($13) $18 ($5) $9 ($5) NA $5 ($0) $12 ($0) NA $23 ($17) NA 
$0.350 
($0.003) 
$5 ($6) $4 ($3) NA $2 ($1) $9 ($7) 
Sampling and laboratory testing 
 Epidemiological survey sampling 
32 
Surveillance trip 
transportation
f
 
/person/day/site 
$52 
($109) 
$14 ($18) $32 ($56) $9 ($2) $6 ($0) NA NA $7 ($1) $21 ($3) NA $30 ($44) NA NA NA $21 ($16) 
33 Personnel
g
 /person/day/site $64 ($25) $10 ($6) $25 ($34) $6 ($0) $25 ($0) $1 ($0) $1 ($0) $13 ($3) $3 ($2) $4 ($2) $17 ($15) $19 ($17) NA $8 ($10) $15 ($17) 
34 Field supplies (annuitized)
h
 /set $68 (NA) $68 (NA) $68 (NA) $68 (NA) $68 (NA) $68 (NA) $68 (NA) $68 (NA) $68 (NA) $68 (NA) $68 (NA) $68 (NA) $68 (NA) $68 (NA) $68 ($0) 
 Entomological survey sampling 
35 Personnel
i
 /person/day/site 
$7.929 
($4.046) 
$1.449 
($0.503) 
$3.087 
($1.431) NA 
$1.148 
($0.000) 
NA NA 
$2.500 
($0.707) 
$1.000 
($0.000) 
$1.468 
($0.000) 
$1.559 
($1.092) 
$3.330 
($2.057) NA 
$0.604 
($0.400) 
$2.407 
($2.138) 
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36 Field supplies (annuitized) 
j
 
/set/person/day/s
ite 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
(NA) 
$1.850 
($0.000) 
 Delivery of samples 
37 
Delivery of samples from 
villages to laboratory  
/site Included in the surveillance trip transportation costs (ID:32) 
38 
Delivery of samples from 
catching site to health 
facility
k
 
/site 
$4.670 
($3.423) 
$1.127 
($0.000) 
$6.145 
($7.657) 
$11.740 
($8.784) 
$6.250 
($0.000) 
NA NA 
$12.500 
($3.536) 
$5.023 
($5.096) 
$18.367 
($14.874) 
$5.761 
($6.033) 
NA NA NA 
$7.954 
($5.249) 
39 
Delivery of samples from 
health facility to MSDC
l
 
/project 
$135 
(NA) 
$135 
(NA) 
$135 (NA) 
$135 
(NA) 
$135 
(NA) 
$135 
(NA) 
$135 
(NA) 
$135 
(NA) 
$135 
(NA) 
$135 
(NA) 
$135 
(NA) 
$135 
(NA) 
$135 (NA) $135 (NA) $135 ($0) 
 Epidemiological laboratory testing 
40 Personnel
m
 /person/day/site $64 ($25) $10 ($6) $25 ($34) $6 ($0) $25 ($0) $1 ($0) $1 ($0) $13 ($3) $3 ($2) $4 ($2) $17 ($15) $19 ($17) NA $8 ($10) $15 ($17) 
41 
Laboratory supplies 
(annuitized)
n
 
/set 
$120 
(NA) 
$120 
(NA) 
$120 (NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 
(NA) 
$120 (NA) $120 (NA) $120 ($0) 
 Entomological laboratory testing 
42 Personnel
o
 /person/day/site $9 (NA) $9 (NA) $9 (NA) $9 (NA) $9 (NA) $9 (NA) $9 (NA) $13 ($3) $9 (NA) $9 (NA) $9 (NA) $9 (NA) $9 (NA) $8 ($10) $9 ($0) 
Category 3. Capital costs 
43 Vehicle (annuitized) /vehicle  
$2,931 
(NA) 
$5,663 
(NA) 
$4,103 
(NA) 
NA NA 
$3,538 
(NA) 
$3,751 
(NA) 
$3,918 
(NA) 
$3,751 
(NA) 
NA 
$3,681 
(NA) 
$3,751 
(NA) 
$3,918 
(NA) 
$4,103 
(NA) 
$3,919 
($661) 
44 Motorcycle (annuitized) /motorcycle 
$469 
(NA) 
$708 
(NA) 
$528 (NA) NA NA 
$352 
(NA) 
$493 
(NA) 
$493 
(NA) 
$493 
(NA) 
NA 
$345 
(NA) 
$879 
(NA) 
$493 (NA) $399 (NA) 
$503 
($156) 
45 Bicycle (annuitized) /bicycle $17 (NA) $19 (NA) $23 (NA) NA NA $22 (NA) $22 (NA) $22 (NA) $15 (NA) $ (NA) $29 (NA) $29 (NA) $22 (NA) $7 (NA) $21 ($6) 
46 IT equipment (annuitized) /set 
$2,287 
(NA) 
$2,330 
(NA) 
$2,288 
(NA) 
$2,171 
(NA) 
$2,181 
(NA) 
$2,181 
(NA) 
$2,197 
(NA) 
$2,181 
(NA) 
$2,187 
(NA) 
$1,924 
(NA) 
$2,299 
(NA) 
$2,132 
(NA) 
$2,181 
(NA) 
$1,998 
(NA) 
$2,181 
($111) 
47 
Power supply equipment 
(annuitized) 
/set 
$514 
(NA) 
$514 
(NA) 
$543 (NA) 
$514 
(NA) 
$514 
(NA) 
$514 
(NA) 
$514 
(NA) 
$514 
(NA) 
$502 
(NA) 
$514 
(NA) 
$528 
(NA) 
$514 
(NA) 
$514 (NA) $483 (NA) 
$514 
($13) 
Category 4. Overhead and administrative costs 
48 Maintenance of vehicle /vehicle 
$444 
(NA) 
$221 
(NA) 
$243 (NA) 
$273 
(NA) 
$293 
(NA) 
$352 
(NA) 
$393 
(NA) 
$204 
(NA) 
$318 
(NA) 
$147 
(NA) 
$289 
(NA) 
$356 
(NA) 
$188 (NA) $200 (NA) 
$280 
($86) 
49 Maintenance of motorcycle /motorcycle 
$133 
(NA) 
$66 (NA) $73 (NA) $82 (NA) $88 (NA) 
$106 
(NA) 
$118 
(NA) 
$61 (NA) $95 (NA) $44 (NA) $87 (NA) 
$107 
(NA) 
$56 (NA) $60 (NA) $84 ($26) 
50 Office supplies /project 
$923 
($327) 
$1,375 
($455) 
$1,714 
($1,058) 
NA 
$9,605 
($0) 
$4,367 
($0) 
NA 
$1,050 
($495) 
$2,343 
($427) 
$4,103 
($0) 
$2,811 
($6,545) 
$1,230 
($464) 
$1,685 
($441) 
$1,541 
($806) 
$2,519 
($2,459) 
51 Communication /project 
$1,944 
($1,264) 
$1,739 
($256) 
$4,585 
($4,136) 
NA $869 ($0) 
$3,565 
($0) 
NA 
$1,800 
($0) 
NA NA 
$1,260 
($1,178) 
$1,936 
($327) 
$11,973 
($2,140) 
$745 
($752) 
$3,042 
($3,354) 
52 Salary top-ups (first 6 years) /project 
$14,708 
($8,284) 
$18,190 
($11,220) 
$52,278 
($66,782) 
$25,691 
($10,150) 
NA 
$41,300 
($0) 
NA NA $28,467 
($4,965) 
NA 
$61,171 
($84,633) 
$9,220 
($575) 
$6,681 
($2,008) 
$811 ($0) 
$25,852 
($20,125) 
53 Other administration /project 
$470 
($285) 
$1,678 
($2,786) 
$10,852 
($13,991) 
NA $222 ($0) 
$20,611 
($0) 
NA NA NA 
$2,710 
($0) 
$817 
($1,342) 
$5,252 
($1,008) 
NA $80 ($0) 
$4,744 
($6,881) 
Category 5. Financial support for CDTi and surveillance in (post) conflict endemic areas 
54 
Support for CDTi and 
surveillance in (post) conflict 
/endemic 
African regions 
$1,052,363 (NA) 
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ID Cost items Unit Angola Burundi Cameroon 
Central 
African 
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Chad Congo 
Eq. 
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+
 
Ethiopia Liberia Malawi Nigeria 
South 
Sudan 
Tanzania Uganda Average
*
 
endemic areas
p
 
Note: if not specified below, all data sourced from available budgets. 
+ Equatorial Guinea 
* Regional average across national averages 
#The nationwide project had ten sub-project budgets available. To compare with projects in other countries, average unit costs per sub-project were shown. 
%The nationwide project had seven sub-project budgets available. To compare with projects in other countries, average unit costs per sub-project were shown. 
@There were two regional projects for which seven sub-project budgets were available. To compare with projects in other countries, average unit costs per sub-project were shown. 
a,b,c Agriculture value added per person-day [86,91] 
d 1) As a proxy for the costs of the microscopic diagnostic tools for L.loa, we used the costs of the epidemiological laboratory testing supplies (ID:41);  
   2) Source for delivery and administration of doxycycline: Wanji et al. 2009 [94] 
e Budget for the training of community volunteers was used. 
f Budget for the fuel support for supervisory visit to districts was used. 
g Budget for the perdiem for health workers who train community drug distributors was used. 
h Prices of 2 liters of distilled water, 200 glass slides, 3 instrument trays, 4 slide trays each holding 3 glass slides, liquid detergent, butane burning stove, dropper bottle, aluminium pressure sterilizer, cotton swabs soaked 
with alcohol, curved tweezer, holth punch, lancets, scissors, sterilizer forcepts. http://www.amazon.com Accessed on 17 August 2014. 
i Budget for the training incentive for community drug distributors was used. 
j Price of aspirator and plastic bottles. http://www.amazon.com Accessed on 17 August 2014. 
k Budget for the transportation support for supervisory visit from health facility to villages was used. 
l DHL service guide. http://www.dhlguide.co.uk Accessed on 17 August 2014. 
m Budget for the perdiem for health workers who train community drug distributors was used. 
n Prices of 1ml test tube, binocular microscope, blood slids, hypodermic syringe and needle, micro pipette with disposable tips, microtitration trays, saline solution, slide trays. http://www.amazon.com Accessed on 17 
August 2014 
o Daily wage of state-certified nurse in Burkina Faso[122] was used as a proxy for the daily wage of laboratory technicians in MSDC. For Ethiopia, Uganda, and Sudan that were identified to conduct the entomological 
laboratory testing in their own laboratories, we used the daily wage for technicians who conduct epidemiological laboratory testing, namely, $13, $8, and $15 (regional average), respectively (ID:40).  
p Annual average funding for (post) conflict areas in Africa based on the APOC budget plan for 2008-2015 (annual average: $756,250) and Sightsavers’s strategic plan for 2011-2021 (annual average: $296,113) [95,123]. 
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Table S6. Agriculture value added per person-day for endemic African countries 
Country Agriculture value added per person-day* 
Angola $2.11 
Benin $0.93 
Burkina Faso $0.88 
Burundi $0.39 
Cameroon $0.92 
Central African Republic $1.00 
Chadɸ $0.57 
Congo, Dem. Rep. $0.40 
Congo, Rep. $0.41 
Côte d'Ivoire $1.28 
Equatorial Guinea† $12.33 
Ethiopia $0.87 
Gabon $1.68 
Ghana $1.45 
Guinea $0.39 
Guinea-Bissau $1.11 
Liberia $0.62 
Malawi $0.29 
Mali $1.13 
Mozambique $0.66 
Nigeria $2.32 
Senegal $0.66 
Sierra Leone $1.38 
South Sudanǂ $0.54 
Sudan $1.80 
Tanzania $0.64 
Togo $0.69 
Uganda $0.55 
Average (SD) $1.36 ($2.22) 
* To estimate daily agriculture value added per worker, agriculture value added per worker as percentage of GDP [91] was multiplied with 
2012 GDP per capita [86], and was divided by 261 days. 
ɸ,†,ǂ Agriculture value added per worker (% of GDP) for sub-Saharan Africa (developing only, 2012) was used, because national data were 
unavailable. 
SD: standard deviation 
 
Table S7. The ratio of volunteers and of health workers over population and population 
per district and per community for endemic African countries 
Country 
Volunteers over 
population 
Health workers 
over population 
Population per 
district 
Population per 
community 
Source 
Angola 1/275 1/2,458 70,460 910 Budgets 
Benin NA NA 51,106 564 Sightsavers[123] 
Burkina Faso NA NA 171,150 NA 
Helen Keller International 
[124] 
Burundi 1/150 1/4,892 149,684 4,270 Budgets 
Cameroon 1/260 1/9,068 109,238 1,317 Budgets 
CAR 1/106 1/3,501 160,356 288 Budgets 
Chad 1/182 1/2,789 99,664 583 Budgets 
Congo 1/251 1/2,118 57,500 1,076 Budgets 
Côte d`Ivoire NA NA NA NA NA 
DRC NA NA NA 646 WHO/APOC [125] 
Equatorial Guinea 1/181 1/5,082 20,330 630 Budgets 
Ethiopia 1/188 1/14,930 40,156 396 Budgets 
Gabon NA NA 32,291 NA 
Direction Générale des 
Statistiques, Gabon 
[126,127] 
Ghana NA NA 36,060 654 
Ministry of health, Ghana 
[128] 
Guinea NA NA 312,617 304 
Institut National de la 
Statistique, the Republic of 
Guinea [129,130], 
Sightsavers[123] 
Guinea-Bissau NA NA 32,358 83 
Instituto Nacional de 
Estatística e Censos, Guinea-
Bissau [131,132], 
Sightsavers[123] 
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Country 
Volunteers over 
population 
Health workers 
over population 
Population per 
district 
Population per 
community 
Source 
Liberia 1/196 1/2,920 165,043 696 Budgets 
Malawi 1/112 1/663 311,425 1,111 Budgets 
Mali NA NA 290,344 1,498 
Institut National de la 
Statistique, Mali [133,134], 
Sightsavers[123] 
Mozambique NA NA 173,837 NA 
Instituto Nacional de 
Estatistica, Mozambique 
[135,136] 
Nigeria 1/265 1/905 94,005 1,307 Budgets 
Senegal NA NA 300,182 NA 
Agence Nationale de la 
Statistique et de la 
Démographie (ANSD), 
Senegal[137,138] 
Sierra Leone NA NA 416,777 403 
Ministry of Health, Sierra 
Leone [139] 
South Sudan 1/379 1/6,180 114,929 958 Budgets 
Sudan NA NA NA 676 APOC [140] 
Tanzania 1/200 1/3,471 72,687 362 Budgets 
Togo NA NA 98,890 960 Sightsavers[123] 
Uganda 1/47 1/1,266 134,919 638 Budgets 
Average (SD) 1/154 (0.0047) 1/2,223 (0.0004) 
140,640 
(107,370) 
884 (823)  
 
Step 2. Costs at cost-item level 
 
To estimate costs for each cost item from 2013 to 2045, we multiplied the unit cost with the unit 
quantity for each year. The unit quantity was adjusted for the relevant phases, that is, it was zero 
outside the relevant phases which are defined in Table S4. 
 
Step 3. Classification into financial and economic costs 
 
We grouped costs at cost-item level into financial and economic costs. Among the total 54 cost items, 
four cost items (ID: 4, 18, 19, 20) were for economic costs, and other were for financial costs. 
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Step 4. Sub-classification of financial and economic costs 
 
From an operational perspective, financial costs consist of those of CDTi and of surveillance. We 
grouped financial costs at cost-item level into those of CDTi and of surveillance based on the five 
categories. We evenly split the costs of capital goods and administration between CDTi and 
surveillance for years when both CDTi and surveillance were conducted; otherwise, allocated the costs 
to CDTi during the phase 1 and surveillance during the phases 2 and 3. We evenly split the support 
costs for (post) conflict areas between CDTi and surveillance for the entire time horizon. Economic 
costs consist of those of community volunteers and of donated ivermectin, and we grouped the 
economic costs at cost-item level into those two.  
Step 5. Total financial and economic costs 
 
To estimate annual financial costs, we summed the annual financial costs of CDTi and surveillance 
(E1). To estimate annual economic costs, we summed the annual economic costs of community 
volunteers and donated ivermectin (E2). 
 
                              (E1) 
                                 (E2) 
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FCt : total financial costs for year t; 
FCCDTi/surveillance,t : financial costs of CDTi/surveillance for year t; 
ECt : total economic costs for year t; 
ECvolunteer/ivermectin,t: economic costs of community volunteers/donated ivermectin for year t 
 
Step 6. Total costs for a project 
 
To calculate annual total costs for a project, we summed the annual financial and economic costs (E3). 
 
            (E3) 
TCt : total costs for year t 
 
To estimate cumulative costs over 2013 to 2045, we aggregated annual total costs with discounting 
(E4). The discount rate to account for time preference was 3%. 
 
            ∑
   
(   )(      )
    
      
 
 
r: discount rate 
 
3. Total costs for a scenario 
To estimate total costs for a scenario, we aggregated costs at project level across the entire target 
projects.   
(E4) 
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II. Uncertainty analysis 
1. Selection of variables 
We conducted sensitivity analysis to assess the robustness of results to parametric uncertainties. The 
parameters for the sensitivity analysis included cost items that had missing unit costs either for more 
than one third of total projects or total countries with budgets available, 22 of 67 projects or 5 of 14 
countries (Table S8). In addition to them, we also included the financial support costs for (post) 
conflict areas, as it was estimated based on only two sources, the strategic plans of APOC [95] and 
Sightsavers[123]. There were no missing data on the determinants of unit quantities for projects with 
budgets available. However, four determinants were time-variant; thus to assess the impact of time 
variation on total costs, we included them: population living in a project area, the number of required 
treatments (determined by population, treatment coverage linked to required treatment duration, and 
possible delay in starting and ending treatments), the number of required community volunteers 
(determined by population and the ratio of community volunteers over population), and the number of 
required community health workers (determined by population and the ratio of community health 
workers over population). 
Table S8. Selected cost items for sensitivity analysis 
Cost items  (ordered by no. of missing values) Number of missing values 
 Country (/14) Project (/67) 
Evaluation 12 64 
Development of IEC material 10 57 
Surveillance trip transportation 6 38 
Monitoring 6 33 
Delivery of fly samples from catching site to health facility 5 35 
Data management 5 26 
Management of severe adverse events 4 30 
Salary top-ups (first 6 years) 4 28 
Assistance for supervisory visits (7th year+) 4 23 
 
2. Statistical distributions 
We applied statistical distributions to the selected variables considering the characteristics of variables 
with reference to standard practices [141]. We applied gamma distributions to the selected cost items 
and fitted them to available unit costs (Table S9).  
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Table S9. Average and standard deviation of unit costs and distribution parameters 
Cost items Average 
Standard 
deviation† 
Gamma distribution# 
Shape (k) Scale (θ) 
1 Evaluation 
  
  
Burundi $3,585 $358 100 36 
Malawi $4,432 $4,309 1 4,190 
Average $4,008 $599 45 90 
2 Development of IEC material     
Ethiopia $2,200 $1,697 2 1,309 
Liberia $4,532 $99 2,107 2 
Nigeria $1,889 $1,566 1 1,299 
Uganda $382 $38 100 4 
Average $2,250 $1,716 2 1,308 
3 Surveillance trip transportation     
Angola $52 $109 >0 228 
Burundi $14 $18 1 24 
Cameroon $32 $56 >0 100 
CAR $9 $2 13 1 
Chad $6 $1 100 >0 
Ethiopia $7 $1 61 >0 
Liberia $21 $3 49 >0 
Nigeria $30 $44 1 63 
Average $21 $16 2 12 
4 Monitoring     
Angola $5,203 $4,630 1 4120 
Burundi $1,617 $19 7593 >0 
Cameroon $10,482 $7,449 2 5,293 
Chad $1,468 $676 5 312 
Ethiopia $375 $177 5 83 
Liberia $1,735 $17 10,034 >0 
Malawi $4,963 $5,201 1 5,451 
Nigeria $3,135 $4,353 1 6,044 
Average $3,622 $3,259 1 2,933 
5 Delivery of fly samples from catching site to health facility     
Angola $5 $3 2 3 
Burundi $1 >$0 100 >0 
Cameroon $6 $8 1 10 
CAR $12 $9 2 7 
Chad $6 $1 100 >0 
Ethiopia $13 $4 13 1 
Liberia $5 $5 1 5 
Malawi $18 $15 2 12 
Nigeria $6 $6 1 6 
Average $8 $5 2 3 
6 Data management     
Angola $1,400 $140 100 14 
Burundi $6,793 $9,598 1 13,562 
Cameroon $5,574 $7,273 1 9,491 
Chad $175 $207 1 244 
Congo $1,463 $146 100 15 
Equatorial Guinea $800 $80 100 8 
Malawi $1,344 $540 6 217 
Nigeria $975 $2,220 >0 5,053 
Uganda $2,258 $2,210 1 2,163 
Average $2,309 $2,287 1 2,265 
7 Management of severe adverse events     
Angola $1,360 $381 13 107 
Burundi $1,070 $840 2 659 
Cameroon $5,329 $8,271 >0 12,839 
Congo $175 $18 100 2 
Equatorial Guinea $1,275 $128 100 13 
Ethiopia $2,465 $247 100 25 
Liberia $13,195 $4,185 10 1,327 
Nigeria $3,245 $2,266 2 1,582 
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Cost items Average 
Standard 
deviation† 
Gamma distribution# 
Shape (k) Scale (θ) 
South Sudan $544 $345 2 219 
Uganda $1,277 $128 100 13 
Average $2,993 $3,888 1 5,051 
8 Salary top-ups (first 6 years)     
Angola $14,708 $8,284 3 4,666 
Burundi $18,190 $11,220 3 6,920 
Cameroon $52,278 $66,782 1 85,310 
CAR $25,691 $10,150 6 4,010 
Congo $41,300 $4,130 100 413 
Liberia $28,467 $4,965 33 866 
Nigeria $61,171 $84,633 1 117,094 
South Sudan $9,220 $575 257 36 
Tanzania $6,681 $2,008 11 604 
Uganda $811 $81 100 8 
Average $25,852 $20,125 2 15,668 
9 Assistance for supervisory visits (7th year+)     
Angola $4,000 $1,414 8 500 
Burundi $3,001 $2,434 2 1,974 
Cameroon $2,460 $1,098 5 490 
Chad $635 $352 3 195 
Congo $2,489 $249 100 25 
Equatorial Guinea $1,450 $145 100 15 
Malawi $1,253 $655 4 342 
Nigeria $1,702 $1,480 1 1,287 
South Sudan $1,500 $150 100 15 
Uganda $2,498 $566 19 128 
Average $2,099 $981 5 459 
10 Financial support for post-conflict areas (annual average)     
APOC $756,250 $7,563 100 7,563 
Sightsaver $296,113 $2,961 100 2,961 
† If there was only one data point, the standard deviation was assumed to be 10% of the data. 
# Parameters of Gamma(k, θ) were estimated with a method of moments: 
      ̂  
  ̅̅ ̅
 ̅
       ̂  
 ̅
 ̅
      ̅               ̅                  
 
We used normal distributions to model the uncertainty about population growth rates from 2013 to 
2045 for all endemic countries. We fitted the distribution to national low-high ranges[55], assuming 
the ranges to be the 95% confidence intervals.  
To model the uncertainty about the number of treatments, we identified its determinants with reference 
to the study by Kim and colleagues [6]. The determinants were population living in a project area, 
treatment coverage, and the delay in starting and ending CDTi. We used normal distributions to model 
the uncertainty about population growth rates as described in the previous step. We used beta 
distributions to model the uncertainty about treatment coverage by fitting them to the treatment 
coverage data over 2010−2012 for APOC countries (source: APOC treatment database) (Table S10). 
Projects in former OCP countries had no historical treatment coverage available, yet had the most 
recent year’s data. To estimate distribution parameters for the former OCP countries, we assumed that 
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the standard deviation is 10% of treatment coverage. The change of treatment coverage was linked to 
the required duration of CDTi based on ONCHOSIM simulation results for the elimination and 
eradication scenarios. For the control scenario, the required duration of CDTi was extended for another 
25 years if the treatment coverage decreased below the minimum required level, 65%. To model the 
uncertainty about the delay in starting and ending CDTi, we used a gamma distribution in which 90% 
of samples fall into the range of zero to five (shape=1, scale=2.25), assuming the delay can be as long 
as five years [6]. 
Table S10. Average and standard deviation of treatment coverage and distribution 
parameters 
Country Average 
Standard 
deviation 
Beta distributionγ 
Alpha (α) Beta (β) 
APOC countries     
Angola 67% 0.11 12 6 
Burundi 77% 0.04 106 31 
Cameroon 78% 0.05 63 18 
CAR 80% 0.03 168 41 
Chad 81% >0.00 124,658 29,241 
Congo 81% 0.02 208 47 
DRC 71% 0.13 7 3 
Equatorial Guinea 71% >0.00 292,469 119,749 
Ethiopia 79% 0.04 78 21 
Liberia 77% 0.10 13 4 
Malawi 83% >0.00 5,113 1,066 
Nigeria 80% 0.04 83 21 
South Sudan 60% 0.12 9 6 
Sudan 82% 0.03 167 38 
Tanzania 81% 0.01 868 210 
Uganda 75% 0.11 10 3 
Average 76% 0.06 35 11 
Former OCP countries     
Benin 48% 0.05 51 55 
Burkina Faso 84% 0.08 16 3 
Côte d’Ivoire 84% 0.08 16 3 
Ghana 73% 0.07 27 10 
Guinea 73% 0.07 27 10 
Guinea-Bissau 73% 0.07 27 10 
Mali 73% 0.07 27 10 
Senegal 77% 0.08 22 6 
Sierra Leone 80% 0.08 19 5 
Togo 77% 0.08 22 6 
Average 74% 0.10 13 5 
 
γ Parameters of Beta(α, β) were estimated using a method of moments: 
 ̂   ̅ (
 ̅(   ̅)
 ̅
  )   ̂  (   ̅) (
 ̅(   ̅)
 ̅
  )     ̅   ̅(   ̅)        ̅                  ̅                      
 
To model the uncertainty about the number of volunteers and of health workers, we identified their 
determinants, namely, population living in a project area and the ratio of volunteers and of health 
workers over population. We used normal distributions to model the uncertainty about population 
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growth rates as described previously. We used beta distributions to model the uncertainty about the 
ratio of volunteers over population and the ratio of health workers over population by fitting them to 
relevant data (Table S11).  
For all selected variables, if there was no distribution at country level, we used the distribution for the 
endemic regions which was estimated based on available national averages for endemic African 
countries. 
Table S11. Average and standard deviation of the ratio of volunteers over population 
and the ratio of health workers over population and distribution parameters 
Country Average Standard deviation 
Beta distributionδ 
Alpha (α) Beta (β) 
1 Ratio of volunteers over population 
  
  
Angola 1/257 0.0029 2 429 
Burundi 1/150 0.0005 164 24,462 
Cameroon 1/260 0.0040 1 238 
CAR 1/106 0.0019 25 2,600 
Chad 1/182 0.0011 25 4,500 
Congo 1/251 0.0008 25 6,225 
Equatorial Guinea 1/181 0.0011 25 4,475 
Ethiopia 1/188 0.0003 404 75,638 
Liberia 1/196 0.0028 3 662 
Malawi 1/112 0.0013 44 4,865 
Nigeria 1/265 0.0028 2 472 
South Sudan 1/379 0.0017 3 949 
Tanzania 1/200 0.0010 25 4,950 
Uganda 1/47 0.0155 2 85 
Average 1/154 0.0047 2 294 
2 Ratio of health workers over population 
  
  
Angola 1/2,458 0.0004 1 2,241 
Burundi 1/4,892 >0.0000 23 114,727 
Cameroon 1/9,068 0.0003 0.2 1,602 
CAR 1/3,501 0.0001 25 87,483 
Chad 1/2,789 0.0001 25 69,676 
Congo 1/2,118 0.0001 25 52,911 
Equatorial Guinea 1/5,082 >0.0000 25 127,009 
Ethiopia 1/14,930 0.0001 1 21,589 
Liberia 1/2,920 0.0001 6 18,393 
Malawi 1/663 0.0006 7 4,688 
Nigeria 1/905 0.0010 1 1,080 
South Sudan 1/6,180 0.0001 4 24,603 
Tanzania 1/3,471 0.0001 25 86,715 
Uganda 1/1,266 0.0002 16 20,812 
Average 1/2,223 0.0004 1 2614 
δ Parameters of Beta(α, β) were estimated using a method of moments: 
 ̂   ̅ (
 ̅(   ̅)
 ̅
  )   ̂  (   ̅) (
 ̅(   ̅)
 ̅
  )     ̅   ̅(   ̅)        ̅                  ̅                     
 
3. Simulation 
We conducted one-way sensitivity analysis to examine the impact of parameters related to CDTi 
performance (treatment coverage, the delay in starting and ending CDTi), the selected cost items with 
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high uncertainty, and discount rates (0%, 3%, 6%) on total costs. We also conducted multivariate PSA 
to examine the joint effects of uncertainties about all selected variables on total costs by running the 
micro-costing simulation 1,000 times using samples drawn from the distributions of the selected 
variables.   
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III. Literature review 
To find literature on regional elimination strategies for onchocerciasis in Africa, we used the PubMed 
(MEDLINE) database to search for documents in English and French, published between 2004 and 
2014, with the following search terms: “onchocerciasis or river blindness” in title and “elimination or 
eradication” in abstract. We reviewed abstracts to determine relevance, and reviewed the full texts of 
selected documents. We also searched the bibliographies of identified references and the gray 
literature. We found two manuscripts on elimination strategies for endemic African regions: one a 
conceptual and operational framework of onchocerciasis elimination developed by APOC [68] and the 
other a manuscript on control, elimination, and eradication scenarios for onchocerciasis by Kim and 
colleagues which was developed based on the former [6] (Table S12).  
Table S12. Literature on regional elimination strategies in Africa 
 Title Authors Published year Reference 
1 Conceptual and Operational Framework of 
Onchocerciasis Elimination with Ivermectin 
Treatment. 
African Programme for Onchocerciasis 
Control 
2010 [68] 
2 Control, elimination, and eradication of river 
blindness: scenarios, timelines, and ivermectin 
treatment needs in Africa 
Kim YE, Remme JHF, Steinmann P, 
Stolk WA, Roungou J, Tediosi F. 
2015 [6] 
 
To estimate costs associated with potential elimination strategies proposed by Kim and colleagues, we 
searched literature on onchocerciasis intervention costs. Keating and colleagues searched literature on 
onchocerciasis intervention costs, published in English and French between 1990 and 2010, using 
PubMed (MEDLINE), EMBASE, and JSTOR databases with the following search terms: 
onchocerciasis, cost, cost–benefit, cost-effectiveness, economic, economics, internal rate of return, 
elimination, eradication, health systems, vertical, integration [142]. They selected publications after 
reviewing abstracts for relevance, and reviewed the full texts of the selected ones. They also searched 
the bibliographies of identified references and the gray literature. They found ten publications on costs 
for onchocerciasis treatment with ivermectin or doxycycline. We have extended the search period to 
include 2011−2015 using the same method, and found four more documents (Table S13). Considering 
our objective was to estimate costs for potential elimination strategies in Africa using a micro-costing 
method, the identified publications were insufficient, because they focused on a limited number of 
countries, and many of them were outdated and lacked detailed data on resource utilization (e.g., unit 
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costs and unit quantities). Also, all identified publications estimated costs for control strategies without 
regular surveillance. 
Table S13. Literature on costs of onchocerciasis treatment with ivermectin or 
doxycycline in Africa 
 Title Authors 
Published 
year 
Country/region Reference 
1 Ivermectin-based onchocerciasis control in 
Cameroon 
Ngoumou P, Essomba RO, 
Godin C. 
1996 Cameroon [143] 
2 Delivery  systems  and  cost  recovery  in  
Mectizan  treatment  for  onchocerciasis 
Amazigo U, Noma M, Boatin 
BA, Etya'ale DE, Seketeli A, 
Dadzie KY. 
1998 Endemic 
African regions 
[144] 
3 Ivermectin distribution using community 
volunteers in Kabarole district, Uganda 
Kipp W, Burnham G, Bamuhiiga 
J, Weis P, Buttner DW. 
1998 Uganda [145] 
4 The  Mectizan  (Ivermectin)  Donation  
Program  for Riverblindness  as  a  Paradigm  
for  Pharmaceutical  Industry  Donation  
Programs 
Philip E.Coyne, David W.Berk. 2001 NA [121] 
5 Implementing community-directed  treatment  
with  ivermectin  for  the  control  of  
onchocerciasis  in  Uganda  (1997–2000):  an  
evaluation 
Katabarwa MN, Habomugisha P, 
Richards FO, Jr. 
2002 Uganda [146] 
6 Community-directed  treatment  with  
ivermectin  in  two  Nigerian  communities:  
an  analysis  of  first  year start-up  processes,  
costs  and  consequences 
Onwujekwe O, Chima R, Shu E, 
Okonkwo P. 
2002 Nigeria [147] 
7 Economic  evaluation  of  Mectizan 
distribution 
Waters HR, Rehwinkel JA, 
Burnham G. 
2004 Endemic 
African regions 
[148] 
8 Progress  towards  the elimination  of  
onchocerciasis  as  a  public-health  problem  
in  Uganda:  opportunities,  challenges  and  
the  way  forward 
Ndyomugyenyi R, Lakwo T, 
Habomugisha P, Male B. 
2007 Uganda [149] 
9 Community-directed delivery  of  
doxycycline  for  the  treatment  of  
onchocerciasis  in  areas  of  coendemicity  
with  loiasis  in  Cameroon 
Wanji S, Tendongfor N, Nji T, 
Esum M, Che JN, Nkwescheu A 
et al. 
2009 Cameroon [94] 
10 Cost-effectiveness  of  triple drug  
administration  (TDA)  with  praziquantel,  
ivermectin  and  albendazole  for the  
prevention  of  neglected  tropical  diseases  
in  Nigeria 
Evans D, McFarland D, Adamani 
W, Eigege A, Miri E, Schulz J et 
al. 
2001 Nigeria [150] 
11 African Programme For Onchocerciasis 
Control 1995-2015: model-estimated health 
impact and cost 
Coffeng LE, Stolk WA, Zoure 
HG, Veerman JL, Agblewonu 
KB, Murdoch ME et al. 
2013 Endemic 
African regions 
[12] 
12 The cost of annual versus biannual 
community-directed treatment of 
onchocerciasis with ivermectin: Ghana as a 
case study 
Turner HC, Osei-Atweneboana 
MY, Walker M, Tettevi EJ, 
Churcher TS, Asiedu O et al. 
2013 Ghana [105] 
13 Reaching the london declaration on neglected 
tropical diseases goals for onchocerciasis: an 
economic evaluation of increasing the 
frequency of ivermectin treatment in Africa 
Turner HC, Walker M, Churcher 
TS, Osei-Atweneboana MY, 
Biritwum NK, Hopkins A et al. 
2014 Endemic 
African regions 
[151] 
14 Onchocerciasis control in the Democratic 
Republic of Congo (DRC): challenges in a 
post-war environment 
MakengaBof JC, Maketa V, 
Bakajika DK, Ntumba F, 
Mpunga D, Murdoch ME et al. 
2015 the Democratic 
Republic of 
Congo 
[152] 
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Figure S3. Incremental cumulative financial and economic costs over 2013−2045 
 
 
 
 
(Note: The line bars represent the 95 central ranges based on PSA. Costs are discounted with 3% and 
reported in 2012 USD.) 
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Figure S4. Incremental cumulative financial costs over 2013−2045 
 
 
 
 
  
(Note: The line bars represent the 95 central ranges based on PSA. Costs are discounted with 3% and 
reported in 2012 USD.) 
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Figure S5. Incremental cumulative economic costs over 2013−2045 
 
 
 
  
(Note: The line bars represent the 95 central ranges based on PSA. Costs are discounted with 3% and 
reported in )2012 USD. 
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Appendix 3. Supplementary Information for Chapter 5 
 
Value of investing in the elimination and eradication of onchocerciasis in 
Africa: the health and economic benefits and the impacts on health systems 
 
Methodological details on probabilistic sensitivity analysis 
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Probabilistic sensitivity analysis 
To examine the robustness of results against the joint uncertainties about associated 
parameters and assumptions, we conducted multivariate probabilistic sensitivity analysis. 
 
Health Impacts 
Parameters against which we assessed the robustness of health impacts (the number of 
cases of severe itching, low vision, and blindness and DALYs) were the treatment 
coverage, the level of infection and morbidity in hypo-endemic areas relative to meso-
endemic areas, the reduction of life-expectancy due to blindness, and the population 
growth rate. 
a. Treatment coverage 
As a treatment coverage rate for the period 2013–2045, we used the average 
treatment coverage over the period 2010–2012 for APOC countries and the most 
recent available data (as of November 2013) for former OCP countries due to the 
lack of history data. To incorporate the uncertainty about treatment coverage rates, 
we assigned a beta distribution and fitted to the pool of treatment coverage data for 
projects at country level. The beta distribution at regional level was fitted to the pool 
of national average treatment coverage (Table S14). The range of treatment coverage 
was restricted to 60% to 84%, because at least 60% is required for effective control 
of the disease and 84% is the maximum achievable considering 16% of the 
population is not eligible for CDTi due to ages less than five years, pregnancy, or 
severe illness [6].  
Table S14. Summary of treatment coverage and distribution parameters for 
probabilistic sensitivity analysis 
Country Average
1
 Standard deviation 
Beta distribution
2
 
Alpha Beta 
APOC countries 
Angola 67% 0.11 12.36 5.97 
Burundi 77% 0.04 105.52 31.48 
Cameroon 78% 0.05 62.60 17.72 
Central African  Republic 80% 0.03 167.75 40.98 
Chad 81% 0.00 124,658.19 29,240.81 
Congo 81% 0.02 207.63 47.39 
Democratic Republic of the Congo 71% 0.13 7.47 3.12 
Equatorial Guinea 71% 0.00 292,469.03 119,749.47 
Ethiopia 79% 0.04 77.58 20.87 
Liberia 77% 0.10 13.31 3.89 
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Malawi 83% 0.00 5,112.61 1,065.77 
Nigeria 80% 0.04 83.33 21.00 
South Sudan 60% 0.12 8.72 5.78 
Sudan 82% 0.03 167.06 37.92 
Tanzania 81% 0.01 868.01 210.26 
Uganda 75% 0.11 10.48 3.46 
APOC 76% 0.06 35.04 10.81 
 
Country Latest
3
 Standard deviation
4
 
Beta distribution 
Alpha Beta 
Former OCP countries 
Benin 48% 0.05 51.42 55.48 
Burkina Faso 84% 0.08 15.56 3.05 
Côte d’Ivoire 84% 0.08 15.56 3.05 
Ghana 73% 0.07 26.67 10.07 
Guinea 73% 0.07 26.67 10.07 
Guinea-Bissau 73% 0.07 26.67 10.07 
Mali 73% 0.07 26.67 10.07 
Senegal 77% 0.08 21.83 6.37 
Sierra Leone 80% 0.08 18.90 4.64 
Togo 77% 0.08 21.83 6.37 
Former OCP 74% 0.10 13.09 4.58 
1 The average treatment coverage over 2010-2012  
2 Parameters of Beta(α, β) were estimated using a method of moments: 
 ̂   ̅ (
 ̅(   ̅)
 ̅
  )   ̂  (   ̅) (
 ̅(   ̅)
 ̅
  )      ̅   ̅(   ̅)   
       ̅                  ̅                      
3
A database for the former OCP countries had only the most recent available treatment coverage as of November 2013. 
4
 The standard deviation was assumed to be 10% of the treatment coverage. 
 
The change of treatment coverage leads to the change of the prevalence of infection 
and morbidity, and consequently to the change of the required treatment duration. In 
the PSA, the prevalence of severe itching and the required treatment duration varied 
depending on the change of treatment coverage based on ONCHOSIM simulation 
results. There was no variation in the prevalence of low vision and blindness, because 
the change of treatment coverage (60%–84%) was not enough to have an impact on 
the prevalence of vision impairment according to ONCHOSIM simulations. 
b. The level of infection and morbidity in hypo-endemic areas relative to meso-
endemic areas 
We did not conduct ONCHOSIM simulations for hypo-endemic areas, as 
ONCHOSIM predicts the infection level in hypo-endemic areas is unsustainable 
without human or vector migration, and data on human or vector migration were 
unavailable. Instead, we assumed that the level of infection and morbidity in hypo-
endemic areas is 1/3 relative to that in meso-endemic areas [12]. To incorporate the 
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uncertainty about this assumption in PSA, we applied a triangular distribution with 
the lower limit to be 1/10, the upper limit to be 1/2, and the mode to be 1/3.  
c. Life-expectancy loss per blindness incidence 
We assumed that blindness causes eight years of life-expectancy loss [12]. To 
incorporate the uncertainty about this assumption, we applied a triangular distribution 
with the lower limit to be six, the upper limit to be ten, and the mode to be eight. 
d. Population growth rate 
We assigned a normal distribution to each country by fitting to low, medium, and 
high population growth rates. The distribution has the medium as the average and 
half of the distance between the low and high rates as the standard deviation. Data 
were available from the United Nations (UN) database [9]. 
 
Health workforce needs 
Parameters against which we examined the robustness of the health workforce needs were 
the ratio of community volunteers over population, the ratio of community health workers 
over population, the possible delay in starting and ending CDTi, and the population 
growth rate. 
a. The ratio of community volunteers over population 
We applied a beta distribution and fitted to available data at country and regional 
levels. The ratio of community volunteers over population was available for 67 of 
total 112 ongoing projects (as of November 2013) in sub-Saharan Africa from project 
budget documents (Y2012). For projects in countries for which data were available, 
we used the fitted distribution at country level; for projects in countries with no data, 
we used the distribution at regional level which was fitted to available national 
average ratios among endemic African countries. The fitted distributions are 
presented in Table S15.  
 
Table S15. Summary of the ratio of community volunteers over population and 
distribution parameters for probabilistic sensitivity analysis 
Country Average 
Standard 
deviation 
Beta distribution1 
Alpha (α) Beta (β) 
Angola 1/257 0.0029 2 429 
Burundi 1/150 0.0005 164 24,462 
Cameroon 1/260 0.0040 1 238 
CAR 1/106 0.0019 25 2,600 
Chad 1/182 0.0011 25 4,500 
Congo 1/251 0.0008 25 6,225 
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Country Average 
Standard 
deviation 
Beta distribution1 
Alpha (α) Beta (β) 
Equatorial Guinea 1/181 0.0011 25 4,475 
Ethiopia 1/188 0.0003 404 75,638 
Liberia 1/196 0.0028 3 662 
Malawi 1/112 0.0013 44 4,865 
Nigeria 1/265 0.0028 2 472 
South Sudan 1/379 0.0017 3 949 
Tanzania 1/200 0.0010 25 4,950 
Uganda 1/47 0.0155 2 85 
Average 1/154 0.0047 2 294 
1 Parameters of Beta(α, β) were estimated using a method of moments: 
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b. The ratio of community health workers over population 
We used the same method for the ratio of community volunteers over population (see 
2-a). The ratio of community health workers over population was available for 67 of 
total 112 ongoing projects (as of November 2013) in sub-Saharan Africa from project 
budget documents (Y2012). The fitted distributions are presented in Table S16.  
 
Table S16. Summary of the ratio of community health workers over population and 
distribution parameters for probabilistic sensitivity analysis 
Country Average 
Standard 
deviation 
Beta distribution1 
Alpha (α) Beta (β) 
Angola 1/2,458 0.0004 1 2,241 
Burundi 1/4,892 >0.0000 23 114,727 
Cameroon 1/9,068 0.0003 0.2 1,602 
CAR 1/3,501 0.0001 25 87,483 
Chad 1/2,789 0.0001 25 69,676 
Congo 1/2,118 0.0001 25 52,911 
Equatorial Guinea 1/5,082 >0.0000 25 127,009 
Ethiopia 1/14,930 0.0001 1 21,589 
Liberia 1/2,920 0.0001 6 18,393 
Malawi 1/663 0.0006 7 4,688 
Nigeria 1/905 0.0010 1 1,080 
South Sudan 1/6,180 0.0001 4 24,603 
Tanzania 1/3,471 0.0001 25 86,715 
Uganda 1/1,266 0.0002 16 20,812 
Average 1/2,223 0.0004 1 2614 
1 Parameters of Beta(α, β) were estimated using a method of moments: 
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c. Delay in starting CDTi 
We assumed that starting CDTi can be delayed as long as five years. We applied a 
gamma distribution in which 90% of samples fall into the range of zero and five (Fig 
S6). 
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Figure S6. Gamma distribution for the delay in starting and ending CDTi: probability 
and cumulative density 
 
d. Delay in ending CDTi 
We assumed that ending CDTi can be also delayed as long as five years. We applied 
a gamma distribution in which 90% of samples fall into the range of zero and five 
(Fig S6). 
e. Population growth rate 
We used the same method described in 1-d. 
 
Outpatient service costs 
Parameters examined to evaluate the robustness of outpatient service costs were outpatient 
cost per visit, the health facility utilization rate, and the number of patients with severe 
itching and low vision. 
a. Outpatient service cost per visit 
We assumed that country-specific outpatient service costs per visit, available from 
WHO database [18], would be stable over the entire time horizon. To incorporate the 
uncertainty about this parameter, we applied a gamma distribution for each country 
assuming the standard deviation to be 20% of the outpatient costs per visit.  
b. Health facility utilization rate 
The proxy for health facility utilization rate was the average treatment coverage for 
CDTi over 2010–2012. We assigned a beta distribution and fitted to available data at 
country and regional levels. For projects in countries for which data were available, 
we used the fitted distribution for the country; for projects in countries without 
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available data, we used the distribution at regional level which was fitted to available 
national average data among endemic African countries. The fitted distributions are 
described inTable S14. 
c. The number of patients with severe itching and low vision 
The number of patients with severe itching and low vision is one of the health impacts 
results. The methods to incorporate the uncertainty about this parameter are described 
in Section 1 (health impacts). 
 
Out-of-pocket payments 
To examine the robustness of out-of-pocket payments, we included the parameters 
selected to examine outpatient service costs (see above), the proportion of total health 
expenditure incurred as out-of-pocket payments by household, and the transportation costs. 
a. Out-of-pocket payments as proportion of total health expenditure 
Out-of-pocket payments as proportion of total health expenditure were available for 
each country from WHO database [88]. To incorporate the uncertainty about this 
parameter, we applied a gamma distribution for each country assuming the standard 
deviation to be 20% of the data.  
b. Transportation costs 
Our assumption on transportation costs, 17% of outpatient visit costs, was based on 
the multi-country survey for 39 countries, available from 2010 World Health Report 
[27]. This survey shows that the average transportation cost as percentage of 
outpatient visit costs across 14 sub-Saharan African countries is 17% and the standard 
deviation is 11%. To incorporate the uncertainty about this parameter, we applied a 
gamma distribution assuming the mean is 17% and the standard deviation to be 11%. 
 
Economic productivity impacts 
To examine the robustness of the economic productivity estimated with the human capital 
approach, we included GDP per capita, the employment rate, the proportion of GDP per 
capita associated with productivity losses due to severe itching, low vision, and blindness. 
a. GDP per capita 
To incorporate the uncertainty about GDP per capita, we applied a normal distribution 
for each country assuming the standard deviation to be 20% of the GDP per capita. 
b. Employment rate 
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To incorporate the uncertainty about employment rate, we applied a normal 
distribution for each country assuming the standard deviation to be 20% of the GDP 
per capita. 
c. Productivity loss due to severe itching 
We based our assumption about the productivity loss due to severe itching (13% of 
GDP per capita) on the survey in Ethiopia  [21]. This study shows that intermediate 
onchocercal skin diseases (OSD) cause the income loss by 10%; and severe OSD, by 
16%. To incorporate the uncertainty about this parameter, we applied a normal 
distribution in which the mean is 13% and the 95% confidence interval is 10% to 16%.  
d. Productivity loss due to low vision 
We based our assumption about the productivity loss due to low vision (38% of GDP 
per capita) on the survey in Guinea [22]. We applied a normal distribution in which 
the mean is 38% and the standard deviation is 20% of the mean.  
e. Productivity loss due to blindness 
We based our assumption about the productivity loss due to blindness (79% of GDP 
per capita) on the survey in Guinea [22]. We applied a normal distribution in which 
the mean is 79% and the standard deviation is 20% of the mean.  
 
Economic welfare impacts 
To evaluate the robustness of the economic welfare impacts associated with life-year gains 
due to prevented blindness, we included the predicted years of life lost (YLL). 
a. Years of life lost 
YLL is one of the health impacts results. The methods to incorporate the uncertainty 
about this parameter are described previously (See above: Health Impacts). 
 
Simulations 
For the PSA for each result, we ran simulation500 times by sampling from the 
distributions described previously.  
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Figure S7. One-way deterministic sensitivity analysis for DALYs averted over 
2013−2045 
 
(CN: control scenario; EL: elimination scenario; ER: eradication scenario) 
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Figure S8. One-way deterministic sensitivity analysis for the saved number of required 
community volunteers over 2013−2045 
 
(CN: control scenario; EL: elimination scenario; ER: eradication scenario) 
 
 
Figure S9. One-way deterministic sensitivity analysis for the saved number of required 
community health workers over 2013−2045 
 
(CN: control scenario; EL: elimination scenario; ER: eradication scenario) 
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Figure S10. One-way deterministic sensitivity analysis for the saved outpatient service 
costs over 2013−2045 
 
(CN: control scenario; EL: elimination scenario; ER: eradication scenario) 
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Figure S11. One-way deterministic sensitivity analysis for the saved out-of-pocket 
payments over 2013−2045 
 
(CN: control scenario; EL: elimination scenario; ER: eradication scenario) 
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Figure S12. One-way deterministic sensitivity analysis for the economic productivity 
gains over 2013−2045 
 
(CN: control scenario; EL: elimination scenario; ER: eradication scenario) 
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Figure S13. One-way deterministic sensitivity analysis for the economic welfare gains 
over 2013−2045 
 
(CN: control scenario; EL: elimination scenario; ER: eradication scenario) 
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